



EMA/95098/2010 Rev.10

# The European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP) Guide on Methodological Standards in Pharmacoepidemiology (Revision 10)

## References

The hyperlinks in the document were last accessed online in June 2022.

### 1. Introduction

Altman, D. (2020). *Practical Statistics for Medical Research* (2nd ed.). Chapman & Hall.

Andrews, E., & Moore, N. (2014). *Mann's Pharmacovigilance, Third Edition* (3rd ed.). Wiley-Blackwell.

Ayad, A., & Hartzema, A. (2018). *Post-Authorization Safety Studies of Medicinal Products: The PASS Book*. Academic Press.

Directive 2001/83/EC. <https://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=CONSLEG:2001L0083:20070126:en:PDF>

Elseviers, M., Wettermark, B., & Almarsdóttir, A. (2016). *Drug Utilization Research: Methods and Applications*. Wiley Blackwel.

Good pharmacovigilance practices. European Medicines Agency.  
<https://www.ema.europa.eu/en/human-regulatory/post-authorisation/pharmacovigilance/good-pharmacovigilance-practices>

Guidelines for Good Pharmacoepidemiology Practices (GPP)—International Society for Pharmacoepidemiology. (1996). ISPE. <https://www.pharmacoepi.org/resources/policies/guidelines-08027/>

Hartzema, A. G., Tilson, H. H., & Chan, K. A. (2008). *Pharmacoepidemiology and Therapeutic Risk Management*. Harvey Whitney Books Company.

Hernan, M., & Robins, J. (2020). *Causal Inference: What If*. Chapman & Hall/CRC.

Hoffmann, W., Latza, U., Baumeister, S. E., Brünger, M., Buttmann-Schweiger, N., Hardt, J., Hoffmann, V., Karch, A., Richter, A., Schmidt, C. O., Schmidtman, I., Swart, E., & van den Berg, N.

**Official address** Domenico Scarlattilaan 6 • 1083 HS Amsterdam • The Netherlands

**Address for visits and deliveries** Refer to [www.ema.europa.eu/how-to-find-us](http://www.ema.europa.eu/how-to-find-us)

**Send us a question** Go to [www.ema.europa.eu/contact](http://www.ema.europa.eu/contact) **Telephone** +31 (0)88 781 6000

An agency of the European Union



(2019). Guidelines and recommendations for ensuring Good Epidemiological Practice (GEP): A guideline developed by the German Society for Epidemiology. *European Journal of Epidemiology*, 34(3), 301–317. <https://doi.org/10.1007/s10654-019-00500-x>

IEA Good Epidemiology Practice (GEP). (2007). IEA. [https://ieaweb.org/IEAWeb/Content/IEA\\_Publications.aspx](https://ieaweb.org/IEAWeb/Content/IEA_Publications.aspx)

Lash, T., VanderWeele, T., Haneuse, S., & Rothman, K. (2020). *Modern Epidemiology* (4th ed.). Wolters Kluwer.

Miettinen, O. S. (1985). *Theoretical Epidemiology: Principles of Occurrence Research in Medicines*. Wiley.

Parfrey, P., & Barret, B. (2015). *Clinical epidemiology: Practice and methods* (2nd ed.). Human Press.

Porta, M. (2014). *A Dictionary of Epidemiology* (6th ed.). Oxford University Press.

Pottegård, A., Morin, L., Hallas, J., Gerhard, T., Winterstein, A. G., Perez-Gutthann, S., & Tadrous, M. (2022). Where to begin? Thirty must-read papers for newcomers to pharmacoepidemiology. *Pharmacoepidemiology and Drug Safety*, 31(2), 257–259. <https://doi.org/10.1002/pds.5382>

Scientific guidance on post-authorisation efficacy studies. European Medicines Agency. [https://www.ema.europa.eu/en/documents/scientific-guideline/scientific-guidance-post-authorisation-efficacy-studies-first-version\\_en.pdf](https://www.ema.europa.eu/en/documents/scientific-guideline/scientific-guidance-post-authorisation-efficacy-studies-first-version_en.pdf)

Strom, B., Kimmel, S. E., & Hennessy, S. (2019). *Pharmacoepidemiology*. Wiley.

Woodward, M. (2014). *Epidemiology: Study Design and Data Analysis* (3rd ed.). Chapman & Hall.

## **2. Formulating the research question and objectives and assessing study feasibility**

Brown, P., Brunnhuber, K., Chalkidou, K., Chalmers, I., Clarke, M., Fenton, M., Forbes, C., Glanville, J., Hicks, N. J., Moody, J., Twaddle, S., Timimi, H., & Young, P. (2006). How to formulate research recommendations. *BMJ*, 333(7572), 804–806. <https://doi.org/10.1136/bmj.38987.492014.94>

Criteria to select and prioritize health technologies for additional evidence generation. EUnetHTA. <https://www.eunetha.eu/wp-content/uploads/2018/01/Selection-prioritisation-criteria-1.pdf>

Doody, O., & E. Bailey, M. (2014). Setting a research question, aim and objective. <https://doi.org/10.7748/nr.23.4.19.s5>

European Medicines Agency. European Medicines Agency. <https://www.ema.europa.eu/en>

EUnetHTA Position paper on how to formulate research recommendations. [https://www.eunetha.eu/wp-content/uploads/2018/01/eunetha\\_position\\_paper\\_on\\_research\\_recommendations\\_0-1.pdf](https://www.eunetha.eu/wp-content/uploads/2018/01/eunetha_position_paper_on_research_recommendations_0-1.pdf)

Gatto, N. M., Campbell, U. B., Rubinstein, E., Jaksa, A., Mattox, P., Mo, J., & Reynolds, R. F. (2022). The Structured Process to Identify Fit-For-Purpose Data: A Data Feasibility Assessment Framework. *Clinical Pharmacology and Therapeutics*, 111(1), 122–134. <https://doi.org/10.1002/cpt.2466>

Gatto, N. M., Reynolds, R. F., & Campbell, U. B. (2019). A Structured Preapproval and Postapproval Comparative Study Design Framework to Generate Valid and Transparent Real-World Evidence for Regulatory Decisions. *Clinical Pharmacology and Therapeutics*, 106(1), 103–115. <https://doi.org/10.1002/cpt.1480>

Good pharmacovigilance practices. European Medicines Agency.

<https://www.ema.europa.eu/en/human-regulatory/post-authorisation/pharmacovigilance/good-pharmacovigilance-practices>

ISPE Guidelines for Good Pharmacoepidemiology Practices (GPP)—International Society for Pharmacoepidemiology. <https://www.pharmacoepi.org/resources/policies/guidelines-08027/>

Jansen, E., Hines, P. A., Berntgen, M., & Brand, A. (2022). Strengthening the Interface of Evidence-Based Decision Making Across European Regulators and Health Technology Assessment Bodies. *Value in Health*. <https://doi.org/10.1016/j.ival.2022.01.026>

Kloda, L., & Bartlett, J. C. (2013). Formulating Answerable Questions: Question Negotiation in Evidence-based Practice. *Journal of the Canadian Health Libraries Association / Journal de l'Association Des Bibliothèques de La Santé Du Canada*, 34(2), 55–60. <https://doi.org/10.5596/c13-019>

Lipowski, E. E. (2008). Developing great research questions. *American Journal of Health-System Pharmacy*, 65(17), 1667–1670. <https://doi.org/10.2146/ajhp070276>

Ritchev, M. E., & Girman, C. J. (2020). Evaluating the Feasibility of Electronic Health Records and Claims Data Sources for Specific Research Purposes. *Therapeutic Innovation & Regulatory Science*, 54(6), 1296–1302. <https://doi.org/10.1007/s43441-020-00139-x>

Rivera, D. R., Gokhale, M. N., Reynolds, M. W., Andrews, E. B., Chun, D., Haynes, K., Jonsson-Funk, M. L., Lynch, K. E., Lund, J. L., Strongman, H., Bhullar, H., & Raman, S. R. (2020). Linking electronic health data in pharmacoepidemiology: Appropriateness and feasibility. *Pharmacoepidemiology and Drug Safety*, 29(1), 18–29. <https://doi.org/10.1002/pds.4918>

Thabane, L., Thomas, T., Ye, C., & Paul, J. (2008). Posing the research question: Not so simple. *Canadian Journal of Anesthesia/Journal Canadien d'anesthésie*, 56(1), 71. <https://doi.org/10.1007/s12630-008-9007-4>

There's a S.M.A.R.T. way to write management's goals and objectives.

<https://community.mis.temple.edu/mis0855002fall2015/files/2015/10/S.M.A.R.T-Way-Management-Review.pdf>

Tully, M. P. (2014). Research: Articulating Questions, Generating Hypotheses, and Choosing Study Designs. *The Canadian Journal of Hospital Pharmacy*, 67(1), 31–34. <https://doi.org/10.4212/cjhp.v67i1.1320>

Wang, S. V., Pinheiro, S., Hua, W., Arlett, P., Uyama, Y., Berlin, J. A., Bartels, D. B., Kahler, K. H., Bessette, L. G., & Schneeweiss, S. (2021). STaRT-RWE: Structured template for planning and reporting on the implementation of real world evidence studies. *BMJ (Clinical Research Ed.)*, 372, m4856. <https://doi.org/10.1136/bmj.m4856>

Willame, C., Baril, L., van den Bosch, J., Ferreira, G. L. C., Williams, R., Rosillon, D., & Cohet, C. (2016). Importance of feasibility assessments before implementing non-interventional pharmacoepidemiologic studies of vaccines: Lessons learned and recommendations for future studies. *Pharmacoepidemiology and Drug Safety*, 25(12), 1397–1406. <https://doi.org/10.1002/pds.4081>

### 3. Development of the study protocol

Agency for Healthcare Research and Quality (AHRQ). AHQR. <https://www.ahrq.gov/>

Clinical Trial Regulation (EU) 536/2014. (2014). <http://data.europa.eu/eli/reg/2014/536/oj/eng>

ClinicalTrials.gov. ClinicalTrials.Gov. <https://clinicaltrials.gov/>

Commission Implementing Regulation (EU) No 520/2012. [https://eur-lex.europa.eu/eli/reg\\_impl/2012/520/oj](https://eur-lex.europa.eu/eli/reg_impl/2012/520/oj)

Developing a Protocol for Observational Comparative Effectiveness Research: A User's Guide | Effective Health Care (EHC) Program. AHQR. <https://effectivehealthcare.ahrq.gov/products/observational-cer-protocol/research>

Draft Volume 10—Guidance documents applying to clinical trials. [https://www.ejprarediseases.org/wp-content/uploads/2021/10/Regulation5362014\\_qa\\_en\\_V4\\_2021.pdf](https://www.ejprarediseases.org/wp-content/uploads/2021/10/Regulation5362014_qa_en_V4_2021.pdf)

EMA Guidance for the format and content of the final study report of non-interventional post-authorisation safety studies. [https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guidance-format-content-final-study-report-non-interventional-post-authorisation-safety-studies\\_en.pdf](https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guidance-format-content-final-study-report-non-interventional-post-authorisation-safety-studies_en.pdf)

EMA Guidance for the format and content of the protocol of non-interventional post-authorisation safety studies. European Medicines Agency.

[https://www.ema.europa.eu/en/documents/other/guidance-format-content-protocol-non-interventional-post-authorisation-safety-studies\\_en.pdf](https://www.ema.europa.eu/en/documents/other/guidance-format-content-protocol-non-interventional-post-authorisation-safety-studies_en.pdf)

ENCePP Checklist for Study Protocols. ENCePP.

[https://www.encepp.eu/standards\\_and\\_guidances/checkListProtocols.shtml](https://www.encepp.eu/standards_and_guidances/checkListProtocols.shtml)

EU PAS Register. <https://www.encepp.eu/encepp/studiesDatabase.jsp>

Good pharmacovigilance practices. (2018, September 17). European Medicines Agency.

<https://www.ema.europa.eu/en/human-regulatory/post-authorisation/pharmacovigilance/good-pharmacovigilance-practices>

ISPE Guidelines for Good Pharmacoepidemiology Practices (GPP)—International Society for Pharmacoepidemiology. ISPE. <https://www.pharmacoepi.org/resources/policies/guidelines-08027/>

OSF. Open Science. <https://osf.io/>

Research, C. for D. E. and. (2020). Best Practices for Conducting and Reporting Pharmacoepidemiologic Safety Studies Using Electronic Healthcare Data Sets. FDA.

<https://www.fda.gov/regulatory-information/search-fda-guidance-documents/best-practices-conducting-and-reporting-pharmacoepidemiologic-safety-studies-using-electronic>

Schneeweiss, S., Rassen, J. A., Brown, J. S., Rothman, K. J., Happe, L., Arlett, P., Dal Pan, G., Goettsch, W., Murk, W., & Wang, S. V. (2019). Graphical Depiction of Longitudinal Study Designs in Health Care Databases. *Annals of Internal Medicine*, 170(6), 398–406. <https://doi.org/10.7326/M18-3079>

## **4. Study design**

### **4.1. Overview**

Amrhein, V., Greenland, S., & McShane, B. (2019). Scientists rise up against statistical significance. *Nature*, 567(7748), 305–307. <https://doi.org/10.1038/d41586-019-00857-9>

Greenland, S., Senn, S. J., Rothman, K. J., Carlin, J. B., Poole, C., Goodman, S. N., & Altman, D. G. (2016). Statistical tests, P values, confidence intervals, and power: A guide to misinterpretations. *European Journal of Epidemiology*, 31(4), 337–350. <https://doi.org/10.1007/s10654-016-0149-3>

ICMJE Recommendations. Preparing a Manuscript for Submission to a Medical Journal. ICMJE. <https://icmje.org/recommendations/browse/manuscript-preparation/preparing-for-submission.html#two>

It's time to talk about ditching statistical significance. (2019). *Nature*, 567(7748), 283–283. <https://doi.org/10.1038/d41586-019-00874-8>

Pottegård, A., Kurz, X., Moore, N., Christiansen, C. F., & Klungel, O. (2020). Considerations for pharmacoepidemiological analyses in the SARS-CoV-2 pandemic. *Pharmacoepidemiology and Drug Safety*, 29(8), 825–831. <https://doi.org/10.1002/pds.5029>

Renoux, C., Azoulay, L., & Suissa, S. (2021). Biases in Evaluating the Safety and Effectiveness of Drugs for the Treatment of COVID-19: Designing Real-World Evidence Studies. *American Journal of Epidemiology*, 190(8), 1452–1456. <https://doi.org/10.1093/aje/kwab028>

Song, J. W., & Chung, K. C. (2010). Observational Studies: Cohort and Case-Control Studies. *Plastic and Reconstructive Surgery*, 126(6), 2234–2242. <https://doi.org/10.1097/PRS.0b013e3181f44abc>

Wasserstein, R. L., & Lazar, N. A. (2016). The ASA Statement on p-Values: Context, Process, and Purpose. *The American Statistician*, 70(2), 129–133. <https://doi.org/10.1080/00031305.2016.1154108>

#### **4.2. Types of study design**

Burningham, Z., He, T., Teng, C.-C., Zhou, X., Nebeker, J., & Sauer, B. C. (2017). Evaluation of the Case-Crossover (CCO) Study Design for Adverse Drug Event Detection. *Drug Safety*, 40(9), 789–798. <https://doi.org/10.1007/s40264-017-0540-3>

Cadarette, S. M., Maclure, M., Delaney, J. A. C., Whitaker, H. J., Hayes, K. N., Wang, S. V., Tadrous, M., Gagne, J. J., Consiglio, G. P., & Hallas, J. (2021). Control yourself: ISPE-endorsed guidance in the application of self-controlled study designs in pharmacoepidemiology. *Pharmacoepidemiology and Drug Safety*, 30(6), 671–684. <https://doi.org/10.1002/pds.5227>

Coutinho, J. M., Zuurbier, S. M., Aramideh, M., & Stam, J. (2012). The Incidence of Cerebral Venous Thrombosis. *Stroke*, 43(12), 3375–3377. <https://doi.org/10.1161/STROKEAHA.112.671453>

Farrington, C. P. (2004). Control without separate controls: Evaluation of vaccine safety using case-only methods. *Vaccine*, 22(15), 2064–2070. <https://doi.org/10.1016/j.vaccine.2004.01.017>

Feychting, M., Kaune, W. T., Savitz, D. A., & Ahlbom, A. (1996). Estimating Exposure in Studies of Residential Magnetic Fields and Cancer: Importance of Short-Term Variability, Time Interval between Diagnosis and Measurement, and Distance to Power Line. *Epidemiology*, 7(3), 220–224.

Greenland, S. (1996). Confounding and exposure trends in case-crossover and case-time-control designs. *Epidemiology (Cambridge, Mass.)*, 7(3), 231–239. <https://doi.org/10.1097/00001648-199605000-00003>

Hallas, J. (1996). Evidence of depression provoked by cardiovascular medication: A prescription sequence symmetry analysis. *Epidemiology (Cambridge, Mass.)*, 7(5), 478–484.

Hallas, J., Pottegård, A., Wang, S., Schneeweiss, S., & Gagne, J. J. (2016). Persistent User Bias in Case-Crossover Studies in Pharmacoepidemiology. *American Journal of Epidemiology*, 184(10), 761–769. <https://doi.org/10.1093/aje/kww079>

Harris, R. J., Hall, J. A., Zaidi, A., Andrews, N. J., & Dunbar, J. K. Impact of vaccination on household transmission of SARS-COV-2 in England. *Public Health England*, 32.

Lash, T., VanderWeele, T., Haneuse, S., & Rothman, K. (2020). *Modern Epidemiology* (4th ed.). Wolters Kluwer.

Levin, K. A. (2006). Study Design VI - Ecological Studies. *Evidence-Based Dentistry*, 7(4), 108–108. <https://doi.org/10.1038/sj.ebd.6400454>

Maclure, M. (1991). The Case-Crossover Design: A Method for Studying Transient Effects on the Risk of Acute Events. *American Journal of Epidemiology*, 133(2), 144–153. <https://doi.org/10.1093/oxfordjournals.aje.a115853>

Morales, D. R., Conover, M. M., You, S. C., Pratt, N., Kostka, K., Duarte-Salles, T., Fernández-Bertolín, S., Aragón, M., DuVall, S. L., Lynch, K., Falconer, T., van Bochove, K., Sung, C., Matheny, M. E., Lambert, C. G., Nyberg, F., Alshammari, T. M., Williams, A. E., Park, R. W., ... Suchard, M. A. (2021). Renin-angiotensin system blockers and susceptibility to COVID-19: An international, open science, cohort analysis. *The Lancet Digital Health*, 3(2), e98–e114. [https://doi.org/10.1016/S2589-7500\(20\)30289-2](https://doi.org/10.1016/S2589-7500(20)30289-2)

Morgenstern, H. (1995). Ecologic Studies in Epidemiology: Concepts, Principles, and Methods. *Annual Review of Public Health*, 16(1), 61–81. <https://doi.org/10.1146/annurev.pu.16.050195.000425>

Schuemie, M. J., Ryan, P. B., Man, K. K. C., Wong, I. C. K., Suchard, M. A., & Hripcsak, G. (2019). A plea to stop using the case-control design in retrospective database studies. *Statistics in Medicine*, 38(22), 4199–4208. <https://doi.org/10.1002/sim.8215>

Simpson, C. R., Shi, T., Vasileiou, E., Katikireddi, S. V., Kerr, S., Moore, E., McCowan, C., Agrawal, U., Shah, S. A., Ritchie, L. D., Murray, J., Pan, J., Bradley, D. T., Stock, S. J., Wood, R., Chuter, A., Beggs, J., Stagg, H. R., Joy, M., ... Sheikh, A. (2021). First-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland. *Nature Medicine*, 27(7), 1290–1297. <https://doi.org/10.1038/s41591-021-01408-4>

Suissa, S. (1995). The case-time-control design. *Epidemiology*, 6(3), 248–253.

Wang, S., Linkletter, C., Maclure, M., Dore, D., Mor, V., Buka, S., & Wellenius, G. A. (2011). Future Cases as Present Controls to Adjust for Exposure Trend Bias in Case-only Studies. *Epidemiology*, 22(4), 568–574. <https://doi.org/10.1097/EDE.0b013e31821d09cd>

Wang, X., & Cheng, Z. (2020). Cross-Sectional Studies: Strengths, Weaknesses, and Recommendations. *Chest*, 158(1, Supplement), S65–S71. <https://doi.org/10.1016/j.chest.2020.03.012>

Whitaker, H. J., Ghebremichael-Weldeslassie, Y., Douglas, I. J., Smeeth, L., & Farrington, C. P. (2018). Investigating the assumptions of the self-controlled case series method. *Statistics in Medicine*, 37(4), 643–658. <https://doi.org/10.1002/sim.7536>

Whitaker, H. J., Paddy Farrington, C., Spiessens, B., & Musonda, P. (2006). Tutorial in biostatistics: The self-controlled case series method. *Statistics in Medicine*, 25(10), 1768–1797. <https://doi.org/10.1002/sim.2302>

### **4.3. Definition and validation of drug exposure, outcomes and covariates**

Banda, J. M., Seneviratne, M., Hernandez-Boussard, T., & Shah, N. H. (2018). Advances in Electronic Phenotyping: From Rule-Based Definitions to Machine Learning Models. *Annual Review of Biomedical Data Science*, 1(1), 53–68. <https://doi.org/10.1146/annurev-biodatasci-080917-013315>

- Brenner, H., & Gefeller, O. (1993). Use of the Positive Predictive Value to Correct for Disease Misclassification in Epidemiologic Studies. *American Journal of Epidemiology*, 138(11), 1007–1015. <https://doi.org/10.1093/oxfordjournals.aje.a116805>
- Brighton Collaboration. Brighton Collaboration. <https://brightoncollaboration.us/>
- Brunelli, S. M., Gagne, J. J., Huybrechts, K. F., Wang, S. V., Patrick, A. R., Rothman, K. J., & Seeger, J. D. (2013). Estimation using all available covariate information versus a fixed look-back window for dichotomous covariates. *Pharmacoepidemiology and Drug Safety*, 22(5), 542–550. <https://doi.org/10.1002/pds.3434>
- Carnahan, R. M., & Moores, K. G. (2012). Mini-Sentinel's systematic reviews of validated methods for identifying health outcomes using administrative and claims data: Methods and lessons learned. *Pharmacoepidemiology and Drug Safety*, 21(S1), 82–89. <https://doi.org/10.1002/pds.2321>
- ClinicalCodes Repository. ClinicalCodes.Org. <https://clinicalcodes.rss.mhs.man.ac.uk/>
- Davé, S., & Petersen, I. (2009). Creating medical and drug code lists to identify cases in primary care databases. *Pharmacoepidemiology and Drug Safety*, 18(8), 704–707. <https://doi.org/10.1002/pds.1770>
- Elseviers, M., Wettermark, B., & Almarsdóttir, A. B. (2016). *Drug Utilization Research. Methods and Applications*. Wiley-Blackwell.
- Fox, M. P., Lash, T. L., & Bodnar, L. M. (2020). Common misconceptions about validation studies. *International Journal of Epidemiology*, 49(4), 1392–1396. <https://doi.org/10.1093/ije/dyaa090>
- Greenland, S. (1980). The effect of misclassification in the presence of covariates. *American Journal of Epidemiology*, 112(4), 564–569. <https://doi.org/10.1093/oxfordjournals.aje.a113025>
- GREENLAND, S. (1996). Basic Methods for Sensitivity Analysis of Biases. *International Journal of Epidemiology*, 25(6), 1107–1116. <https://doi.org/10.1093/ije/25.6.1107-a>
- Hall, G. C., Lanes, S., Bollaerts, K., Zhou, X., Ferreira, G., & Gini, R. (2020). Outcome misclassification: Impact, usual practice in pharmacoepidemiology database studies and an online aid to correct biased estimates of risk ratio or cumulative incidence. *Pharmacoepidemiology and Drug Safety*, 29(11), 1450–1455. <https://doi.org/10.1002/pds.5109>
- Jurek, A. M., Greenland, S., Maldonado, G., & Church, T. R. (2005). Proper interpretation of non-differential misclassification effects: Expectations vs observations. *International Journal of Epidemiology*, 34(3), 680–687. <https://doi.org/10.1093/ije/dyi060>
- Khan, N. F., Harrison, S. E., & Rose, P. W. (2010). Validity of diagnostic coding within the General Practice Research Database: A systematic review. *British Journal of General Practice*, 60(572), e128–e136. <https://doi.org/10.3399/bjgp10X483562>
- Lash, T. L., Fox, M. P., & Fink, A. K. (2009). *Applying quantitative bias analysis to epidemiologic data*. Springer-Verlag.
- Lash, T. L., Fox, M. P., MacLehose, R. F., Maldonado, G., McCandless, L. C., & Greenland, S. (2014). Good practices for quantitative bias analysis. *International Journal of Epidemiology*, 43(6), 1969–1985. <https://doi.org/10.1093/ije/dyu149>
- Lee, W.-J., Lee, T. A., Pickard, A. S., Shoaibi, A., & Schumock, G. T. (2015). Using linked electronic data to validate algorithms for health outcomes in administrative databases. *Journal of Comparative Effectiveness Research*, 4(4), 359–366. <https://doi.org/10.2217/cer.15.14>

Pottegård, A., Christensen, R. dePont, Houji, A., Christiansen, C. B., Paulsen, M. S., Thomsen, J. L., & Hallas, J. (2014). Primary non-adherence in general practice: A Danish register study. *European Journal of Clinical Pharmacology*, 70(6), 757–763. <https://doi.org/10.1007/s00228-014-1677-y>

Pye, S. R., Sheppard, T., Joseph, R. M., Lunt, M., Girard, N., Haas, J. S., Bates, D. W., Buckeridge, D. L., van Staa, T. P., Tamblyn, R., & Dixon, W. G. (2018). Assumptions made when preparing drug exposure data for analysis have an impact on results: An unreported step in pharmacoepidemiology studies. *Pharmacoepidemiology and Drug Safety*, 27(7), 781–788. <https://doi.org/10.1002/pds.4440>

Schneeweiss, S., & Avorn, J. (2005). A review of uses of health care utilization databases for epidemiologic research on therapeutics. *Journal of Clinical Epidemiology*, 58(4), 323–337. <https://doi.org/10.1016/j.jclinepi.2004.10.012>

Strom, B., Kimmel, S. E., & Hennessy, S. (2019). *Pharmacoepidemiology* (6th ed.). Wiley-Blackwell.

Yih, W. K. (2017). *Quantitative Bias Analysis Methodology Development: Sequential Bias Adjustment for Outcome Misclassification*. Final Report, 19.

Yland, J. J., Wesselink, A. K., Lash, T. L., & Fox, M. P. (2022). Misconceptions About Misclassification: Non-Differential Misclassification Does Not Always Bias Results Toward the Null. *American Journal of Epidemiology*, kwac035. <https://doi.org/10.1093/aje/kwac035>

#### **4.4. Specific aspects of study design**

Arnold, B. F., Ercumen, A., Benjamin-Chung, J., & Colford, J. M. J. (2016). Brief Report: Negative Controls to Detect Selection Bias and Measurement Bias in Epidemiologic Studies. *Epidemiology*, 27(5), 637–641. <https://doi.org/10.1097/EDE.0000000000000504>

Bernal, J. L., Cummins, S., & Gasparrini, A. (2017). Interrupted time series regression for the evaluation of public health interventions: A tutorial. *International Journal of Epidemiology*, 46(1), 348–355. <https://doi.org/10.1093/ije/dyw098>

Collier, S., Harvey, C., Brewster, J., Bakerly, N. D., Elkhenini, H. F., Stanciu, R., Williams, C., Brereton, J., New, J. P., McCrae, J., McCorkindale, S., & Leather, D. (2017). Monitoring safety in a phase III real-world effectiveness trial: Use of novel methodology in the Salford Lung Study. *Pharmacoepidemiology and Drug Safety*, 26(3), 344–352. <https://doi.org/10.1002/pds.4118>

Collins, R., Bowman, L., Landray, M., & Peto, R. (2020). The Magic of Randomization versus the Myth of Real-World Evidence. *New England Journal of Medicine*, 382(7), 674–678. <https://doi.org/10.1056/NEJMs1901642>

Dagan, N., Barda, N., Kepten, E., Miron, O., Perchik, S., Katz, M. A., Hernán, M. A., Lipsitch, M., Reis, B., & Balicer, R. D. (2021). BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting. *New England Journal of Medicine*, 384(15), 1412–1423. <https://doi.org/10.1056/NEJMoa2101765>

de Abajo, F. J., Rodríguez-Martín, S., Lerma, V., Mejía-Abril, G., Aguilar, M., García-Luque, A., Laredo, L., Laosa, O., Centeno-Soto, G. A., Ángeles Gálvez, M., Puerro, M., González-Rojano, E., Pedraza, L., de Pablo, I., Abad-Santos, F., Rodríguez-Mañas, L., Gil, M., Tobías, A., Rodríguez-Miguel, A., ... Elvira, C. (2020). Use of renin-angiotensin-aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: A case-population study. *The Lancet*, 395(10238), 1705–1714. [https://doi.org/10.1016/S0140-6736\(20\)31030-8](https://doi.org/10.1016/S0140-6736(20)31030-8)

Desai, J. R., Hyde, C. L., Kabadi, S., St Louis, M., Bonato, V., Katrina Loomis, A., Galaznik, A., & Berger, M. L. (2017). Utilization of Positive and Negative Controls to Examine Comorbid Associations in



Observational Database Studies. *Medical Care*, 55(3), 244–251.

<https://doi.org/10.1097/MLR.0000000000000640>

Dickerman, B. A., García-Albéniz, X., Logan, R. W., Denaxas, S., & Hernán, M. A. (2020). Emulating a target trial in case-control designs: An application to statins and colorectal cancer. *International Journal of Epidemiology*, 49(5), 1637–1646. <https://doi.org/10.1093/ije/dyaa144>

Dickerman, B. A., Gerlovin, H., Madenci, A. L., Kurgansky, K. E., Ferolito, B. R., Figueroa Muñiz, M. J., Gagnon, D. R., Gaziano, J. M., Cho, K., Casas, J. P., & Hernán, M. A. (2022). Comparative Effectiveness of BNT162b2 and mRNA-1273 Vaccines in U.S. Veterans. *New England Journal of Medicine*, 386(2), 105–115. <https://doi.org/10.1056/NEJMoa2115463>

Dormuth, C. R., Patrick, A. R., Shrank, W. H., Wright, J. M., Glynn, R. J., Sutherland, J., & Brookhart, M. A. (2009). Statin Adherence and Risk of Accidents. *Circulation*, 119(15), 2051–2057.

<https://doi.org/10.1161/CIRCULATIONAHA.108.824151>

Dusetzina, S. B., Brookhart, M. A., & Maciejewski, M. L. (2015). Control Outcomes and Exposures for Improving Internal Validity of Nonrandomized Studies. *Health Services Research*, 50(5), 1432–1451.

<https://doi.org/10.1111/1475-6773.12279>

Emulating Randomized Clinical Trials With Nonrandomized Real-World Evidence Studies | *Circulation*.

<https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.120.051718>

Eworuke, E., Welch, E. C., Tobenkin, A., & Maro, J. C. (2019). Use of FDA’s Sentinel System to Quantify Seizure Risk Immediately Following New Ranolazine Exposure. *Drug Safety*, 42(7), 897–906.

<https://doi.org/10.1007/s40264-019-00798-2>

Farrington, C. P., Whitaker, H. J., & Hocine, M. N. (2009). Case series analysis for censored, perturbed, or curtailed post-event exposures. *Biostatistics*, 10(1), 3–16.

<https://doi.org/10.1093/biostatistics/kxn013>

Farrington, P., Whitaker, H., & Ghebremichael-Weldeselassie, Y. (2021). *Self-Controlled Case Series Studies: A Modelling Guide with R*. Chapman and Hall/CRC. [https://www.routledge.com/Self-](https://www.routledge.com/Self-Controlled-Case-Series-Studies-A-Modelling-Guide-with-R/Farrington-Whitaker-Weldeselassie/p/book/9781032095530)

[Controlled-Case-Series-Studies-A-Modelling-Guide-with-R/Farrington-Whitaker-](https://www.routledge.com/Self-Controlled-Case-Series-Studies-A-Modelling-Guide-with-R/Farrington-Whitaker-Weldeselassie/p/book/9781032095530)

[Weldeselassie/p/book/9781032095530](https://www.routledge.com/Self-Controlled-Case-Series-Studies-A-Modelling-Guide-with-R/Farrington-Whitaker-Weldeselassie/p/book/9781032095530)

Ford, I., & Norrie, J. (2016). Pragmatic Trials. *New England Journal of Medicine*, 375(5), 454–463.

<https://doi.org/10.1056/NEJMra1510059>

Franklin, J. M., Glynn, R. J., Suissa, S., & Schneeweiss, S. (2020). Emulation Differences vs. Biases When Calibrating Real-World Evidence Findings Against Randomized Controlled Trials. *Clinical Pharmacology & Therapeutics*, 107(4), 735–737. <https://doi.org/10.1002/cpt.1793>

<https://doi.org/10.1002/cpt.1793>

Fredriksson, A., & Oliveira, G. M. de. (2019). Impact evaluation using Difference-in-Differences. *RAUSP Management Journal*, 54(4), 519–532. <https://doi.org/10.1108/RAUSP-05-2019-0112>

Fröbert, O., Lagerqvist, B., Olivecrona, G. K., Omerovic, E., Gudnason, T., Maeng, M., Aasa, M., Angerås, O., Calais, F., Danielewicz, M., Erlinge, D., Hellsten, L., Jensen, U., Johansson, A. C., Kåregren, A., Nilsson, J., Robertson, L., Sandhall, L., Sjögren, I., ... James, S. K. (2013). Thrombus Aspiration during ST-Segment Elevation Myocardial Infarction. *New England Journal of Medicine*, 369(17), 1587–1597. <https://doi.org/10.1056/NEJMoa1308789>

GetReal Glossary of Definitions of Common Terms. IMI. [https://www.imi-](https://www.imi-getreal.eu/Portals/1/Documents/01%20deliverables/D1.3%20-%20Revised%20GetReal%20glossary%20-%20FINAL%20updated%20version_25Oct16_webversion.pdf)

[getreal.eu/Portals/1/Documents/01%20deliverables/D1.3%20-](https://www.imi-getreal.eu/Portals/1/Documents/01%20deliverables/D1.3%20-%20Revised%20GetReal%20glossary%20-%20FINAL%20updated%20version_25Oct16_webversion.pdf)

[%20Revised%20GetReal%20glossary%20-](https://www.imi-getreal.eu/Portals/1/Documents/01%20deliverables/D1.3%20-%20Revised%20GetReal%20glossary%20-%20FINAL%20updated%20version_25Oct16_webversion.pdf)

[%20FINAL%20updated%20version\\_25Oct16\\_webversion.pdf](https://www.imi-getreal.eu/Portals/1/Documents/01%20deliverables/D1.3%20-%20Revised%20GetReal%20glossary%20-%20FINAL%20updated%20version_25Oct16_webversion.pdf)

- Goodman-Bacon, A. (2021). Difference-in-differences with variation in treatment timing. *Journal of Econometrics*, 225(2), 254–277. <https://doi.org/10.1016/j.jeconom.2021.03.014>
- Gruber, S., & Tchetgen Tchetgen, E. (2016). Limitations of empirical calibration of p-values using observational data. *Statistics in Medicine*, 35(22), 3869–3882. <https://doi.org/10.1002/sim.6936>
- Gulmez, S. E., Larrey, D., Pageaux, G.-P., Lignot, S., Lassalle, R., Jové, J., Gatta, A., McCormick, P. A., Metselaar, H. J., Monteiro, E., Thorburn, D., Bernal, W., Zouboulis-Vafiadis, I., de Vries, C., Perez-Gutthann, S., Sturkenboom, M., Bénichou, J., Montastruc, J.-L., Horsmans, Y., ... Moore, N. (2013). Transplantation for Acute Liver Failure in Patients Exposed to NSAIDs or Paracetamol (Acetaminophen). *Drug Safety*, 36(2), 135–144. <https://doi.org/10.1007/s40264-012-0013-7>
- Hallas, J., Whitaker, H., Delaney, J. A., Cadarette, S. M., Pratt, N., & Maclure, M. (2021). The Use of Active Comparators in Self-Controlled Designs. *American Journal of Epidemiology*, 190(10), 2181–2187. <https://doi.org/10.1093/aje/kwab110>
- Hauben, M., Aronson, J. K., & Ferner, R. E. (2016). Evidence of Misclassification of Drug–Event Associations Classified as Gold Standard ‘Negative Controls’ by the Observational Medical Outcomes Partnership (OMOP). *Drug Safety*, 39(5), 421–432. <https://doi.org/10.1007/s40264-016-0392-2>
- Hernán, M. A. (2018). How to estimate the effect of treatment duration on survival outcomes using observational data. *BMJ*, 360, k182. <https://doi.org/10.1136/bmj.k182>
- Hernán, M. A., & Robins, J. (2020). *Causal Inference: What If (the book)*. Chapman & Hall/CRC. <https://www.hsph.harvard.edu/miguel-hernan/causal-inference-book/>
- Hernán, M. A., & Robins, J. M. (2016a). Using Big Data to Emulate a Target Trial When a Randomized Trial Is Not Available. *American Journal of Epidemiology*, 183(8), 758–764. <https://doi.org/10.1093/aje/kwv254>
- Hernán, M. A., Sauer, B. C., Hernández-Díaz, S., Platt, R., & Shrier, I. (2016). Specifying a target trial prevents immortal time bias and other self-inflicted injuries in observational analyses. *Journal of Clinical Epidemiology*, 79, 70–75. <https://doi.org/10.1016/j.jclinepi.2016.04.014>
- Horby, P. W., Mafham, M., Bell, J. L., Linsell, L., Staplin, N., Emberson, J., Palfreeman, A., Raw, J., Elmahi, E., Prudon, B., Green, C., Carley, S., Chadwick, D., Davies, M., Wise, M. P., Baillie, J. K., Chappell, L. C., Faust, S. N., Jaki, T., ... Landray, M. J. (2020a). Lopinavir–ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): A randomised, controlled, open-label, platform trial. *The Lancet*, 396(10259), 1345–1352. [https://doi.org/10.1016/S0140-6736\(20\)32013-4](https://doi.org/10.1016/S0140-6736(20)32013-4)
- Informatics, O. H. D. S. and. Chapter 18 Method Validity | The Book of OHDSI. <https://ohdsi.github.io/TheBookOfOhdsi/>
- Informatics, O. H. D. S. and. The Book of OHDSI. <https://ohdsi.github.io/TheBookOfOhdsi/>
- Kontopantelis, E., Doran, T., Springate, D. A., Buchan, I., & Reeves, D. (2015). Regression based quasi-experimental approach when randomisation is not an option: Interrupted time series analysis. *BMJ*, 350, h2750. <https://doi.org/10.1136/bmj.h2750>
- Lane, J. C. E., Weaver, J., Kostka, K., Duarte-Salles, T., Abrahao, M. T. F., Alghoul, H., Alser, O., Alshammari, T. M., Areia, C., Biedermann, P., Banda, J. M., Burn, E., Casajust, P., Fister, K., Hardin, J., Hester, L., Hripcsak, G., Kaas-Hansen, B. S., Khosla, S., ... for the OHDSI-COVID-19 consortium. (2021). Risk of depression, suicide and psychosis with hydroxychloroquine treatment for rheumatoid arthritis: A multinational network cohort study. *Rheumatology*, 60(7), 3222–3234. <https://doi.org/10.1093/rheumatology/keaa771>

Lauer, M. S., & D'Agostino, R. B. (2013). The Randomized Registry Trial—The Next Disruptive Technology in Clinical Research? *New England Journal of Medicine*, 369(17), 1579–1581. <https://doi.org/10.1056/NEJMp1310102>

Leather, D. A., Jones, R., Woodcock, A., Vestbo, J., Jacques, L., & Thomas, M. (2020). Real-World Data and Randomised Controlled Trials: The Salford Lung Study. *Advances in Therapy*, 37(3), 977–997. <https://doi.org/10.1007/s12325-019-01192-1>

Lesko, S. M., & Mitchell, A. A. (1995). An assessment of the safety of pediatric ibuprofen. A practitioner-based randomized clinical trial. *JAMA*, 273(12), 929–933.

Li, L., Kulldorff, M., Russek-Cohen, E., Kawai, A. T., & Hua, W. (2015). Quantifying the impact of time-varying baseline risk adjustment in the self-controlled risk interval design. *Pharmacoepidemiology and Drug Safety*, 24(12), 1304–1312. <https://doi.org/10.1002/pds.3885>

Lipsitch, M., Tchetgen Tchetgen, E., & Cohen, T. (2010). Negative Controls: A Tool for Detecting Confounding and Bias in Observational Studies. *Epidemiology*, 21(3), 383–388. <https://doi.org/10.1097/EDE.0b013e3181d61eeb>

Lopes, R. D., Macedo, A. V. S., de Barros E Silva, P. G. M., Moll-Bernardes, R. J., dos Santos, T. M., Mazza, L., Feldman, A., D'Andréa Saba Arruda, G., de Albuquerque, D. C., Camiletti, A. S., de Sousa, A. S., de Paula, T. C., Giusti, K. G. D., Domiciano, R. A. M., Noya-Rabelo, M. M., Hamilton, A. M., Loures, V. A., Dionísio, R. M., Furquim, T. A. B., ... BRACE CORONA Investigators. (2021). Effect of Discontinuing vs Continuing Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on Days Alive and Out of the Hospital in Patients Admitted With COVID-19: A Randomized Clinical Trial. *JAMA*, 325(3), 254–264. <https://doi.org/10.1001/jama.2020.25864>

Loudon, K., Treweek, S., Sullivan, F., Donnan, P., Thorpe, K. E., & Zwarenstein, M. (2015). The PRECIS-2 tool: Designing trials that are fit for purpose. *BMJ*, 350, h2147. <https://doi.org/10.1136/bmj.h2147>

Lufkin, B., Lo, A.-C., Shangguan, S., Ngaiza, M., Wernecke, M., Choradia, N., Feinberg, L., Nelson, L., Simard, J., & Goodman, S. (2021). Master Protocol: Assessment of Risk of Safety Outcomes Following COVID-19 Vaccination. 28.

Lund, J. L., Richardson, D. B., & Stürmer, T. (2015). The Active Comparator, New User Study Design in Pharmacoepidemiology: Historical Foundations and Contemporary Application. *Current Epidemiology Reports*, 2(4), 221–228. <https://doi.org/10.1007/s40471-015-0053-5>

Maclure, M., Fireman, B., Nelson, J. C., Hua, W., Shoaibi, A., Paredes, A., & Madigan, D. (2012). When should case-only designs be used for safety monitoring of medical products? *Pharmacoepidemiology and Drug Safety*, 21(S1), 50–61. <https://doi.org/10.1002/pds.2330>

Matthews, A. A., Szummer, K., Dahabreh, I. J., Lindahl, B., Erlinge, D., Feychting, M., Jernberg, T., Berglund, A., & Hernán, M. A. (2021). Comparing Effect Estimates in Randomized Trials and Observational Studies From the Same Population: An Application to Percutaneous Coronary Intervention. *Journal of the American Heart Association*, 10(11), e020357. <https://doi.org/10.1161/JAHA.120.020357>

Mentz, R. J., Hernandez, A. F., Berdan, L. G., Rorick, T., O'Brien, E. C., Ibarra, J. C., Curtis, L. H., & Peterson, E. D. (2016). Good Clinical Practice Guidance and Pragmatic Clinical Trials. *Circulation*, 133(9), 872–880. <https://doi.org/10.1161/CIRCULATIONAHA.115.019902>

Miettinen, O. S. (1989). The clinical trial as a paradigm for epidemiologic research. *Journal of Clinical Epidemiology*, 42(6), 491–496. [https://doi.org/10.1016/0895-4356\(89\)90143-1](https://doi.org/10.1016/0895-4356(89)90143-1)

- Moore, N., Gulmez, S. E., Larrey, D., Pageaux, G.-P., Lignot, S., Lassalle, R., Jové, J., Pariente, A., Blin, P., Bénichou, J., & Bégaud, B. (2013). Choice of the denominator in case population studies: Event rates for registration for liver transplantation after exposure to NSAIDs in the SALT study in France. *Pharmacoepidemiology and Drug Safety*, 22(2), 160–167. <https://doi.org/10.1002/pds.3371>
- Peach, E. J., Pearce, F. A., Gibson, J., Cooper, A. J., Chen, L.-C., & Knaggs, R. D. (2021). Opioids and the Risk of Fracture: A Self-Controlled Case Series Study in the Clinical Practice Research Datalink. *American Journal of Epidemiology*, 190(7), 1324–1331. <https://doi.org/10.1093/aje/kwab042>
- Petersen, I., Douglas, I., & Whitaker, H. (2016). Self controlled case series methods: An alternative to standard epidemiological study designs. *BMJ*, 354, i4515. <https://doi.org/10.1136/bmj.i4515>
- PRINCIPLE Trial. <https://www.principletrial.org>
- Rao, S. V., Hess, C. N., Barham, B., Aberle, L. H., Anstrom, K. J., Patel, T. B., Jorgensen, J. P., Mazzaferri, E. L., Jolly, S. S., Jacobs, A., Newby, L. K., Gibson, C. M., Kong, D. F., Mehran, R., Waksman, R., Gilchrist, I. C., McCourt, B. J., Messenger, J. C., Peterson, E. D., ... Krucoff, M. W. (2014). A Registry-Based Randomized Trial Comparing Radial and Femoral Approaches in Women Undergoing Percutaneous Coronary Intervention: The SAFE-PCI for Women (Study of Access Site for Enhancement of PCI for Women) Trial. *JACC: Cardiovascular Interventions*, 7(8), 857–867. <https://doi.org/10.1016/j.jcin.2014.04.007>
- Rassen, J. A., & Schneeweiss, S. (2012). Newly marketed medications present unique challenges for nonrandomized comparative effectiveness analyses. *Journal of Comparative Effectiveness Research*, 1(2), 109–111. <https://doi.org/10.2217/ceer.12.12>
- RECOVERY Trial. <https://www.recoverytrial.net/>
- Schneeweiss, S., Gagne, J. J., Glynn, R. J., Ruhl, M., & Rassen, J. A. (2011). Assessing the Comparative Effectiveness of Newly Marketed Medications: Methodological Challenges and Implications for Drug Development. *Clinical Pharmacology & Therapeutics*, 90(6), 777–790. <https://doi.org/10.1038/clpt.2011.235>
- Schneider, R., Reinau, D., Stoffel, S., Jick, S. s., Meier, C. r., & Spöndlin, J. (2021). Risk of skin cancer in new users of thiazides and thiazide-like diuretics: A cohort study using an active comparator group\*. *British Journal of Dermatology*, 185(2), 343–352. <https://doi.org/10.1111/bjd.19880>
- Schuemie, M. J., Hripcsak, G., Ryan, P. B., Madigan, D., & Suchard, M. A. (2016). Robust empirical calibration of p-values using observational data. *Statistics in Medicine*, 35(22), 3883–3888. <https://doi.org/10.1002/sim.6977>
- Schuemie, M. J., Hripcsak, G., Ryan, P. B., Madigan, D., & Suchard, M. A. (2018). Empirical confidence interval calibration for population-level effect estimation studies in observational healthcare data. *Proceedings of the National Academy of Sciences*, 115(11), 2571–2577. <https://doi.org/10.1073/pnas.1708282114>
- Schuemie, M. J., Ryan, P. B., DuMouchel, W., Suchard, M. A., & Madigan, D. (2014). Interpreting observational studies: Why empirical calibration is needed to correct p-values. *Statistics in Medicine*, 33(2), 209–218. <https://doi.org/10.1002/sim.5925>
- SELF-CONTROLLED CASE SERIES STUDIES. SELF-CONTROLLED CASE SERIES STUDIES. <http://sccs-studies.info/>
- Staa, T.-P. van, Goldacre, B., Gulliford, M., Cassell, J., Pirmohamed, M., Taweel, A., Delaney, B., & Smeeth, L. (2012). Pragmatic randomised trials using routine electronic health records: Putting them to the test. *BMJ*, 344, e55. <https://doi.org/10.1136/bmj.e55>

- Sterne, J. A., Hernán, M. A., Reeves, B. C., Savović, J., Berkman, N. D., Viswanathan, M., Henry, D., Altman, D. G., Ansari, M. T., Boutron, I., Carpenter, J. R., Chan, A.-W., Churchill, R., Deeks, J. J., Hróbjartsson, A., Kirkham, J., Jüni, P., Loke, Y. K., Pigott, T. D., ... Higgins, J. P. (2016). ROBINS-I: A tool for assessing risk of bias in non-randomised studies of interventions. *BMJ*, 355, i4919. <https://doi.org/10.1136/bmj.i4919>
- Strom, B. L., Eng, S. M., Faich, G., Reynolds, R. F., D'Agostino, R. B., Ruskin, J., & Kane, J. M. (2011). Comparative Mortality Associated With Ziprasidone and Olanzapine in Real-World Use Among 18,154 Patients With Schizophrenia: The Ziprasidone Observational Study of Cardiac Outcomes (ZODIAC). *American Journal of Psychiatry*, 168(2), 193–201. <https://doi.org/10.1176/appi.ajp.2010.08040484>
- Suchard, M. A., Zorych, I., Simpson, S. E., Schuemie, M. J., Ryan, P. B., & Madigan, D. (2013). Empirical Performance of the Self-Controlled Case Series Design: Lessons for Developing a Risk Identification and Analysis System. *Drug Safety*, 36(1), 83–93. <https://doi.org/10.1007/s40264-013-0100-4>
- Théophile, H., Laporte, J.-R., Moore, N., Martin, K.-L., & Bégaud, B. (2011). The Case-Population Study Design. *Drug Safety*, 34(10), 861–868. <https://doi.org/10.2165/11592140-000000000-00000>
- Théophile, H., Moore, N., Robinson, P., Bégaud, B., & Pariente, A. (2016). Vaccine Case–Population: A New Method for Vaccine Safety Surveillance. *Drug Safety*, 39(12), 1197–1209. <https://doi.org/10.1007/s40264-016-0449-2>
- Thorpe, K. E., Zwarenstein, M., Oxman, A. D., Treweek, S., Furberg, C. D., Altman, D. G., Tunis, S., Bergel, E., Harvey, I., Magid, D. J., & Chalkidou, K. (2009). A pragmatic–explanatory continuum indicator summary (PRECIS): A tool to help trial designers. *CMAJ*, 180(10), E47–E57. <https://doi.org/10.1503/cmaj.090523>
- Thurin, N. H., Lassalle, R., Schuemie, M., Pénichon, M., Gagne, J. J., Rassen, J. A., Benichou, J., Weill, A., Blin, P., Moore, N., & Droz-Perroteau, C. (2021). Empirical assessment of case-based methods for identification of drugs associated with acute liver injury in the French National Healthcare System database (SNDS). *Pharmacoepidemiology and Drug Safety*, 30(3), 320–333. <https://doi.org/10.1002/pds.5161>
- van Staa, T.-P., Dyson, L., McCann, G., Padmanabhan, S., Belatri, R., Goldacre, B., Cassell, J., Pirmohamed, M., Torgerson, D., Ronaldson, S., Adamson, J., Taweel, A., Delaney, B., Mahmood, S., Baracaia, S., Round, T., Fox, R., Hunter, T., Gulliford, M., & Smeeth, L. (2014). The opportunities and challenges of pragmatic point-of-care randomised trials using routinely collected electronic records: Evaluations of two exemplar trials. *Health Technology Assessment*, 18(43), 1–146. <https://doi.org/10.3310/hta18430>
- Weldeslassie, Y. G., Whitaker, H. J., & Farrington, C. P. (2011). Use of the self-controlled case-series method in vaccine safety studies: Review and recommendations for best practice. *Epidemiology & Infection*, 139(12), 1805–1817. <https://doi.org/10.1017/S0950268811001531>
- Whitaker, H. J., Paddy Farrington, C., Spiessens, B., & Musonda, P. (2006). Tutorial in biostatistics: The self-controlled case series method. *Statistics in Medicine*, 25(10), 1768–1797. <https://doi.org/10.1002/sim.2302>
- Wing, C., Simon, K., & Bello-Gomez, R. A. (2018). Designing Difference in Difference Studies: Best Practices for Public Health Policy Research. *Annual Review of Public Health*, 39(1), 453–469. <https://doi.org/10.1146/annurev-publhealth-040617-013507>

Yoshida, K., Solomon, D. H., & Kim, S. C. (2015). Active-comparator design and new-user design in observational studies. *Nature Reviews Rheumatology*, 11(7), 437–441.

<https://doi.org/10.1038/nrrheum.2015.30>

Yu, L.-M., Bafadhel, M., Dorward, J., Hayward, G., Saville, B. R., Gbinigie, O., Van Hecke, O., Ogburn, E., Evans, P. H., Thomas, N. P. B., Patel, M. G., Richards, D., Berry, N., Detry, M. A., Saunders, C., Fitzgerald, M., Harris, V., Shanyinde, M., de Lusignan, S., ... Butler, C. C. (2021). Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): A randomised, controlled, open-label, adaptive platform trial. *The Lancet*, 398(10303), 843–855.

[https://doi.org/10.1016/S0140-6736\(21\)01744-X](https://doi.org/10.1016/S0140-6736(21)01744-X)

Zuidgeest, M. G. P., Goetz, I., Groenwold, R. H. H., Irving, E., van Thiel, G. J. M. W., & Grobbee, D. E. (2017). Series: Pragmatic trials and real world evidence: Paper 1. Introduction. *Journal of Clinical Epidemiology*, 88, 7–13.

<https://doi.org/10.1016/j.jclinepi.2016.12.023>

Zwarenstein, M., Treweek, S., Gagnier, J. J., Altman, D. G., Tunis, S., Haynes, B., Oxman, A. D., & Moher, D. (2008). Improving the reporting of pragmatic trials: An extension of the CONSORT statement. *BMJ*, 337, a2390.

<https://doi.org/10.1136/bmj.a2390>

## 5. Methods to address bias and confounding

### 5.1. Bias

Arana, A., Pottegård, A., Kuiper, J. G., Booth, H., Reutfors, J., Calingaert, B., Lund, L. C., Crellin, E., Schmitt-Egenolf, M., Kaye, J. A., Gembert, K., Rothman, K. J., Kieler, H., Dedman, D., Houben, E., Gutiérrez, L., Hallas, J., & Perez-Gutthann, S. (2021). Long-Term Risk of Skin Cancer and Lymphoma in Users of Topical Tacrolimus and Pimecrolimus: Final Results from the Extension of the Cohort Study Protopic Joint European Longitudinal Lymphoma and Skin Cancer Evaluation (JOELLE). *Clinical Epidemiology*, 13, 1141–1153.

<https://doi.org/10.2147/CLEP.S331287>

Coughlin, S. S. (1990). Recall bias in epidemiologic studies. *Journal of Clinical Epidemiology*, 43(1), 87–91.

[https://doi.org/10.1016/0895-4356\(90\)90060-3](https://doi.org/10.1016/0895-4356(90)90060-3)

Gagne, J. J. (2017). New-user designs with conditional propensity scores: A unified complement to the traditional active comparator new-user approach. *Pharmacoepidemiology and Drug Safety*, 26(4), 469–471.

<https://doi.org/10.1002/pds.4189>

Gerhard, T. (2008). Bias: Considerations for research practice. *American Journal of Health-System Pharmacy*, 65(22), 2159–2168.

<https://doi.org/10.2146/ajhp070369>

Griffith, G. J., Morris, T. T., Tudball, M. J., Herbert, A., Mancano, G., Pike, L., Sharp, G. C., Sterne, J., Palmer, T. M., Davey Smith, G., Tilling, K., Zuccolo, L., Davies, N. M., & Hemani, G. (2020). Collider bias undermines our understanding of COVID-19 disease risk and severity. *Nature Communications*, 11, 5749.

<https://doi.org/10.1038/s41467-020-19478-2>

Haut, E. R., & Pronovost, P. J. (2011). Surveillance Bias in Outcomes Reporting. *JAMA*, 305(23), 2462–2463.

<https://doi.org/10.1001/jama.2011.822>

Horwitz, R. I., & Feinstein, A. R. (1978). Alternative Analytic Methods for Case-Control Studies of Estrogens and Endometrial Cancer. *New England Journal of Medicine*, 299(20), 1089–1094.

<https://doi.org/10.1056/NEJM197811162992001>

Kiri, V. A., & MacKenzie, G. (2009). RE: "IMMORTAL TIME BIAS IN PHARMACOEPIDEMIOLOGY".

*American Journal of Epidemiology*, 170(5), 667–668. <https://doi.org/10.1093/aje/kwp239>

- Lévesque, L. E., Hanley, J. A., Kezouh, A., & Suissa, S. (2010). Problem of immortal time bias in cohort studies: Example using statins for preventing progression of diabetes. *BMJ*, 340, b5087. <https://doi.org/10.1136/bmj.b5087>
- Lewis, M. (1999). The transnational study on oral contraceptives and the health of young women. Methods, results, new analyses and the healthy user effect. *Human Reproduction Update*, 5(6), 707–720. <https://doi.org/10.1093/humupd/5.6.707>
- Lund, J. L., Richardson, D. B., & Stürmer, T. (2015). The Active Comparator, New User Study Design in Pharmacoepidemiology: Historical Foundations and Contemporary Application. *Current Epidemiology Reports*, 2(4), 221–228. <https://doi.org/10.1007/s40471-015-0053-5>
- Menni, C., Klaser, K., May, A., Polidori, L., Capdevila, J., Louca, P., Sudre, C. H., Nguyen, L. H., Drew, D. A., Merino, J., Hu, C., Selvachandran, S., Antonelli, M., Murray, B., Canas, L. S., Molteni, E., Graham, M. S., Modat, M., Joshi, A. D., ... Spector, T. D. (2021). Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: A prospective observational study. *The Lancet Infectious Diseases*, 21(7), 939–949. [https://doi.org/10.1016/S1473-3099\(21\)00224-3](https://doi.org/10.1016/S1473-3099(21)00224-3)
- Ray, W. A. (2003). Evaluating Medication Effects Outside of Clinical Trials: New-User Designs. *American Journal of Epidemiology*, 158(9), 915–920. <https://doi.org/10.1093/aje/kwg231>
- Renoux, C., Azoulay, L., & Suissa, S. (2021a). Biases in Evaluating the Safety and Effectiveness of Drugs for the Treatment of COVID-19: Designing Real-World Evidence Studies. *American Journal of Epidemiology*, 190(8), 1452–1456. <https://doi.org/10.1093/aje/kwab028>
- Salas, M., Hotman, A., & Stricker, B. H. (1999). Confounding by Indication: An Example of Variation in the Use of Epidemiologic Terminology. *American Journal of Epidemiology*, 149(11), 981–983. <https://doi.org/10.1093/oxfordjournals.aje.a009758>
- Sharma, M., Nazareth, I., & Petersen, I. (2018). Observational studies of treatment effectiveness: Worthwhile or worthless? *Clinical Epidemiology*, 11, 35–42. <https://doi.org/10.2147/CLEP.S178723>
- Shrank, W. H., Patrick, A. R., & Brookhart, M. A. (2011). Healthy user and related biases in observational studies of preventive interventions: A primer for physicians. *Journal of General Internal Medicine*, 26(5), 546–550. <https://doi.org/10.1007/s11606-010-1609-1>
- Suissa, S. (2007). Immortal time bias in observational studies of drug effects. *Pharmacoepidemiology and Drug Safety*, 16(3), 241–249. <https://doi.org/10.1002/pds.1357>
- Suissa, S. (2008a). Immortal Time Bias in Pharmacoepidemiology. *American Journal of Epidemiology*, 167(4), 492–499. <https://doi.org/10.1093/aje/kwm324>
- Suissa, S. (2008b). Immeasurable Time Bias in Observational Studies of Drug Effects on Mortality. *American Journal of Epidemiology*, 168(3), 329–335. <https://doi.org/10.1093/aje/kwn135>
- Suissa, S., & Azoulay, L. (2012). Metformin and the Risk of Cancer: Time-related biases in observational studies. *Diabetes Care*, 35(12), 2665–2673. <https://doi.org/10.2337/dc12-0788>
- Suissa, S., & Dell’Aniello, S. (2020). Time-related biases in pharmacoepidemiology. *Pharmacoepidemiology and Drug Safety*, 29(9), 1101–1110. <https://doi.org/10.1002/pds.5083>
- Suissa, S., Moodie, E. E. M., & Dell’Aniello, S. (2017). Prevalent new-user cohort designs for comparative drug effect studies by time-conditional propensity scores. *Pharmacoepidemiology and Drug Safety*, 26(4), 459–468. <https://doi.org/10.1002/pds.4107>

Zhou, Z., Rahme, E., Abrahamowicz, M., & Pilote, L. (2005). Survival Bias Associated with Time-to-Treatment Initiation in Drug Effectiveness Evaluation: A Comparison of Methods. *American Journal of Epidemiology*, 162(10), 1016–1023. <https://doi.org/10.1093/aje/kwi307>

## **5.2. Confounding**

Ali, M. S., Groenwold, R. H. H., Belitser, S. V., Pestman, W. R., Hoes, A. W., Roes, K. C. B., Boer, A. de, & Klungel, O. H. (2015). Reporting of covariate selection and balance assessment in propensity score analysis is suboptimal: A systematic review. *Journal of Clinical Epidemiology*, 68(2), 122–131. <https://doi.org/10.1016/j.jclinepi.2014.08.011>

Ali, M. S., Groenwold, R. H. H., Pestman, W. R., Belitser, S. V., Roes, K. C. B., Hoes, A. W., de Boer, A., & Klungel, O. H. (2014). Propensity score balance measures in pharmacoepidemiology: A simulation study. *Pharmacoepidemiology and Drug Safety*, 23(8), 802–811. <https://doi.org/10.1002/pds.3574>

Arbogast, P. G., & Ray, W. A. (2009). Use of disease risk scores in pharmacoepidemiologic studies. *Statistical Methods in Medical Research*, 18(1), 67–80. <https://doi.org/10.1177/0962280208092347>

Austin, P. C. (2011a). A Tutorial and Case Study in Propensity Score Analysis: An Application to Estimating the Effect of In-Hospital Smoking Cessation Counseling on Mortality. *Multivariate Behavioral Research*, 46(1), 119–151. <https://doi.org/10.1080/00273171.2011.540480>

Austin, P. C. (2011b). An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies. *Multivariate Behavioral Research*, 46(3), 399–424. <https://doi.org/10.1080/00273171.2011.568786>

Austin, P. C., & Stuart, E. A. (2015). Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. *Statistics in Medicine*, 34(28), 3661–3679. <https://doi.org/10.1002/sim.6607>

Baiocchi, M., Cheng, J., & Small, D. S. (2014). Instrumental variable methods for causal inference. *Statistics in Medicine*, 33(13), 2297–2340. <https://doi.org/10.1002/sim.6128>

Belitser, S. V., Martens, E. P., Pestman, W. R., Groenwold, R. H. H., de Boer, A., & Klungel, O. H. (2011). Measuring balance and model selection in propensity score methods. *Pharmacoepidemiology and Drug Safety*, 20(11), 1115–1129. <https://doi.org/10.1002/pds.2188>

Brookhart, M. A., Rassen, J. A., & Schneeweiss, S. (2010). Instrumental variable methods in comparative safety and effectiveness research. *Pharmacoepidemiology and Drug Safety*, 19(6), 537–554. <https://doi.org/10.1002/pds.1908>

Brookhart, M. A., Schneeweiss, S., Rothman, K. J., Glynn, R. J., Avorn, J., & Stürmer, T. (2006). Variable Selection for Propensity Score Models. *American Journal of Epidemiology*, 163(12), 1149–1156. <https://doi.org/10.1093/aje/kwj149>

Brookhart, M. A., Wang, P. S., Solomon, D. H., & Schneeweiss, S. (2006). Evaluating Short-Term Drug Effects Using a Physician-Specific Prescribing Preference as an Instrumental Variable. *Epidemiology*, 17(3), 268–275. <https://doi.org/10.1097/01.ede.0000193606.58671.c5>

Cole, S. R., Hernán, M. A., Robins, J. M., Anastos, K., Chmiel, J., Detels, R., Ervin, C., Feldman, J., Greenblatt, R., Kingsley, L., Lai, S., Young, M., Cohen, M., & Muñoz, A. (2003). Effect of Highly Active Antiretroviral Therapy on Time to Acquired Immunodeficiency Syndrome or Death using Marginal Structural Models. *American Journal of Epidemiology*, 158(7), 687–694. <https://doi.org/10.1093/aje/kwg206>



Daniel, R. m., Cousens, S. n., De Stavola, B. l., Kenward, M. G., & Sterne, J. a. C. (2013). Methods for dealing with time-dependent confounding. *Statistics in Medicine*, 32(9), 1584–1618.

<https://doi.org/10.1002/sim.5686>

Desai, R. J., Rothman, K. J., Bateman, B. T., Hernandez-Diaz, S., & Huybrechts, K. F. (2017). A Propensity-score-based Fine Stratification Approach for Confounding Adjustment When Exposure Is Infrequent. *Epidemiology*, 28(2), 249–257. <https://doi.org/10.1097/EDE.0000000000000595>

DrugEpi Software Tools. BWH Division of Pharmacoepidemiology and Pharmacoeconomics Department of Medicine. <https://www.drugEpi.org/dope/software#Sensitivity>

Fewell, Z., Davey Smith, G., & Sterne, J. A. C. (2007). The Impact of Residual and Unmeasured Confounding in Epidemiologic Studies: A Simulation Study. *American Journal of Epidemiology*, 166(6), 646–655. <https://doi.org/10.1093/aje/kwm165>

Franklin, J. M., Rassen, J. A., Ackermann, D., Bartels, D. B., & Schneeweiss, S. (2014). Metrics for covariate balance in cohort studies of causal effects. *Statistics in Medicine*, 33(10), 1685–1699.

<https://doi.org/10.1002/sim.6058>

Garabedian, L. F., Chu, P., Toh, S., Zaslavsky, A. M., & Soumerai, S. B. (2014). Potential Bias of Instrumental Variable Analyses for Observational Comparative Effectiveness Research. *Annals of Internal Medicine*, 161(2), 131–138. <https://doi.org/10.7326/M13-1887>

Glynn, R. J., Gagne, J. J., & Schneeweiss, S. (2012). Role of disease risk scores in comparative effectiveness research with emerging therapies. *Pharmacoepidemiology and Drug Safety*, 21(S2), 138–147. <https://doi.org/10.1002/pds.3231>

Greenland, S. (2000). An introduction to instrumental variables for epidemiologists. *International Journal of Epidemiology*, 29(4), 722–729. <https://doi.org/10.1093/ije/29.4.722>

Grobbée, D. E., & Hoes, A. W. (1997). Confounding and indication for treatment in evaluation of drug treatment for hypertension. *BMJ*, 315(7116), 1151–1154. <https://doi.org/10.1136/bmj.315.7116.1151>

Groenwold, R. H. H., de Vries, F., de Boer, A., Pestman, W. R., Rutten, F. H., Hoes, A. W., & Klungel, O. H. (2011). Balance measures for propensity score methods: A clinical example on beta-agonist use and the risk of myocardial infarction. *Pharmacoepidemiology and Drug Safety*, 20(11), 1130–1137.

<https://doi.org/10.1002/pds.2251>

Hernán, M. Á., Brumback, B., & Robins, J. M. (2000). Marginal Structural Models to Estimate the Causal Effect of Zidovudine on the Survival of HIV-Positive Men. *Epidemiology*, 11(5), 561–570.

Ji, X., Small, D. S., Leonard, C. E., & Hennessy, S. (2017). The Trend-in-trend Research Design for Causal Inference. *Epidemiology*, 28(4), 529–536. <https://doi.org/10.1097/EDE.0000000000000579>

Joffe, M. M., & Rosenbaum, P. R. (1999). Invited Commentary: Propensity Scores. *American Journal of Epidemiology*, 150(4), 327–333. <https://doi.org/10.1093/oxfordjournals.aje.a010011>

Karim, M. E., Petkau, J., Gustafson, P., Platt, R. W., & Tremlett, H. (2018). Comparison of statistical approaches dealing with time-dependent confounding in drug effectiveness studies. *Statistical Methods in Medical Research*, 27(6), 1709–1722. <https://doi.org/10.1177/0962280216668554>

Klungel, O. H., Martens, E. P., Psaty, B. M., Grobbée, D. E., Sullivan, S. D., Stricker, B. H. Ch., Leufkens, H. G. M., & de Boer, A. (2004). Methods to assess intended effects of drug treatment in observational studies are reviewed. *Journal of Clinical Epidemiology*, 57(12), 1223–1231.

<https://doi.org/10.1016/j.jclinepi.2004.03.011>

- Martens, E. P., Pestman, W. R., de Boer, A., Belitser, S. V., & Klungel, O. H. (2006). Instrumental Variables: Application and Limitations. *Epidemiology*, 17(3), 260–267. <https://doi.org/10.1097/01.ede.0000215160.88317.cb>
- McMahon, A. D. (2003). Approaches to combat with confounding by indication in observational studies of intended drug effects. *Pharmacoepidemiology and Drug Safety*, 12(7), 551–558. <https://doi.org/10.1002/pds.883>
- MIETTINEN, O. S. (1976). STRATIFICATION BY A MULTIVARIATE CONFOUNDER SCORE. *American Journal of Epidemiology*, 104(6), 609–620. <https://doi.org/10.1093/oxfordjournals.aje.a112339>
- Moodie, E. E. M., & Stephens, D. A. (2010). Using Directed Acyclic Graphs to detect limitations of traditional regression in longitudinal studies. *International Journal of Public Health*, 55(6), 701–703. <https://doi.org/10.1007/s00038-010-0184-x>
- Rassen, J. A., Glynn, R. J., Brookhart, M. A., & Schneeweiss, S. (2011). Covariate Selection in High-Dimensional Propensity Score Analyses of Treatment Effects in Small Samples. *American Journal of Epidemiology*, 173(12), 1404–1413. <https://doi.org/10.1093/aje/kwr001>
- Rassen, J. A., & Schneeweiss, S. (2012). Using high-dimensional propensity scores to automate confounding control in a distributed medical product safety surveillance system. *Pharmacoepidemiology and Drug Safety*, 21(S1), 41–49. <https://doi.org/10.1002/pds.2328>
- Rassen, J. A., Shelat, A. A., Franklin, J. M., Glynn, R. J., Solomon, D. H., & Schneeweiss, S. (2013). Matching by Propensity Score in Cohort Studies with Three Treatment Groups. *Epidemiology*, 24(3), 401–409. <https://doi.org/10.1097/EDE.0b013e318289dedf>
- Rassen, J. A., Shelat, A. A., Myers, J., Glynn, R. J., Rothman, K. J., & Schneeweiss, S. (2012). One-to-many propensity score matching in cohort studies. *Pharmacoepidemiology and Drug Safety*, 21(S2), 69–80. <https://doi.org/10.1002/pds.3263>
- Robins, J. M., Hernán, M. Á., & Brumback, B. (2000). Marginal Structural Models and Causal Inference in Epidemiology. *Epidemiology*, 11(5), 550–560.
- Salas, M., Hotman, A., & Stricker, B. H. (1999). Confounding by Indication: An Example of Variation in the Use of Epidemiologic Terminology. *American Journal of Epidemiology*, 149(11), 981–983. <https://doi.org/10.1093/oxfordjournals.aje.a009758>
- Sanni Ali, M., Groenwold, R. H. H., Pestman, W. R., Belitser, S. V., Hoes, A. W., de Boer, A., & Klungel, O. H. (2013). Time-dependent propensity score and collider-stratification bias: An example of beta2-agonist use and the risk of coronary heart disease. *European Journal of Epidemiology*, 28(4), 291–299. <https://doi.org/10.1007/s10654-013-9766-2>
- Schmidt, A. F., Klungel, O. H., Groenwold, R. H. H., & Consortium, on behalf of the G. (2016). Adjusting for Confounding in Early Postlaunch Settings: Going Beyond Logistic Regression Models. *Epidemiology*, 27(1), 133–142. <https://doi.org/10.1097/EDE.0000000000000388>
- Schneeweiss, S. (2006). Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeutics. *Pharmacoepidemiology and Drug Safety*, 15(5), 291–303. <https://doi.org/10.1002/pds.1200>
- Schneeweiss, S. (2018). Automated data-adaptive analytics for electronic healthcare data to study causal treatment effects. *Clinical Epidemiology*, 10, 771–788. <https://doi.org/10.2147/CLLEP.S166545>

- Schneeweiss, S., Rassen, J. A., Glynn, R. J., Avorn, J., Mogun, H., & Brookhart, M. A. (2009). High-dimensional Propensity Score Adjustment in Studies of Treatment Effects Using Health Care Claims Data. *Epidemiology*, 20(4), 512–522. <https://doi.org/10.1097/EDE.0b013e3181a663cc>
- Simpson, C. R., Shi, T., Vasileiou, E., Katikireddi, S. V., Kerr, S., Moore, E., McCowan, C., Agrawal, U., Shah, S. A., Ritchie, L. D., Murray, J., Pan, J., Bradley, D. T., Stock, S. J., Wood, R., Chuter, A., Beggs, J., Stagg, H. R., Joy, M., ... Sheikh, A. (2021). First-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland. *Nature Medicine*, 27(7), 1290–1297. <https://doi.org/10.1038/s41591-021-01408-4>
- Stürmer, T., Rothman, K. J., Avorn, J., & Glynn, R. J. (2010). Treatment Effects in the Presence of Unmeasured Confounding: Dealing With Observations in the Tails of the Propensity Score Distribution—A Simulation Study. *American Journal of Epidemiology*, 172(7), 843–854. <https://doi.org/10.1093/aje/kwq198>
- Stürmer, T., Schneeweiss, S., Rothman, K. J., Avorn, J., & Glynn, R. J. (2007). Performance of Propensity Score Calibration—A Simulation Study. *American Journal of Epidemiology*, 165(10), 1110–1118. <https://doi.org/10.1093/aje/kwm074>
- Swanson, S. A., Robins, J. M., Miller, M., & Hernán, M. A. (2015). Selecting on Treatment: A Pervasive Form of Bias in Instrumental Variable Analyses. *American Journal of Epidemiology*, 181(3), 191–197. <https://doi.org/10.1093/aje/kwu284>
- Tadrous, M., Gagne, J. J., Stürmer, T., & Cadarette, S. M. (2013). Disease risk score as a confounder summary method: Systematic review and recommendations. *Pharmacoepidemiology and Drug Safety*, 22(2), 122–129. <https://doi.org/10.1002/pds.3377>
- Tannen, R. L., Weiner, M. G., & Xie, D. (2008). Replicated studies of two randomized trials of angiotensin- converting enzyme inhibitors: Further empiric validation of the 'prior event rate ratio' to adjust for unmeasured confounding by indication. *Pharmacoepidemiology and Drug Safety*, 17(7), 671–685. <https://doi.org/10.1002/pds.1584>
- Toh, S., García Rodríguez, L. A., & Hernán, M. A. (2011). Confounding adjustment via a semi-automated high-dimensional propensity score algorithm: An application to electronic medical records. *Pharmacoepidemiology and Drug Safety*, 20(8), 849–857. <https://doi.org/10.1002/pds.2152>
- Uddin, M. J., Groenwold, R. H. H., van Staa, T. P., de Boer, A., Belitser, S. V., Hoes, A. W., Roes, K. C. B., & Klungel, O. H. (2015). Performance of prior event rate ratio adjustment method in pharmacoepidemiology: A simulation study. *Pharmacoepidemiology and Drug Safety*, 24(5), 468–477. <https://doi.org/10.1002/pds.3724>
- Uddin, Md. J., Groenwold, R. H. H., de Boer, A., Afonso, A. S. M., Primatesta, P., Becker, C., Belitser, S. V., Hoes, A. W., Roes, K. C. B., & Klungel, O. H. (2016). Evaluating different physician's prescribing preference based instrumental variables in two primary care databases: A study of inhaled long-acting beta2-agonist use and the risk of myocardial infarction. *Pharmacoepidemiology and Drug Safety*, 25(S1), 132–141. <https://doi.org/10.1002/pds.3860>
- Uddin, Md. J., Groenwold, R. H. H., de Boer, A., Belitser, S. V., Roes, K. C. B., Hoes, A. W., & Klungel, O. H. (2014). Performance of instrumental variable methods in cohort and nested case-control studies: A simulation study. *Pharmacoepidemiology and Drug Safety*, 23(2), 165–177. <https://doi.org/10.1002/pds.3555>
- Williamson, E., Morley, R., Lucas, A., & Carpenter, J. (2012). Propensity scores: From naïve enthusiasm to intuitive understanding. *Statistical Methods in Medical Research*, 21(3), 273–293. <https://doi.org/10.1177/0962280210394483>

Witteaman, J. C. M., D'Agostino, R. B., Stijnen, T., Kannel, W. B., Cobb, J. C., de Ridder, M. A. J., Hofman, A., & Robins, J. M. (1998). G-estimation of Causal Effects: Isolated Systolic Hypertension and Cardiovascular Death in the Framingham Heart Study. *American Journal of Epidemiology*, 148(4), 390–401. <https://doi.org/10.1093/oxfordjournals.aje.a009658>

Wyss, R., Girman, C. J., LoCasale, R. J., Alan Brookhart, M., & Stürmer, T. (2013). Variable selection for propensity score models when estimating treatment effects on multiple outcomes: A simulation study. *Pharmacoepidemiology and Drug Safety*, 22(1), 77–85. <https://doi.org/10.1002/pds.3356>

### **5.3. Missing data**

Buuren, S. van, & Groothuis-Oudshoorn, K. (2011). mice: Multivariate Imputation by Chained Equations in R. *Journal of Statistical Software*, 45, 1–67. <https://doi.org/10.18637/jss.v045.i03>

Gail, M., & Benichou, J. (2009). *Encyclopedia of Epidemiologic Methods*. Wiley.

Jones, M. P. (1996). Indicator and Stratification Methods for Missing Explanatory Variables in Multiple Linear Regression. *Journal of the American Statistical Association*, 91(433), 222–230. <https://doi.org/10.1080/01621459.1996.10476680>

Lash, T., VanderWeele, T., Haneuse, S., & Rothman, K. (2020). *Modern Epidemiology* (4th ed.). Wolters Kluwer.

Lee, K. J., Tilling, K. M., Cornish, R. P., Little, R. J. A., Bell, M. L., Goetghebeur, E., Hogan, J. W., & Carpenter, J. R. (2021). Framework for the treatment and reporting of missing data in observational studies: The Treatment And Reporting of Missing data in Observational Studies framework. *Journal of Clinical Epidemiology*, 134, 79–88. <https://doi.org/10.1016/j.jclinepi.2021.01.008>

Little, R., & Rubin, D. (2019). *Statistical analysis with missing data* (3rd ed.). Wiley.

Moons, K. G. M., Donders, R. A. R. T., Stijnen, T., & Harrell, F. E. (2006). Using the outcome for imputation of missing predictor values was preferred. *Journal of Clinical Epidemiology*, 59(10), 1092–1101. <https://doi.org/10.1016/j.jclinepi.2006.01.009>

Royston, P. (2004). Multiple Imputation of Missing Values. *The Stata Journal*, 4(3), 227–241. <https://doi.org/10.1177/1536867X0400400301>

Rubin, D. (2004). *Multiple Imputation for Nonresponse in Surveys*. Wiley.

Schafer, J. (1997). *Analysis of Incomplete Multivariate Data*. Chapman & Hall/CRC.

The MI Procedure—SAS.

[https://documentation.sas.com/api/docsets/statug/15.2/content/mi.pdf?locale=en#nameddest=statug\\_mi\\_toc](https://documentation.sas.com/api/docsets/statug/15.2/content/mi.pdf?locale=en#nameddest=statug_mi_toc)

Tompsett, D. M., Leacy, F., Moreno-Betancur, M., Heron, J., & White, I. R. (2018). On the use of the not-at-random fully conditional specification (NARFCS) procedure in practice. *Statistics in Medicine*, 37(15), 2338–2353. <https://doi.org/10.1002/sim.7643>

Van Buuren, S. (2018). *Flexible Imputation of Missing Data* (2nd ed.). Chapman and Hall/CRC. <https://stefvanbuuren.name/fimdl/>

Welch, C. A., Petersen, I., Bartlett, J. W., White, I. R., Marston, L., Morris, R. W., Nazareth, I., Walters, K., & Carpenter, J. (2014). Evaluation of two-fold fully conditional specification multiple imputation for longitudinal electronic health record data. *Statistics in Medicine*, 33(21), 3725–3737. <https://doi.org/10.1002/sim.6184>

#### **5.4. Triangulation**

Lawlor, D. A., Tilling, K., & Davey Smith, G. (2016). Triangulation in aetiological epidemiology. *International Journal of Epidemiology*, 45(6), 1866–1886. <https://doi.org/10.1093/ije/dyw314>

Nagashima, T., Hayakawa, T., Akimoto, H., Minagawa, K., Takahashi, Y., & Asai, S. Identifying Antidepressants Less Likely to Cause Hyponatremia: Triangulation of Retrospective Cohort, Disproportionality, and Pharmacodynamic Studies. *Clinical Pharmacology & Therapeutics*. <https://doi.org/10.1002/cpt.2573>

Sujan, A. C., Rickert, M. E., Öberg, A. S., Quinn, P. D., Hernández-Díaz, S., Almqvist, C., Lichtenstein, P., Larsson, H., & D'Onofrio, B. M. (2017). Associations of Maternal Antidepressant Use During the First Trimester of Pregnancy With Preterm Birth, Small for Gestational Age, Autism Spectrum Disorder, and Attention-Deficit/Hyperactivity Disorder in Offspring. *JAMA*, 317(15), 1553–1562. <https://doi.org/10.1001/jama.2017.3413>

Winterstein, A. G., & Antonelli, P. J. (2022). Triangulation of pharmacoepidemiology and laboratory science to tackle otic quinolone safety. *Basic & Clinical Pharmacology & Toxicology*, 130(S1), 75–80. <https://doi.org/10.1111/bcpt.13668>

#### **6. Effect measure modification and interaction**

Altman, D. G., & Bland, J. M. (2003). Interaction revisited: The difference between two estimates. *BMJ*, 326(7382), 219. <https://doi.org/10.1136/bmj.326.7382.219>

Chandan, J. S., Zemedikun, D. T., Thayakaran, R., Byne, N., Dhalla, S., Acosta-Mena, D., Gokhale, K. M., Thomas, T., Sainsbury, C., Subramanian, A., Cooper, J., Anand, A., Okoth, K. O., Wang, J., Adderley, N. J., Taverner, T., Denniston, A. K., Lord, J., Thomas, G. N., ... Haroon, S. (2021). Nonsteroidal Antiinflammatory Drugs and Susceptibility to COVID-19. *Arthritis & Rheumatology*, 73(5), 731–739. <https://doi.org/10.1002/art.41593>

Cohen, J. B., D'Agostino McGowan, L., Jensen, E. T., Rigdon, J., & South, A. M. (2021). Evaluating sources of bias in observational studies of angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker use during COVID-19: Beyond confounding. *Journal of Hypertension*, 39(4), 795–805. <https://doi.org/10.1097/HJH.0000000000002706>

Corraini, P., Olsen, M., Pedersen, L., Dekkers, O. M., & Vandenbroucke, J. P. (2017). Effect modification, interaction and mediation: An overview of theoretical insights for clinical investigators. *Clinical Epidemiology*, 9, 331–338. <https://doi.org/10.2147/CLEP.S129728>

Hosmer, D. W., & Lemeshow, S. (1992). Confidence Interval Estimation of Interaction. *Epidemiology*, 3(5), 452–456. <https://doi.org/10.1097/00001648-199209000-00012>

Karmakar, B., Heller, R., & Small, D. S. (2018). False discovery rate control for effect modification in observational studies. *Electronic Journal of Statistics*, 12(2), 3232–3253. <https://doi.org/10.1214/18-EJS1476>

Knol, M. J., & VanderWeele, T. J. (2012). Recommendations for presenting analyses of effect modification and interaction. *International Journal of Epidemiology*, 41(2), 514–520. <https://doi.org/10.1093/ije/dyr218>

Knol, M. J., VanderWeele, T. J., Groenwold, R. H. H., Klungel, O. H., Rovers, M. M., & Grobbee, D. E. (2011). Estimating measures of interaction on an additive scale for preventive exposures. *European Journal of Epidemiology*, 26(6), 433–438. <https://doi.org/10.1007/s10654-011-9554-9>

Langan, S. M., Schmidt, S. A., Wing, K., Ehrenstein, V., Nicholls, S. G., Fillion, K. B., Klungel, O., Petersen, I., Sorensen, H. T., Dixon, W. G., Guttman, A., Harron, K., Hemkens, L. G., Moher, D., Schneeweiss, S., Smeeth, L., Sturkenboom, M., Elm, E. von, Wang, S. V., & Benchimol, E. I. (2018). The reporting of studies conducted using observational routinely collected health data statement for pharmacoepidemiology (RECORD-PE). *BMJ*, 363, k3532. <https://doi.org/10.1136/bmj.k3532>

Lash, T., VanderWeele, T., Haneuse, S., & Rothman, K. (2020). *Modern Epidemiology* (4th ed.). Wolters Kluwer.

Moher, D., Hopewell, S., Schulz, K. F., Montori, V., Gøtzsche, P. C., Devereaux, P. J., Elbourne, D., Egger, M., & Altman, D. G. (2010). CONSORT 2010 Explanation and Elaboration: Updated guidelines for reporting parallel group randomised trials. *Journal of Clinical Epidemiology*, 63(8), e1–e37. <https://doi.org/10.1016/j.jclinepi.2010.03.004>

Schmidt, A. F., Groenwold, R. H. H., Knol, M. J., Hoes, A. W., Nielen, M., Roes, K. C. B., de Boer, A., & Klungel, O. H. (2014). Exploring interaction effects in small samples increases rates of false-positive and false-negative findings: Results from a systematic review and simulation study. *Journal of Clinical Epidemiology*, 67(7), 821–829. <https://doi.org/10.1016/j.jclinepi.2014.02.008>

Spiegelman, D., & VanderWeele, T. J. (2017). Evaluating Public Health Interventions: 6. Modeling Ratios or Differences? Let the Data Tell Us. *American Journal of Public Health*, 107(7), 1087–1091. <https://doi.org/10.2105/AJPH.2017.303810>

Strengthening the Reporting of Observational Studies in Epidemiology: Epidemiology.

[https://journals.lww.com/epidem/Fulltext/2007/11000/Strengthening\\_the\\_Reporting\\_of\\_Observational\\_28.aspx](https://journals.lww.com/epidem/Fulltext/2007/11000/Strengthening_the_Reporting_of_Observational_28.aspx)

Tharmarajah, E., Buazon, A., Patel, V., Hannah, J. R., Adas, M., Allen, V. B., Bechman, K., Clarke, B. D., Nagra, D., Norton, S., Russell, M. D., Rutherford, A. I., Yates, M., & Galloway, J. B. (2021). IL-6 inhibition in the treatment of COVID-19: A meta-analysis and meta-regression. *Journal of Infection*, 82(5), 178–185. <https://doi.org/10.1016/j.jinf.2021.03.008>

Vandenbroucke, J. P., von Elm, E., Altman, D. G., Gøtzsche, P. C., Mulrow, C. D., Pocock, S. J., Poole, C., Schlesselman, J. J., Egger, M., & Initiative, for the S. (2007). Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): Explanation and Elaboration. *Epidemiology*, 18(6), 805–835. <https://doi.org/10.1097/EDE.0b013e3181577511>

Yola, M., & Lucien, A. (1994). Evidence of the depletion of susceptibles effect in non-experimental pharmacoepidemiologic research. *Journal of Clinical Epidemiology*, 47(7), 731–737. [https://doi.org/10.1016/0895-4356\(94\)90170-8](https://doi.org/10.1016/0895-4356(94)90170-8)

## **7. Approaches to data collection**

### **7.1. Primary data collection**

AAPOR - andard Definitions—Final Dispositions of Case Codes and Outcome Rates for Surveys. (2016). *THE AMERICAN ASSOCIATION FOR PUBLIC OPINION RESEARCH*, 81.

Abenhaim, L., Moride, Y., Brenot, F., Rich, S., Benichou, J., Kurz, X., Higenbottam, T., Oakley, C., Wouters, E., Aubier, M., Simonneau, G., & Bégaud, B. (1996). Appetite-Suppressant Drugs and the Risk of Primary Pulmonary Hypertension. *New England Journal of Medicine*, 335(9), 609–616. <https://doi.org/10.1056/NEJM199608293350901>

- Artime, E., Qizilbash, N., Garrido-Esteba, M., Vora, P., Soriano-Gabarró, M., Asimwe, A., & Pocock, S. (2019a). Are risk minimization measures for approved drugs in Europe effective? A systematic review. *Expert Opinion on Drug Safety*, 18(5), 443–454. <https://doi.org/10.1080/14740338.2019.1612875>
- Artime, E., Qizilbash, N., Herruzo, R., & Garrido-Esteba, M. (2020). Risk Minimisation Evaluation with Process Indicators and Behavioural or Health Outcomes in Europe: Systematic Review. *Pharmaceutical Medicine*, 34(6), 387–400. <https://doi.org/10.1007/s40290-020-00361-w>
- Check, J., & Schutt, R. (2011). *Research Methods in Education*. Sage Publications.
- Clinical Trial Regulation (EU) 536/2014. (2014). European Commission. <http://data.europa.eu/eli/reg/2014/536/oj/eng>
- Draft Volume 10—Guidance documents applying to clinical trials. [https://www.ejprarediseases.org/wp-content/uploads/2021/10/Regulation5362014\\_ga\\_en\\_V4\\_2021.pdf](https://www.ejprarediseases.org/wp-content/uploads/2021/10/Regulation5362014_ga_en_V4_2021.pdf)
- Fayers, P. M., & Machin, D. (2016). *The book Quality of Life: The assessment, analysis and interpretation of patient-related outcomes* (3rd ed.). Wiley.
- FDA/CDER, L. M. (2019). *REMS Assessment: Planning and Reporting Guidance for Industry*. 26. <https://www.fda.gov/media/119790/download>
- Fischer, F., & Kleen, S. (2021). Possibilities, Problems, and Perspectives of Data Collection by Mobile Apps in Longitudinal Epidemiological Studies: Scoping Review. *Journal of Medical Internet Research*, 23(1), e17691. <https://doi.org/10.2196/17691>
- Good pharmacovigilance practices. European Medicines Agency. <https://www.ema.europa.eu/en/human-regulatory/post-authorisation/pharmacovigilance/good-pharmacovigilance-practices>
- Groves, R. M., Fowler, F. J., & Couper, M. P. (2009). *Survey Methodology* (2nd ed.). Wiley.
- ICH E6 (R2) Good clinical practice. European Medicines Agency. <https://www.ema.europa.eu/en/ich-e6-r2-good-clinical-practice>
- Kaufman, D. W., Rosenberg, L., & Mitchell, A. A. (2001). Signal generation and clarification: Use of case-control data. *Pharmacoepidemiology and Drug Safety*, 10(3), 197–203. <https://doi.org/10.1002/pds.571>
- Kish, L. (1995). *Survey Sampling*. Wiley.
- Menni, C., May, A., Polidori, L., Louca, P., Wolf, J., Capdevila, J., Hu, C., Ourselin, S., Steves, C. J., Valdes, A. M., & Spector, T. D. (2022). COVID-19 vaccine waning and effectiveness and side-effects of boosters: A prospective community study from the ZOE COVID Study. *The Lancet. Infectious Diseases*, S1473-3099(22)00146-3. [https://doi.org/10.1016/S1473-3099\(22\)00146-3](https://doi.org/10.1016/S1473-3099(22)00146-3)
- Roujeau, J.-C., Kelly, J. P., Naldi, L., Rzany, B., Stern, R. S., Anderson, T., Auquier, A., Bastuji-Garin, S., Correia, O., Locati, F., Mockenhaupt, M., Paoletti, C., Shapiro, S., Shear, N., Schöpf, E., & Kaufman, D. W. (1995). Medication Use and the Risk of Stevens–Johnson Syndrome or Toxic Epidermal Necrolysis. *New England Journal of Medicine*, 333(24), 1600–1608. <https://doi.org/10.1056/NEJM199512143332404>
- Shapiro, S. (1983). The design of a study of the drug etiology of agranulocytosis and aplastic anemia. *European Journal of Clinical Pharmacology*, 24(6), 833–836. <https://doi.org/10.1007/BF00607096>

Smith, M. Y., Russell, A., Bahri, P., Mol, P. G. M., Frise, S., Freeman, E., & Morrato, E. H. (2018). The RIMES Statement: A Checklist to Assess the Quality of Studies Evaluating Risk Minimization Programs for Medicinal Products. *Drug Safety*, 41(4), 389–401. <https://doi.org/10.1007/s40264-017-0619-x>

*Survey Methodologies to Assess REMS Goals That Relate to Knowledge*. (2020a, May 5). U.S. Food and Drug Administration; FDA. <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/survey-methodologies-assess-rems-goals-relate-knowledge>

## **7.2. Secondary use of data**

Arlett, P., Kjær, J., Broich, K., & Cooke, E. (2022). Real-World Evidence in EU Medicines Regulation: Enabling Use and Establishing Value. *Clinical Pharmacology & Therapeutics*, 111(1), 21–23. <https://doi.org/10.1002/cpt.2479>

Berger, M. L., Sox, H., Willke, R. J., Brixner, D. L., Eichler, H.-G., Goettsch, W., Madigan, D., Makady, A., Schneeweiss, S., Tarricone, R., Wang, S. V., Watkins, J., & Mullins, C. D. (2017). Good Practices for Real-World Data Studies of Treatment and/or Comparative Effectiveness: Recommendations from the Joint ISPOR-ISPE Special Task Force on Real-World Evidence in Health Care Decision Making. *Value in Health*, 20(8), 1003–1008. <https://doi.org/10.1016/j.jval.2017.08.3019>

Cave, A., Kurz, X., & Arlett, P. (2019). Real-World Data for Regulatory Decision Making: Challenges and Possible Solutions for Europe. *Clinical Pharmacology & Therapeutics*, 106(1), 36–39. <https://doi.org/10.1002/cpt.1426>

ENCePP Resources Database. <https://www.encepp.eu/encepp/resourcesDatabase.jsp>

Gatto, N. M., Campbell, U. B., Rubinstein, E., Jaksa, A., Mattox, P., Mo, J., & Reynolds, R. F. (2022). The Structured Process to Identify Fit-For-Purpose Data: A Data Feasibility Assessment Framework. *Clinical Pharmacology and Therapeutics*, 111(1), 122–134. <https://doi.org/10.1002/cpt.2466>

Gini, R., Sturkenboom, M. C. J., Sultana, J., Cave, A., Landi, A., Pacurariu, A., Roberto, G., Schink, T., Candore, G., Slattery, J., Trifirò, G., & the Working Group 3 of ENCePP (Inventory of EU data sources and methodological approaches for multisource studies). (2020). Different Strategies to Execute Multi-Database Studies for Medicines Surveillance in Real-World Setting: A Reflection on the European Model. *Clinical Pharmacology & Therapeutics*, 108(2), 228–235. <https://doi.org/10.1002/cpt.1833>

Guidelines for Good Pharmacoepidemiology Practices (GPP)—International Society for Pharmacoepidemiology. ISPE. <https://www.pharmacoepi.org/resources/policies/guidelines-08027/>

List of metadata for Real World Data catalogues. European Medicines Agency. [https://www.ema.europa.eu/en/documents/other/list-metadata-real-world-data-catalogues\\_en.pdf](https://www.ema.europa.eu/en/documents/other/list-metadata-real-world-data-catalogues_en.pdf)

MHRA guidance on the use of real-world data in clinical studies to support regulatory decisions. <https://www.gov.uk/government/publications/mhra-guidance-on-the-use-of-real-world-data-in-clinical-studies-to-support-regulatory-decisions>

Research, C. for D. E. and. (2020). Best Practices for Conducting and Reporting Pharmacoepidemiologic Safety Studies Using Electronic Healthcare Data Sets. US Food and Drug Administration (FDA). <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/best-practices-conducting-and-reporting-pharmacoepidemiologic-safety-studies-using-electronic>

Research, C. for D. E. and. (2021a). Considerations for the Use of Real-World Data and Real-World Evidence To Support Regulatory Decision-Making for Drug and Biological Products. US Food and Drug Administration (FDA). <https://www.fda.gov/regulatory-information/search-fda-guidance->



[documents/considerations-use-real-world-data-and-real-world-evidence-support-regulatory-decision-making-drug](#)

Research, C. for D. E. and. (2021b). Real-World Data: Assessing Electronic Health Records and Medical Claims Data To Support Regulatory Decision-Making for Drug and Biological Products. US Food and Drug Administration (FDA). <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/real-world-data-assessing-electronic-health-records-and-medical-claims-data-support-regulatory>

Schneeweiss, S., & Avorn, J. (2005). A review of uses of health care utilization databases for epidemiologic research on therapeutics. *Journal of Clinical Epidemiology*, 58(4), 323–337. <https://doi.org/10.1016/j.jclinepi.2004.10.012>

### **7.3. Patient registries**

CHMP Guideline on Conduct of Pharmacovigilance for Medicines Used by the Paediatric Population—EMA [https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-conduct-pharmacovigilance-medicines-used-paediatric-population\\_en.pdf](https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-conduct-pharmacovigilance-medicines-used-paediatric-population_en.pdf)

Draft Guideline on good pharmacovigilance practices. Product- or Population-Specific Considerations III – Pregnancy prevention programme and other pregnancy-specific risk minimisation measures – European Medicines Agency. [https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/draft-guideline-good-pharmacovigilance-practices-gvp-module-xvi-addendum-iii-pregnancy-prevention\\_en.pdf](https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/draft-guideline-good-pharmacovigilance-practices-gvp-module-xvi-addendum-iii-pregnancy-prevention_en.pdf)

EHDEN data partners listing. EHDEN. Ehdn.Eu. <https://www.ehdn.eu/datapartners/>

EMIF Catalogue. EMIF Catalogue. <https://emif-catalogue.eu/login>

Emilsson, L., Lindahl, B., Köster, M., Lambe, M., & Ludvigsson, J. F. (2015). Review of 103 Swedish Healthcare Quality Registries. *Journal of Internal Medicine*, 277(1), 94–136. <https://doi.org/10.1111/joim.12303>

ENCePP Resources Database. ENCePP. <https://www.encepp.eu/encepp/resourcesDatabase.jsp>

EUnetHTA Joint Action 3. EUnetHTA. <https://www.eunethta.eu/ja3-archive/>

EU-RD set of common data elements for rare diseases registration. [https://eu-rd-platform.jrc.ec.europa.eu/sites/default/files/CDS/EU\\_RD\\_Platform\\_CDS\\_Final.pdf](https://eu-rd-platform.jrc.ec.europa.eu/sites/default/files/CDS/EU_RD_Platform_CDS_Final.pdf)

EUROCAT. European Commission. <https://eu-rd-platform.jrc.ec.europa.eu>

European Platform on Rare Disease Registration (EU RD Platform). (n.d.-a). <https://eu-rd-platform.jrc.ec.europa.eu>

European Platform on Rare Disease Registration (EU RD Platform). <https://eu-rd-platform.jrc.ec.europa.eu>

Flynn, R., Plueschke, K., Quinten, C., Strassmann, V., Duijnhoven, R. G., Gordillo-Marañón, M., Rueckbeil, M., Cohet, C., & Kurz, X. (2022). Marketing Authorization Applications Made to the European Medicines Agency in 2018–2019: What was the Contribution of Real-World Evidence? *Clinical Pharmacology & Therapeutics*, 111(1), 90–97. <https://doi.org/10.1002/cpt.2461>

Furu, K., Kieler, H., Haglund, B., Engeland, A., Selmer, R., Stephansson, O., Valdimarsdóttir, U. A., Zoega, H., Artama, M., Gissler, M., Malm, H., & Nørgaard, M. (2015). Selective serotonin reuptake inhibitors and venlafaxine in early pregnancy and risk of birth defects: Population based cohort study and sibling design. *BMJ*, 350, h1798. <https://doi.org/10.1136/bmj.h1798>

Guideline on registry-based studies. (2021). European Medicines Agency.

[https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-registry-based-studies\\_en-0.pdf](https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-registry-based-studies_en-0.pdf)

Informatics, O. H. D. S. and. The Book of OHDSI. <https://ohdsi.github.io/TheBookOfOhdsi/>

Karanatsios, B., Prang, K.-H., Verbunt, E., Yeung, J. M., Kelaher, M., & Gibbs, P. (2020). Defining key design elements of registry-based randomised controlled trials: A scoping review. *Trials*, 21(1), 552. <https://doi.org/10.1186/s13063-020-04459-z>

Lauer, M. S., & D'Agostino, R. B. (2013). The Randomized Registry Trial—The Next Disruptive Technology in Clinical Research? *New England Journal of Medicine*, 369(17), 1579–1581. <https://doi.org/10.1056/NEJMp1310102>

Li, G., Sajobi, T. T., Menon, B. K., Korngut, L., Lowerison, M., James, M., Wilton, S. B., Williamson, T., Gill, S., Drogos, L. L., Smith, E. E., Vohra, S., Hill, M. D., & Thabane, L. (2016). Registry-based randomized controlled trials- what are the advantages, challenges, and areas for future research? *Journal of Clinical Epidemiology*, 80, 16–24. <https://doi.org/10.1016/j.jclinepi.2016.08.003>

McGettigan, P., Alonso Olmo, C., Plueschke, K., Castillon, M., Noguera Zondag, D., Bahri, P., Kurz, X., & Mol, P. G. M. (2019). Patient Registries: An Underused Resource for Medicines Evaluation. *Drug Safety*, 42(11), 1343–1351. <https://doi.org/10.1007/s40264-019-00848-9>

Norwegian Patient Registry—Norsk pasientregister (NPR). Helsedirektoratet.

<https://www.helsedirektoratet.no/tema/statistikk-registre-og-rapporter/helsedata-og-helseregistre/norsk-pasientregister-npr>

OHSDI - Our Journey. <https://www.ohdsi.org/wp-content/uploads/2021/09/OHSDI-OurJourney2021-Final.pdf>

Pacurariu, A., Plueschke, K., Olmo, C. A., & Kurz, X. (2018). Imposed registries within the European postmarketing surveillance system: Extended analysis and lessons learned for regulators. *Pharmacoepidemiology and Drug Safety*, 27(7), 823–826. <https://doi.org/10.1002/pds.4449>

Patient registries. European Medicines Agency. <https://www.ema.europa.eu/en/human-regulatory/post-authorisation/patient-registries>

PRINTO - Pharmachild. PRINTO - Paediatric Rheumatology International Trials Organization. <https://www.printo.it/projects/ongoing/15>

Qualification opinion on Cellular therapy module of the European Society for Blood & Marrow Transplantation (EBMT) Registry. European Medicines Agency. [https://www.ema.europa.eu/en/documents/scientific-guideline/qualification-opinion-cellular-therapy-module-european-society-blood-marrow-transplantation-ebmt\\_en.pdf](https://www.ema.europa.eu/en/documents/scientific-guideline/qualification-opinion-cellular-therapy-module-european-society-blood-marrow-transplantation-ebmt_en.pdf)

Qualification opinion—The European Cystic Fibrosis Society Patient Registry (ECFSRP). (2017). European Medicines Agency. [https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/qualification-opinion-european-cystic-fibrosis-society-patient-registry-ecfspr\\_en.pdf](https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/qualification-opinion-european-cystic-fibrosis-society-patient-registry-ecfspr_en.pdf)

Registries for Evaluating Patient Outcomes: A User's Guide: 4th Edition | Effective Health Care (EHC) Program. (2020). AHRQ. <https://effectivehealthcare.ahrq.gov/products/registries-guide-4th-edition/users-guide>

REQueST Tool and its vision paper—EUnetHTA. (2019, October 10). EUnetHTA. <https://www.eunetha.eu/request-tool-and-its-vision-paper/>

Research, C. for D. E. and. (2020, May 15). Postapproval Pregnancy Safety Studies Guidance for Industry. U.S. Food and Drug Administration; FDA. <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/postapproval-pregnancy-safety-studies-guidance-industry>

Research, C. for D. E. and. (2021, November 29). Real-World Data: Assessing Registries to Support Regulatory Decision-Making for Drug and Biological Products Guidance for Industry. U.S. Food and Drug Administration; FDA. <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/real-world-data-assessing-registries-support-regulatory-decision-making-drug-and-biological-products>

Schmidt, M., Schmidt, S. A. J., Sandegaard, J. L., Ehrenstein, V., Pedersen, L., & Sørensen, H. T. (2015). The Danish National Patient Registry: A review of content, data quality, and research potential. *Clinical Epidemiology*, 7, 449–490. <https://doi.org/10.2147/CLEP.S91125>

Scientific guidance on post-authorisation efficacy studies—EMA. (2016). European Medicines Agency. [https://www.ema.europa.eu/en/documents/scientific-guideline/scientific-guidance-post-authorisation-efficacy-studies-first-version\\_en.pdf](https://www.ema.europa.eu/en/documents/scientific-guideline/scientific-guidance-post-authorisation-efficacy-studies-first-version_en.pdf)

Swedish National Patient Register. Socialstyrelsen. <https://www.socialstyrelsen.se/en/statistics-and-data/registers/national-patient-register/>

Systematic overview of data sources for drug safety in pregnancy research. (2016). ENCePP. [https://www.encepp.eu/structure/documents/Data\\_sources\\_for\\_medicines\\_in\\_pregnancy\\_research.pdf](https://www.encepp.eu/structure/documents/Data_sources_for_medicines_in_pregnancy_research.pdf)

UK Renal Registry | The UK Kidney Association. UK Kidney Association. <https://ukkidney.org/about-us/who-we-are/uk-renal-registry>

#### **7.4. Spontaneous reports**

Al Dweik, R., Stacey, D., Kohen, D., & Yaya, S. (2017). Factors affecting patient reporting of adverse drug reactions: A systematic review. *British Journal of Clinical Pharmacology*, 83(4), 875–883. <https://doi.org/10.1111/bcp.13159>

Alvarez, Y., Hidalgo, A., Maignen, F., & Slattery, J. (2010). Validation of Statistical Signal Detection Procedures in EudraVigilance Post-Authorization Data. *Drug Safety*, 33(6), 475–487. <https://doi.org/10.2165/11534410-000000000-00000>

Aronson, J. K., & Hauben, M. (2006). Anecdotes that provide definitive evidence. *BMJ*, 333(7581), 1267–1269. <https://doi.org/10.1136/bmj.39036.666389.94>

Banovac, M., Candore, G., Slattery, J., Houyez, F., Haerry, D., Genov, G., & Arlett, P. (2017). Patient Reporting in the EU: Analysis of EudraVigilance Data. *Drug Safety*, 40(7), 629–645. <https://doi.org/10.1007/s40264-017-0534-1>

Bate, A., Lindquist, M., & Edwards, I. r. (2008). The application of knowledge discovery in databases to post-marketing drug safety: Example of the WHO database. *Fundamental & Clinical Pharmacology*, 22(2), 127–140. <https://doi.org/10.1111/j.1472-8206.2007.00552.x>

Centre, U. M. VigiBase. Uppsala Monitoring Centre. <https://who-umc.org/vigibase/>

Detailed guide regarding the EudraVigilance data management activities by the European Medicines Agency Rev 1. [https://www.ema.europa.eu/en/documents/other/detailed-guide-regarding-eudravigilance-data-management-activities-european-medicines-agency\\_en.pdf](https://www.ema.europa.eu/en/documents/other/detailed-guide-regarding-eudravigilance-data-management-activities-european-medicines-agency_en.pdf)

EudraVigilance. (2018, September 17). European Medicines Agency. <https://www.ema.europa.eu/en/human-regulatory/research-development/pharmacovigilance/eudravigilance>

ICPE 2012 Abstracts. (2012). *Pharmacoepidemiology and Drug Safety*, 21(s3), 1–481. <https://doi.org/10.1002/pds.3324>

Inácio, P., Cavaco, A., & Airaksinen, M. (2017). The value of patient reporting to the pharmacovigilance system: A systematic review. *British Journal of Clinical Pharmacology*, 83(2), 227–246. <https://doi.org/10.1111/bcp.13098>

Kreimeyer, K., Menschik, D., Winiiecki, S., Paul, W., Barash, F., Woo, E. J., Alimchandani, M., Arya, D., Zinderman, C., Forshee, R., & Botsis, T. (2017). Using Probabilistic Record Linkage of Structured and Unstructured Data to Identify Duplicate Cases in Spontaneous Adverse Event Reporting Systems. *Drug Safety*, 40(7), 571–582. <https://doi.org/10.1007/s40264-017-0523-4>

Pacurariu, A. C., Coloma, P. M., van Haren, A., Genov, G., Sturkenboom, M. C. J. M., & Straus, S. M. J. M. (2014). A Description of Signals During the First 18 Months of the EMA Pharmacovigilance Risk Assessment Committee. *Drug Safety*, 37(12), 1059–1066. <https://doi.org/10.1007/s40264-014-0240-1>

Postigo, R., Brosch, S., Slattery, J., van Haren, A., Dogné, J.-M., Kurz, X., Candore, G., Domergue, F., & Arlett, P. (2018). EudraVigilance Medicines Safety Database: Publicly Accessible Data for Research and Public Health Protection. *Drug Safety*, 41(7), 665–675. <https://doi.org/10.1007/s40264-018-0647-1>

Practical Aspects of Signal Detection in Pharmacovigilance: Report of CIOMS Working Group VIII • COUNCIL FOR INTERNATIONAL ORGANIZATIONS OF MEDICAL SCIENCES. (2010). CIOMS. <https://cioms.ch/publications/product/practical-aspects-of-signal-detection-in-pharmacovigilance-report-of-cioms-working-group-viii/>

Research, C. for B. E. and. (2021). VAERS Overview. FDA. <https://www.fda.gov/vaccines-blood-biologics/vaccine-adverse-events/vaers-overview>

Research, C. for D. E. and. (2019, May 22). Questions and Answers on FDA’s Adverse Event Reporting System (FAERS). FDA. <https://www.fda.gov/drugs/surveillance/questions-and-answers-fdas-adverse-event-reporting-system-faers>

Tregunno, P. M., Fink, D. B., Fernandez-Fernandez, C., Lázaro-Bengoa, E., & Norén, G. N. (2014). Performance of Probabilistic Method to Detect Duplicate Individual Case Safety Reports. *Drug Safety*, 37(4), 249–258. <https://doi.org/10.1007/s40264-014-0146-y>

## **7.5. Social media**

Audeh, B., Bellet, F., Beyens, M.-N., Lillo-Le Louët, A., & Bousquet, C. (2020). Use of Social Media for Pharmacovigilance Activities: Key Findings and Recommendations from the Vigi4Med Project. *Drug Safety*, 43(9), 835–851. <https://doi.org/10.1007/s40264-020-00951-2>

Bahri, P. (Ed.). (2020). *Communicating about Risks and Safe Use of Medicines: Real Life and Applied Research*. Springer. <https://doi.org/10.1007/978-981-15-3013-5>

Banerjee, A. K., & Ingate, S. (2012). Web-Based Patient-Reported Outcomes in Drug Safety and Risk Management. *Drug Safety*, 35(6), 437–446. <https://doi.org/10.2165/11632390-000000000-00000>

Bhattacharya, M., Snyder, S., Malin, M., Truffa, M. M., Marinic, S., Engelmann, R., & Raheja, R. R. (2017). Using Social Media Data in Routine Pharmacovigilance: A Pilot Study to Identify Safety Signals and Patient Perspectives. *Pharmaceutical Medicine*, 31(3), 167–174. <https://doi.org/10.1007/s40290-017-0186-6>

- Brosch, S., de Ferran, A.-M., Newbould, V., Farkas, D., Lengsavath, M., & Tregunno, P. (2019). Establishing a Framework for the Use of Social Media in Pharmacovigilance in Europe. *Drug Safety*, 42(8), 921–930. <https://doi.org/10.1007/s40264-019-00811-8>
- Caster, O., Dietrich, J., Kürzinger, M.-L., Lerch, M., Maskell, S., Norén, G. N., Tcherny-Lessenot, S., Vroman, B., Wisniewski, A., & van Stekelenborg, J. (2018). Assessment of the Utility of Social Media for Broad-Ranging Statistical Signal Detection in Pharmacovigilance: Results from the WEB-RADR Project. *Drug Safety*, 41(12), 1355–1369. <https://doi.org/10.1007/s40264-018-0699-2>
- Cocos, A., Fiks, A. G., & Masino, A. J. (2017). Deep learning for pharmacovigilance: Recurrent neural network architectures for labeling adverse drug reactions in Twitter posts. *Journal of the American Medical Informatics Association*, 24(4), 813–821. <https://doi.org/10.1093/jamia/ocw180>
- Coloma, P. M., Becker, B., Sturkenboom, M. C. J. M., van Mulligen, E. M., & Kors, J. A. (2015). Evaluating Social Media Networks in Medicines Safety Surveillance: Two Case Studies. *Drug Safety*, 38(10), 921–930. <https://doi.org/10.1007/s40264-015-0333-5>
- Dasgupta, N., Winokur, C., & Pierce, C. (2020). Social Media Research. In P. Bahri (Ed.), *Communicating about Risks and Safe Use of Medicines: Real Life and Applied Research* (pp. 307–332). Springer. [https://doi.org/10.1007/978-981-15-3013-5\\_11](https://doi.org/10.1007/978-981-15-3013-5_11)
- EMA. (2018, September 17). Good pharmacovigilance practices. European Medicines Agency. <https://www.ema.europa.eu/en/human-regulatory/post-authorisation/pharmacovigilance/good-pharmacovigilance-practices>
- ENISA. <https://www.enisa.europa.eu>
- European Commission’s Digital Single Market Glossary. Shaping Europe’s Digital Future - European Commission. <https://wayback.archive-it.org/12090/20210302044434/https://ec.europa.eu/digital-single-market/en/glossary>
- Gattepaille, L. M., Hedfors Vidlin, S., Bergvall, T., Pierce, C. E., & Ellenius, J. (2020). Prospective Evaluation of Adverse Event Recognition Systems in Twitter: Results from the Web-RADR Project. *Drug Safety*, 43(8), 797–808. <https://doi.org/10.1007/s40264-020-00942-3>
- General Data Protection Regulation (GDPR) Compliance Guidelines. GDPR.Eu. <https://gdpr.eu/>
- Martin, S., Kilich, E., Dada, S., Kummervold, P. E., Denny, C., Paterson, P., & Larson, H. J. (2020). “Vaccines for pregnant women...?! Absurd” – Mapping maternal vaccination discourse and stance on social media over six months. *Vaccine*, 38(42), 6627–6637. <https://doi.org/10.1016/j.vaccine.2020.07.072>
- Opinion 1/2015 Mobile Health-Reconciling technological innovation with data protection—EDPS. [https://edps.europa.eu/sites/edp/files/publication/15-05-21\\_mhealth\\_en\\_0.pdf](https://edps.europa.eu/sites/edp/files/publication/15-05-21_mhealth_en_0.pdf)
- Powell, G. E., Seifert, H. A., Reblin, T., Burstein, P. J., Blowers, J., Menius, J. A., Painter, J. L., Thomas, M., Pierce, C. E., Rodriguez, H. W., Brownstein, J. S., Freifeld, C. C., Bell, H. G., & Dasgupta, N. (2016). Social Media Listening for Routine Post-Marketing Safety Surveillance. *Drug Safety*, 39(5), 443–454. <https://doi.org/10.1007/s40264-015-0385-6>
- Sloane, R., Osanlou, O., Lewis, D., Bollegala, D., Maskell, S., & Pirmohamed, M. (2015). Social media and pharmacovigilance: A review of the opportunities and challenges. *British Journal of Clinical Pharmacology*, 80(4), 910–920. <https://doi.org/10.1111/bcp.12717>
- Smartphone Secure Development Guidelines. [Report/Study]. ENISA. <https://www.enisa.europa.eu/publications/smartphone-secure-development-guidelines-2016>

van Stekelenborg, J., Ellenius, J., Maskell, S., Bergvall, T., Caster, O., Dasgupta, N., Dietrich, J., Gama, S., Lewis, D., Newbould, V., Brosch, S., Pierce, C. E., Powell, G., Ptasińska-Neophytou, A., Wiśniewski, A. F. Z., Tregunno, P., Norén, G. N., & Pirmohamed, M. (2019). Recommendations for the Use of Social Media in Pharmacovigilance: Lessons from IMI WEB-RADR. *Drug Safety*, 42(12), 1393–1407. <https://doi.org/10.1007/s40264-019-00858-7>

## 8. Research networks for multi-database studies

Association of angiotensin converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARB) on coronavirus disease (COVID-19) incidence and complications. (2020).

<https://doi.org/10.1101/2020.06.11.20125849>

Background rates of Adverse Events of Special Interest for monitoring COVID-19 vaccines (2.0). (2020). <https://doi.org/10.5281/ZENODO.5255870>

Becker, B. F. H., Avillach, P., Romio, S., van Mulligen, E. M., Weibel, D., Sturkenboom, M. C. J. M., Kors, J. A., & Consortium, for the A. (2017). CodeMapper: Semiautomatic coding of case definitions. A contribution from the ADVANCE project. *Pharmacoepidemiology and Drug Safety*, 26(8), 998–1005.

<https://doi.org/10.1002/pds.4245>

Candore, G., Hedenmalm, K., Slattery, J., Cave, A., Kurz, X., & Arlett, P. (2020). Can We Rely on Results From IQVIA Medical Research Data UK Converted to the Observational Medical Outcome Partnership Common Data Model? *Clinical Pharmacology and Therapeutics*, 107(4), 915–925.

<https://doi.org/10.1002/cpt.1785>

CNODES. Canadian Network for Observational Drug Effects Studies. <https://www.cnodes.ca/>

ConcePTION. <https://www.imi-conception.eu/wp-content/uploads/2020/10/ConcePTION-D7.5-Report-on-existing-common-data-models-and-proposals-for-ConcePTION.pdf>

Data Analysis and Real World Interrogation Network (DARWIN EU). European Medicines Agency.

<https://www.ema.europa.eu/en/about-us/how-we-work/big-data/data-analysis-real-world-interrogation-network-darwin-eu>

Dedman, D., Cabecinha, M., Williams, R., Evans, S. J. W., Bhaskaran, K., & Douglas, I. J. (2020). Approaches for combining primary care electronic health record data from multiple sources: A systematic review of observational studies. *BMJ Open*, 10(10), e037405.

<https://doi.org/10.1136/bmjopen-2020-037405>

Description of international collaboration in the area of medicines use and effects in COVID-19 affected pregnancies (CONSIGN-International). (2021). <https://doi.org/10.5281/ZENODO.5211395>

EMIF. <http://www.emif.eu/>

ENCePP Resources Database. <https://www.encepp.eu/encepp/resourcesDatabase.jsp>

EU Health: European Health Data Space (EHDS). European Commission - European Commission.

[https://ec.europa.eu/commission/presscorner/detail/en/QANDA\\_22\\_2712](https://ec.europa.eu/commission/presscorner/detail/en/QANDA_22_2712)

European Health Data Evidence Network (EHDEN). Ehdn.Eu. <https://www.ehdn.eu/>

Exploring and understanding adverse drug reactions by integrative mining of clinical records and biomedical knowledge—EU-ADR Project, CORDIS, European Commission.

<https://cordis.europa.eu/project/id/215847>

Flynn, R., Hedenmalm, K., Murray-Thomas, T., Pacurariu, A., Arlett, P., Shepherd, H., Myles, P., & Kurz, X. (2020). Ability of Primary Care Health Databases to Assess Medicinal Products Discussed by the European Union Pharmacovigilance Risk Assessment Committee. *Clinical Pharmacology & Therapeutics*, 107(4), 957–965. <https://doi.org/10.1002/cpt.1775>

Gini, R., Schuemie, M., Brown, J., Ryan, P., Vacchi, E., Coppola, M., Cazzola, W., Coloma, P., Berni, R., Diallo, G., Oliveira, J., Avillach, P., Trifiro, G., Rijnbeek, P., Bellentani, M., Lei, J., Klazinga, N., & Sturkenboom, M. (2016). Data Extraction and Management in Networks of Observational Health Care Databases for Scientific Research: A Comparison of EU-ADR, OMOP, Mini-Sentinel and MATRICE Strategies. 4(1), 1189–1189. <https://doi.org/10.13063/2327-9214.1189>

Gini, R., Sturkenboom, M. C. J., Sultana, J., Cave, A., Landi, A., Pacurariu, A., Roberto, G., Schink, T., Candore, G., Slattery, J., Trifirò, G., & the Working Group 3 of ENCePP (Inventory of EU data sources and methodological approaches for multisource studies). (2020). Different Strategies to Execute Multi-Database Studies for Medicines Surveillance in Real-World Setting: A Reflection on the European Model. *Clinical Pharmacology & Therapeutics*, 108(2), 228–235. <https://doi.org/10.1002/cpt.1833>

Improving Consistency and Understanding of Discrepancies of Findings from Pharmacoepidemiological Studies: The IMI PROTECT Project. (2016). *Pharmacoepidemiology and Drug Safety*, 25(S1), 1–4. <https://doi.org/10.1002/pds.3987>

Innovative Medicines Initiative (IMI). IMI Innovative Medicines Initiative. <http://www.imi.europa.eu/>

Izem, R., Huang, T.-Y., Hou, L., Pestine, E., Nguyen, M., & Maro, J. C. (2020). Quantifying how small variations in design elements affect risk in an incident cohort study in claims. *Pharmacoepidemiology and Drug Safety*, 29(1), 84–93. <https://doi.org/10.1002/pds.4892>

Joint Action Towards the European Health Data Space – TEHDAS. Tehdas. <https://tehdas.eu/>

Klungel, O. H., Kurz, X., de Groot, M. C. H., Schlienger, R. G., Tcherny-Lessenot, S., Grimaldi, L., Ibáñez, L., Groenwold, R. H. H., & Reynolds, R. F. (2016). Multi-centre, multi-database studies with common protocols: Lessons learnt from the IMI PROTECT project. *Pharmacoepidemiology and Drug Safety*, 25(S1), 156–165. <https://doi.org/10.1002/pds.3968>

Kurz, X., Domergue, F., Slattery, J., Segec, A., Szmigiel, A., & Hidalgo-Simon, A. (2011). Safety monitoring of Influenza A/H1N1 pandemic vaccines in EudraVigilance. *Vaccine*, 29(26), 4378–4387. <https://doi.org/10.1016/j.vaccine.2011.04.005>

Lane, J. C. E., Weaver, J., Kostka, K., Duarte-Salles, T., Abrahao, M. T. F., Alghoul, H., Alser, O., Alshammari, T. M., Biedermann, P., Banda, J. M., Burn, E., Casajust, P., Conover, M. M., Culhane, A. C., Davydov, A., DuVall, S. L., Dymshyts, D., Fernandez-Bertolin, S., Fišter, K., ... Prieto-Alhambra, D. (2020). Risk of hydroxychloroquine alone and in combination with azithromycin in the treatment of rheumatoid arthritis: A multinational, retrospective study. *The Lancet Rheumatology*, 2(11), e698–e711. [https://doi.org/10.1016/S2665-9913\(20\)30276-9](https://doi.org/10.1016/S2665-9913(20)30276-9)

Monitoring of COVID-19 medicines. European Medicines Agency. <https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/treatments-vaccines/monitoring-covid-19-medicines-0>

OHDSI – Observational Health Data Sciences and Informatics. <https://www.ohdsi.org/>

OMOP Common Data Model – OHDSI. <https://www.ohdsi.org/data-standardization/the-common-data-model/>

Overhage, J. M., Ryan, P. B., Reich, C. G., Hartzema, A. G., & Stang, P. E. (2012). Validation of a common data model for active safety surveillance research. *Journal of the American Medical Informatics Association : JAMIA*, 19(1), 54–60. <https://doi.org/10.1136/amiajnl-2011-000376>

Petersen, I., McCrea, R. L., Sammon, C. J., Osborn, D. P., Evans, S. J., Cowen, P. J., Freemantle, N., & Nazareth, I. (2016). Risks and benefits of psychotropic medication in pregnancy: Cohort studies based on UK electronic primary care health records. *Health Technology Assessment*, 20(23), 1–176. <https://doi.org/10.3310/hta20230>

PROTECT. <http://www.imi-protect.eu/about.shtml>

Research, C. for D. E. and. (2019, October 18). FDA's Sentinel Initiative. US Food and Drug Administration (FDA). <https://www.fda.gov/safety/fdas-sentinel-initiative>

Rieke, N., Hancox, J., Li, W., Milletari, F., Roth, H. R., Albarqouni, S., Bakas, S., Galtier, M. N., Landman, B. A., Maier-Hein, K., Ourselin, S., Sheller, M., Summers, R. M., Trask, A., Xu, D., Baust, M., & Cardoso, M. J. (2020). The future of digital health with federated learning. *Npj Digital Medicine*, 3(1), 1–7. <https://doi.org/10.1038/s41746-020-00323-1>

Schuemie, M. J., Ryan, P. B., Pratt, N., Chen, R., You, S. C., Krumholz, H. M., Madigan, D., Hripcsak, G., & Suchard, M. A. (2020). Large-scale evidence generation and evaluation across a network of databases (LEGEND): Assessing validity using hypertension as a case study. *Journal of the American Medical Informatics Association*, 27(8), 1268–1277. <https://doi.org/10.1093/jamia/ocaa124>

Sketris, I. S., Carter, N., Traynor, R. L., Watts, D., Kelly, K., & On behalf of the following contributing members of the CNODES Knowledge Translation Team: Pierre Ernst, JM Gamble, Brenda Hemmelgarn, Colleen Metge, Michael Paterson, Robert Platt W. and Gary Teare. (2020). Building a framework for the evaluation of knowledge translation for the Canadian Network for Observational Drug Effect Studies. *Pharmacoepidemiology and Drug Safety*, 29(S1), 8–25. <https://doi.org/10.1002/pds.4738>

Slattery, J., & Kurz, X. (2020). Assessing strength of evidence for regulatory decision making in licensing: What proof do we need for observational studies of effectiveness? *Pharmacoepidemiology and Drug Safety*, 29(10), 1336–1340. <https://doi.org/10.1002/pds.5005>

Sultana, J., Giorgianni, F., Rea, F., Lucenteforte, E., Lombardi, N., Mugelli, A., Vannacci, A., Liperoti, R., Kirchmayer, U., Vitale, C., Chinellato, A., Roberto, G., Corrao, G., & Trifirò, G. (2019). All-cause mortality and antipsychotic use among elderly persons with high baseline cardiovascular and cerebrovascular risk: A multi-center retrospective cohort study in Italy. *Expert Opinion on Drug Metabolism & Toxicology*, 15(2), 179–188. <https://doi.org/10.1080/17425255.2019.1561860>

Systemic glucocorticoids in the treatment of COVID-19 and risks of adverse outcomes in COVID-19 patients in the primary and secondary care setting. (2020). ENCePP. <https://www.encepp.eu/encepp/viewResource.htm?id=39816>

vac4euorgdev. ADVANCE. VAC4EU. <https://vac4eu.org/>

vac4euorgdev. COVID-19 vaccine monitoring. VAC4EU. <https://vac4eu.org/covid-19-vaccine-monitoring/>

Vaccine Safety Datalink (VSD) | VSD | Monitoring | Ensuring Safety | Vaccine Safety | CDC. (2022, May 11). <https://www.cdc.gov/vaccinesafety/ensuringsafety/monitoring/vsd/index.html>

van den Ham, H. A., Souverein, P. C., Klungel, O. H., Platt, R. W., Ernst, P., Dell'Aniello, S., Schmiedl, S., Grave, B., Rottenkolber, M., Huerta, C., Martín Merino, E., León-Muñoz, L. M., Montero, D., Andersen, M., Aakjær, M., De Bruin, M. L., & Gardarsdottir, H. (2021). Major bleeding in users of direct oral anticoagulants in atrial fibrillation: A pooled analysis of results from multiple population-based



cohort studies. *Pharmacoepidemiology and Drug Safety*, 30(10), 1339–1352.

<https://doi.org/10.1002/pds.5317>

Wood, A., Denholm, R., Hollings, S., Cooper, J., Ip, S., Walker, V., Denaxas, S., Akbari, A., Banerjee, A., Whiteley, W., Lai, A., Sterne, J., & Sudlow, C. (2021). Linked electronic health records for research on a nationwide cohort of more than 54 million people in England: Data resource. *BMJ*, 373, n826.

<https://doi.org/10.1136/bmj.n826>

Xu, Y., Zhou, X., Suehs, B. T., Hartzema, A. G., Kahn, M. G., Moride, Y., Sauer, B. C., Liu, Q., Moll, K., Pasquale, M. K., Nair, V. P., & Bate, A. (2015). A Comparative Assessment of Observational Medical Outcomes Partnership and Mini-Sentinel Common Data Models and Analytics: Implications for Active Drug Safety Surveillance. *Drug Safety*, 38(8), 749–765. <https://doi.org/10.1007/s40264-015-0297-5>

## 9. Systematic reviews and meta-analysis

Amani, B., Khanijahani, A., Amani, B., & Hashemi, P. (2021). Lopinavir/Ritonavir for COVID-19: A Systematic Review and Meta-Analysis. *Journal of Pharmacy & Pharmaceutical Sciences*, 24, 246–257.

<https://doi.org/10.18433/jpps31668>

Bavishi, C., Whelton, P. K., Mancia, G., Corrao, G., & Messerli, F. H. (2021). Renin-angiotensin-system inhibitors and all-cause mortality in patients with COVID-19: A systematic review and meta-analysis of observational studies. *Journal of Hypertension*, 39(4), 784–794.

<https://doi.org/10.1097/HJH.0000000000002784>

Chou, R., & Helfand, M. (2005). Challenges in Systematic Reviews That Assess Treatment Harms.

*Annals of Internal Medicine*, 142(12\_Part\_2), 1090–1099. [https://doi.org/10.7326/0003-4819-142-12\\_Part\\_2-200506211-00009](https://doi.org/10.7326/0003-4819-142-12_Part_2-200506211-00009)

Framework for the synthesis of non-randomised studies and randomised controlled trials: A guidance on conducting a systematic review and meta-analysis for healthcare decision making | *BMJ Evidence-Based Medicine*. <https://ebm.bmj.com/content/27/2/109>

Henry, D., Lim, L. L.-Y., Rodriguez, L. A. G., Gutthann, S. P., Carson, J. L., Griffin, M., Savage, R., Logan, R., Moride, Y., Hawkey, C., Hill, S., & Fries, J. T. (1996). Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: Results of a collaborative meta-analysis. *BMJ*, 312(7046), 1563–1566. <https://doi.org/10.1136/bmj.312.7046.1563>

Hernández-Díaz, S., Bateman, B. T., Straub, L., Zhu, Y., Mogun, H., Fischer, M., & Huybrechts, K. F. (2021). Safety of Tenofovir Disoproxil Fumarate for Pregnant Women Facing the Coronavirus Disease 2019 Pandemic. *American Journal of Epidemiology*, 190(11), 2339–2349.

<https://doi.org/10.1093/aje/kwab109>

NMA incorporating RWE – RWE Navigator. RWE Navigator. <https://rwe-navigator.eu/use-real-world-evidence/summarise-and-synthesise-rwe/overview-of-evidence-synthesis-and-nma/nma-incorporating-rwe/>

Working Group X – Meta-analysis • COUNCIL FOR INTERNATIONAL ORGANIZATIONS OF MEDICAL SCIENCES. COUNCIL FOR INTERNATIONAL ORGANIZATIONS OF MEDICAL SCIENCES.

[https://cioms.ch/working\\_groups/working-group-x/](https://cioms.ch/working_groups/working-group-x/)

## 10. Signal detection methodology and application

Bate, A., & Evans, S. J. W. (2009). Quantitative signal detection using spontaneous ADR reporting. *Pharmacoepidemiology and Drug Safety*, 18(6), 427–436. <https://doi.org/10.1002/pds.1742>

Bayer, S., Clark, C., Dang, O., Aberdeen, J., Brajovic, S., Swank, K., Hirschman, L., & Ball, R. (2021). ADE Eval: An Evaluation of Text Processing Systems for Adverse Event Extraction from Drug Labels for Pharmacovigilance. *Drug Safety*, 44(1), 83–94. <https://doi.org/10.1007/s40264-020-00996-3>

Berlin, C., Blanch, C., Lewis, D. J., Maladorno, D. D., Michel, C., Petrin, M., Sarp, S., & Close, P. (2012). Are all quantitative postmarketing signal detection methods equal? Performance characteristics of logistic regression and Multi-item Gamma Poisson Shrinker. *Pharmacoepidemiology and Drug Safety*, 21(6), 622–630. <https://doi.org/10.1002/pds.2247>

Candore, G., Juhlin, K., Manlik, K., Thakrar, B., Quarcoo, N., Seabroke, S., Wisniewski, A., & Slattery, J. (2015). Comparison of Statistical Signal Detection Methods Within and Across Spontaneous Reporting Databases. *Drug Safety*, 38(6), 577–587. <https://doi.org/10.1007/s40264-015-0289-5>

Caster, O., Aoki, Y., Gattepaille, L. M., & Grundmark, B. (2020). Disproportionality Analysis for Pharmacovigilance Signal Detection in Small Databases or Subsets: Recommendations for Limiting False-Positive Associations. *Drug Safety*, 43(5), 479–487. <https://doi.org/10.1007/s40264-020-00911-w>

Caster, O., Juhlin, K., Watson, S., & Norén, G. N. (2014). Improved Statistical Signal Detection in Pharmacovigilance by Combining Multiple Strength-of-Evidence Aspects in vigiRank. *Drug Safety*, 37(8), 617–628. <https://doi.org/10.1007/s40264-014-0204-5>

Caster, O., Norén, G. N., Madigan, D., & Bate, A. (2010). Large-scale regression-based pattern discovery: The example of screening the WHO global drug safety database. *Statistical Analysis and Data Mining: The ASA Data Science Journal*, 3(4), 197–208. <https://doi.org/10.1002/sam.10078>

Caster, O., Norén, G. N., Madigan, D., & Bate, A. (2013). Logistic Regression in Signal Detection: Another Piece Added to the Puzzle. *Clinical Pharmacology & Therapeutics*, 94(3), 312–312. <https://doi.org/10.1038/clpt.2013.107>

DuMouchel, W., & Harpaz, R. Regression-Adjusted GPS Algorithm (RGPS). 23.

DuMouchel, W., Yuen, N., Payvandi, N., Booth, W., Rut, A., & Fram, D. (2013). Automated Method for Detecting Increases in Frequency of Spontaneous Adverse Event Reports over Time. *Journal of Biopharmaceutical Statistics*, 23(1), 161–177. <https://doi.org/10.1080/10543406.2013.736809>

Good pharmacovigilance practices. European Medicines Agency. <https://www.ema.europa.eu/en/human-regulatory/post-authorisation/pharmacovigilance/good-pharmacovigilance-practices>

Harpaz, R., DuMouchel, W., LePendou, P., Bauer-Mehren, A., Ryan, P., & Shah, N. H. (2013). Performance of Pharmacovigilance Signal Detection Algorithms for the FDA Adverse Event Reporting System. *Clinical Pharmacology and Therapeutics*, 93(6), 10.1038/clpt.2013.24. <https://doi.org/10.1038/clpt.2013.24>

Harpaz, R., DuMouchel, W., Schuemie, M., Bodenreider, O., Friedman, C., Horvitz, E., Ripple, A., Sorbello, A., White, R. W., Winnenburg, R., & Shah, N. H. (2017). Toward multimodal signal detection of adverse drug reactions. *Journal of Biomedical Informatics*, 76, 41–49. <https://doi.org/10.1016/j.jbi.2017.10.013>

- Hauben, M., Madigan, D., Gerrits, C. M., Walsh, L., & Van Puijenbroek, E. P. (2005). The role of data mining in pharmacovigilance. *Expert Opinion on Drug Safety*, 4(5), 929–948. <https://doi.org/10.1517/14740338.4.5.929>
- Juhlin, K., Karimi, G., And er, M., Camilli, S., Dheda, M., Har, T. S., Isahak, R., Lee, S.-J., Vaughan, S., Caduff, P., & Nor en, G. N. (2015). Using VigiBase to Identify Substandard Medicines: Detection Capacity and Key Prerequisites. *Drug Safety*, 38(4), 373–382. <https://doi.org/10.1007/s40264-015-0271-2>
- Juhlin, K., Ye, X., Star, K., & Nor en, G. N. (2013). Outlier removal to uncover patterns in adverse drug reaction surveillance – a simple unmasking strategy. *Pharmacoepidemiology and Drug Safety*, 22(10), 1119–1129. <https://doi.org/10.1002/pds.3474>
- Kreimeyer, K., Dang, O., Spiker, J., Mu oz, M. A., Rosner, G., Ball, R., & Botsis, T. (2021). Feature engineering and machine learning for causality assessment in pharmacovigilance: Lessons learned from application to the FDA Adverse Event Reporting System. *Computers in Biology and Medicine*, 135, 104517. <https://doi.org/10.1016/j.combiomed.2021.104517>
- Low, Y. S., Caster, O., Bergvall, T., Fourches, D., Zang, X., Nor en, G. N., Rusyn, I., Edwards, R., & Tropsha, A. (2016). Cheminformatics-aided pharmacovigilance: Application to Stevens-Johnson Syndrome. *Journal of the American Medical Informatics Association*, 23(5), 968–978. <https://doi.org/10.1093/jamia/ocv127>
- Maignen, F., Hauben, M., Hung, E., Holle, L. V., & Dogne, J.-M. (2014). A conceptual approach to the masking effect of measures of disproportionality. *Pharmacoepidemiology and Drug Safety*, 23(2), 208–217. <https://doi.org/10.1002/pds.3530>
- Maignen, F., Hauben, M., Hung, E., Van Holle, L., & Dogne, J.-M. (2014). Assessing the extent and impact of the masking effect of disproportionality analyses on two spontaneous reporting systems databases. *Pharmacoepidemiology and Drug Safety*, 23(2), 195–207. <https://doi.org/10.1002/pds.3529>
- MedDRA - Medical Dictionary for Regulatory Activities. <https://www.meddra.org/>
- Modern methods of pharmacovigilance: Detecting adverse effects of drugs | RCP Journals. <https://www.rcpjournals.org/content/clinmedicine/9/5/486>
- Montastruc, J.-L., Rousseau, V., de Canecaude, C., Roussin, A., & Montastruc, F. (2020). Role of serotonin and norepinephrine transporters in antidepressant-induced arterial hypertension: A pharmacoepidemiological-pharmacodynamic study. *European Journal of Clinical Pharmacology*, 76(9), 1321–1327. <https://doi.org/10.1007/s00228-020-02913-0>
- Mu oz, M. A., Dal Pan, G. J., Wei, Y.-J. J., Delcher, C., Xiao, H., Kortepeter, C. M., & Winterstein, A. G. (2020). Towards Automating Adverse Event Review: A Prediction Model for Case Report Utility. *Drug Safety*, 43(4), 329–338. <https://doi.org/10.1007/s40264-019-00897-0>
- Nor en, G. N., Meldau, E.-L., & Chandler, R. E. (2021). Consensus clustering for case series identification and adverse event profiles in pharmacovigilance. *Artificial Intelligence in Medicine*, 122, 102199. <https://doi.org/10.1016/j.artmed.2021.102199>
- OMOP Common Data Model – OHDSI. Observational Health Data Sciences and Informatics Community. <https://www.ohdsi.org/data-standardization/the-common-data-model/>
- Pacurariu, A. C., Straus, S. M., Trifir o, G., Schuemie, M. J., Gini, R., Herings, R., Mazzaglia, G., Picelli, G., Scotti, L., Pedersen, L., Arlett, P., van der Lei, J., Sturkenboom, M. C., & Coloma, P. M. (2015).

Useful Interplay Between Spontaneous ADR Reports and Electronic Healthcare Records in Signal Detection. *Drug Safety*, 38(12), 1201–1210. <https://doi.org/10.1007/s40264-015-0341-5>

Pinheiro, L. C., Candore, G., Zaccaria, C., Slattery, J., & Arlett, P. (2018). An algorithm to detect unexpected increases in frequency of reports of adverse events in EudraVigilance. *Pharmacoepidemiology and Drug Safety*, 27(1), 38–45. <https://doi.org/10.1002/pds.4344>

Practical Aspects of Signal Detection in Pharmacovigilance: Report of CIOMS Working Group VIII - COUNCIL FOR INTERNATIONAL ORGANIZATIONS OF MEDICAL SCIENCES (CIOMS). COUNCIL FOR INTERNATIONAL ORGANIZATIONS OF MEDICAL SCIENCES. <https://cioms.ch/publications/product/practical-aspects-of-signal-detection-in-pharmacovigilance-report-of-cioms-working-group-viii/>

PROTECT. <http://www.imi-protect.eu/methodsRep.shtml>

Research, C. for D. E. and. Good Pharmacovigilance Practices and Pharmacoepidemiologic Assessment. U.S. Food and Drug Administration; FDA. <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/good-pharmacovigilance-practices-and-pharmacoepidemiologic-assessment>

Research, C. for D. E. and. (2019, October 18). FDA's Sentinel Initiative. FDA. <https://www.fda.gov/safety/fdas-sentinel-initiative>

Salvo, F., Leborgne, F., Thiessard, F., Moore, N., Bégaud, B., & Pariente, A. (2013). A Potential Event-Competition Bias in Safety Signal Detection: Results from a Spontaneous Reporting Research Database in France. *Drug Safety*, 36(7), 565–572. <https://doi.org/10.1007/s40264-013-0063-5>

Scholl, J. H. G., van Hunsel, F. P. A. M., Hak, E., & van Puijenbroek, E. P. (2018). A prediction model-based algorithm for computer-assisted database screening of adverse drug reactions in the Netherlands. *Pharmacoepidemiology and Drug Safety*, 27(2), 199–205. <https://doi.org/10.1002/pds.4364>

Schotland, P., Racz, R., Jackson, D. B., Soldatos, T. G., Levin, R., Strauss, D. G., & Burkhart, K. (2021). Target Adverse Event Profiles for Predictive Safety in the Postmarket Setting. *Clinical Pharmacology & Therapeutics*, 109(5), 1232–1243. <https://doi.org/10.1002/cpt.2074>

Screening for adverse reactions in EudraVigilance—EMA. [https://www.ema.europa.eu/en/documents/other/screening-adverse-reactions-eudravigilance\\_en.pdf](https://www.ema.europa.eu/en/documents/other/screening-adverse-reactions-eudravigilance_en.pdf)

Seabroke, S., Candore, G., Juhlin, K., Quarcoo, N., Wisniewski, A., Arani, R., Painter, J., Tregunno, P., Norén, G. N., & Slattery, J. (2016). Performance of Stratified and Subgrouped Disproportionality Analyses in Spontaneous Databases. *Drug Safety*, 39(4), 355–364. <https://doi.org/10.1007/s40264-015-0388-3>

Summary of product characteristics. European Medicines Agency. <https://www.ema.europa.eu/en/glossary/summary-product-characteristics>

Stephenson, W. P., & Hauben, M. (2007). Data mining for signals in spontaneous reporting databases: Proceed with caution. *Pharmacoepidemiology and Drug Safety*, 16(4), 359–365. <https://doi.org/10.1002/pds.1323>

Tatonetti, N. P., Ye, P. P., Daneshjou, R., & Altman, R. B. (2012). Data-Driven Prediction of Drug Effects and Interactions. *Science Translational Medicine*, 4(125), 125ra31–125ra31. <https://doi.org/10.1126/scitranslmed.3003377>

Van Holle, L., & Bauchau, V. (2014). Use of Logistic Regression to Combine Two Causality Criteria for Signal Detection in Vaccine Spontaneous Report Data. *Drug Safety*, 37(12), 1047–1057. <https://doi.org/10.1007/s40264-014-0237-9>

Wisniewski, A. F. Z., Bate, A., Bousquet, C., Brueckner, A., Candore, G., Juhlin, K., Macia-Martinez, M. A., Manlik, K., Quarcoo, N., Seabroke, S., Slattery, J., Southworth, H., Thakrar, B., Tregunno, P., Van Holle, L., Kayser, M., & Norén, G. N. (2016). Good Signal Detection Practices: Evidence from IMI PROTECT. *Drug Safety*, 39(6), 469–490. <https://doi.org/10.1007/s40264-016-0405-1>

## 11. Statistical analysis plan

Hammer, G. P., du Prel, J.-B., & Blettner, M. (2009). Avoiding bias in observational studies: Part 8 in a series of articles on evaluation of scientific publications. *Deutsches Arzteblatt International*, 106(41), 664–668. <https://doi.org/10.3238/arztebl.2009.0664>

Hiemstra, B., Keus, F., Wetterslev, J., Gluud, C., & van der Horst, I. C. C. (2019). DEBATE-statistical analysis plans for observational studies. *BMC Medical Research Methodology*, 19(1), 233. <https://doi.org/10.1186/s12874-019-0879-5>

Madsen, M. B., Skrede, S., Bruun, T., Arnell, P., Rosén, A., Nekludov, M., Karlsson, Y., Bergey, F., Saccenti, E., Martins dos Santos, V. a. P., Perner, A., Norrby-Teglund, A., & Hyldegaard, O. (2018). Necrotizing soft tissue infections – a multicentre, prospective observational study (INFECT): Protocol and statistical analysis plan. *Acta Anaesthesiologica Scandinavica*, 62(2), 272–279. <https://doi.org/10.1111/aas.13024>

Rosenbaum, P. R. (2020). *Design of Observational Studies*. Springer Series in Statistics.

Thomas, L., & Peterson, E. D. (2012). The Value of Statistical Analysis Plans in Observational Research: Defining High-Quality Research From the Start. *JAMA*, 308(8), 773–774. <https://doi.org/10.1001/jama.2012.9502>

Yuan, I., Topjian, A. A., Kurth, C. D., Kirschen, M. P., Ward, C. G., Zhang, B., & Mensinger, J. L. (2019). Guide to the statistical analysis plan. *Pediatric Anesthesia*, 29(3), 237–242. <https://doi.org/10.1111/pan.13576>

## 12. Quality management

Blacketer, C., Defalco, F. J., Ryan, P. B., & Rijnbeek, P. R. (2021). Increasing trust in real-world evidence through evaluation of observational data quality. *Journal of the American Medical Informatics Association*, 28(10), 2251–2257. <https://doi.org/10.1093/jamia/ocab132>

Blomgren, K. J., Sundström, A., Steineck, G., & Wiholm, B.-E. (2006). Interviewer Variability – Quality Aspects in a Case–Control Study. *European Journal of Epidemiology*, 21(4), 267–277. <https://doi.org/10.1007/s10654-006-0017-7>

Cave, A., Kurz, X., & Arlett, P. (2019). Real-World Data for Regulatory Decision Making: Challenges and Possible Solutions for Europe. *Clinical Pharmacology & Therapeutics*, 106(1), 36–39. <https://doi.org/10.1002/cpt.1426>

Commission Implementing Regulation (EU) No 520/2012. (2012). European Commission. [https://eur-lex.europa.eu/eli/reg\\_impl/2012/520/oj](https://eur-lex.europa.eu/eli/reg_impl/2012/520/oj)

Determining Real-World Data's Fitness for Use and the Role of Reliability. (2019). Duke-Margolis Center for Health Policy. <https://healthpolicy.duke.edu/publications/determining-real-world-datas-fitness-use-and-role-reliability>

Duke-Margolis Center's Characterizing RWD Quality and Relevancy for Regulatory Purposes. [https://healthpolicy.duke.edu/sites/default/files/2020-03/characterizing\\_rwd.pdf](https://healthpolicy.duke.edu/sites/default/files/2020-03/characterizing_rwd.pdf)

EFGCP - European Forum for Good Clinical Practice. <https://efgcp.eu/>

EMA's Reflection paper on risk-based quality management in clinical trials. [https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-risk-based-quality-management-clinical-trials\\_en.pdf](https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-risk-based-quality-management-clinical-trials_en.pdf)

European Commission's Risk proportionate approaches in clinical trials. [https://ec.europa.eu/health/system/files/2017-08/2017\\_04\\_25\\_risk\\_proportionate\\_approaches\\_in\\_ct\\_0.pdf](https://ec.europa.eu/health/system/files/2017-08/2017_04_25_risk_proportionate_approaches_in_ct_0.pdf)

Furu, K. (2008). Establishment of the nationwide Norwegian Prescription Database (NorPD) – new opportunities for research in pharmacoepidemiology in Norway. *Norsk Epidemiologi*, 18(2), Article 2. <https://doi.org/10.5324/nje.v18i2.23>

Gatto, N. M., Campbell, U. B., Rubinstein, E., Jaksa, A., Mattox, P., Mo, J., & Reynolds, R. F. (2022). The Structured Process to Identify Fit-For-Purpose Data: A Data Feasibility Assessment Framework. *Clinical Pharmacology & Therapeutics*, 111(1), 122–134. <https://doi.org/10.1002/cpt.2466>

Ghadessi, M., Tang, R., Zhou, J., Liu, R., Wang, C., Toyozumi, K., Mei, C., Zhang, L., Deng, C. Q., & Beckman, R. A. (2020). A roadmap to using historical controls in clinical trials – by Drug Information Association Adaptive Design Scientific Working Group (DIA-ADSWG). *Orphanet Journal of Rare Diseases*, 15, 69. <https://doi.org/10.1186/s13023-020-1332-x>

Good pharmacovigilance practices. European Medicines Agency. <https://www.ema.europa.eu/en/human-regulatory/post-authorisation/pharmacovigilance/good-pharmacovigilance-practices>

Guideline on registry-based studies. European Medicines Agency. [https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-registry-based-studies\\_en-0.pdf](https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-registry-based-studies_en-0.pdf)

Guidelines for Good Pharmacoepidemiology Practices (GPP)—International Society for Pharmacoepidemiology. (2015). ISPE. <https://www.pharmacoepi.org/resources/policies/guidelines-08027/>

Herrett, E., Thomas, S. L., Schoonen, W. M., Smeeth, L., & Hall, A. J. (2010). Validation and validity of diagnoses in the General Practice Research Database: A systematic review. *British Journal of Clinical Pharmacology*, 69(1), 4–14. <https://doi.org/10.1111/j.1365-2125.2009.03537.x>

Hoffmann, W., Latza, U., Baumeister, S. E., Brünger, M., Buttmann-Schweiger, N., Hardt, J., Hoffmann, V., Karch, A., Richter, A., Schmidt, C. O., Schmidtman, I., Swart, E., & van den Berg, N. (2019). Guidelines and recommendations for ensuring Good Epidemiological Practice (GEP): A guideline developed by the German Society for Epidemiology. *European Journal of Epidemiology*, 34(3), 301–317. <https://doi.org/10.1007/s10654-019-00500-x>

ICH E6 (R2) Good clinical practice. European Medicines Agency. <https://www.ema.europa.eu/en/ich-e6-r2-good-clinical-practice>

- ICH E8 General considerations for clinical studies. European Medicines Agency.  
<https://www.ema.europa.eu/en/ich-e8-general-considerations-clinical-studies>
- Imperial College Academic Health Science Centre (AHSC)'s Quality Control and Quality Assurance SOP.  
[https://www.imperial.ac.uk/media/imperial-college/research-and-innovation/research-office/public/RGIT\\_SOP\\_025\\_QAQC\\_v8.0\\_19-Oct-2020.pdf](https://www.imperial.ac.uk/media/imperial-college/research-and-innovation/research-office/public/RGIT_SOP_025_QAQC_v8.0_19-Oct-2020.pdf)
- Informatics, O. H. D. S. and. (2021). The Book of OHDSI. OHSDI.  
<https://ohdsi.github.io/TheBookOfOhdsi/>
- ISO 9000:2015—ISO - Quality management systems—Fundamentals and vocabulary. 20.
- ISO Quality management principles. (2022). American Society for Quality.  
<https://www.iso.org/files/live/sites/isoorg/files/store/en/PUB100080.pdf>
- Kahn, M. G., Callahan, T. J., Barnard, J., Bauck, A. E., Brown, J., Davidson, B. N., Estiri, H., Goerg, C., Holve, E., Johnson, S. G., Liaw, S.-T., Hamilton-Lopez, M., Meeker, D., Ong, T. C., Ryan, P., Shang, N., Weiskopf, N. G., Weng, C., Zozus, M. N., & Schilling, L. (2016). A Harmonized Data Quality Assessment Terminology and Framework for the Secondary Use of Electronic Health Record Data. EGEMS (Washington, DC), 4(1), 1244. <https://doi.org/10.13063/2327-9214.1244>
- Kiran, D. R. (2016). Total Quality Management (1st ed.). BSP Books, Elsevier.  
<https://www.elsevier.com/books/total-quality-management/kiran/978-0-12-811035-5>
- OHDSI – Observational Health Data Sciences and Informatics. Observational Health Data Sciences and Informatics. <https://www.ohdsi.org/>
- PCORnet. The National Patient-Centered Clinical Research Network. <https://pcornet.org/data/>
- Quality Control Systems for Secondary Use Data presentation for “Data Quality Framework for medicines regulation” workshop 7 April 2022—Peter Berzin, Odysseus.  
[https://www.ema.europa.eu/en/documents/presentation/presentation-quality-control-systems-secondary-use-data-p-berzin-odysseus\\_en.pdf](https://www.ema.europa.eu/en/documents/presentation/presentation-quality-control-systems-secondary-use-data-p-berzin-odysseus_en.pdf)
- Registries for Evaluating Patient Outcomes: A User’s Guide: 4th Edition | Effective Health Care (EHC) Program. (2020). AHQR. <https://effectivehealthcare.ahrq.gov/products/registries-guide-4th-edition/users-guide>
- Reisch, L. M., Fosse, J. S., Beverly, K., Yu, O., Barlow, W. E., Harris, E. L., Rolnick, S., Barton, M. B., Geiger, A. M., Herrinton, L. J., Greene, S. M., Fletcher, S. W., & Elmore, J. G. (2003). Training, Quality Assurance, and Assessment of Medical Record Abstraction in a Multisite Study. American Journal of Epidemiology, 157(6), 546–551. <https://doi.org/10.1093/aje/kwg016>
- Research, C. for D. E. and. (2013). FDA’s Best Practices for Conducting and Reporting Pharmacoepidemiologic Safety Studies Using Electronic Healthcare Data Sets. U.S. Food and Drug Administration; FDA. <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/best-practices-conducting-and-reporting-pharmacoepidemiologic-safety-studies-using-electronic>
- Sprenger, K., Nickerson, D., Meeker-O’Connell, A., & Morrison, B. W. (2013). Quality by Design in Clinical Trials: A Collaborative Pilot With FDA. Therapeutic Innovation & Regulatory Science, 47(2), 161–166. <https://doi.org/10.1177/0092861512458909>
- Theobald, K., Capan, M., Herbold, M., Schinzel, S., & Hundt, F. (2009). Quality assurance in non-interventional studies. GMS German Medical Science, 7, Doc29. <https://doi.org/10.3205/000088>

What is a Quality Management System (QMS)? | ASQ. (2022). American Society for Quality. <https://asq.org/quality-resources/quality-management%20system>

Whitney, C. W., Lind, B. K., & Wahl, P. W. (1998). Quality Assurance and Quality Control in Longitudinal Studies. *Epidemiologic Reviews*, 20(1), 71–80. <https://doi.org/10.1093/oxfordjournals.epirev.a017973>

### **13. Dissemination and communication of study results**

Benchimol, E. I., Moher, D., Ehrenstein, V., & Langan, S. M. (2020). Retraction of COVID-19 Pharmacoepidemiology Research Could Have Been Avoided by Effective Use of Reporting Guidelines. *Clinical Epidemiology*, 12, 1403–1420. <https://doi.org/10.2147/CLEP.S288677>

Best Practices for Conducting and Reporting Pharmacoepidemiologic Safety Studies Using Electronic Healthcare Data Sets. (2020). US Food and Drug Administration (FDA). <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/best-practices-conducting-and-reporting-pharmacoepidemiologic-safety-studies-using-electronic>

ClinicalTrials.gov. <https://clinicaltrials.gov/>

Cohen, J. F., Korevaar, D. A., Altman, D. G., Bruns, D. E., Gatsonis, C. A., Hooft, L., Irwig, L., Levine, D., Reitsma, J. B., Vet, H. C. W. de, & Bossuyt, P. M. M. (2016). STARD 2015 guidelines for reporting diagnostic accuracy studies: Explanation and elaboration. *BMJ Open*, 6(11), e012799. <https://doi.org/10.1136/bmjopen-2016-012799>

EMA Guidance for the format and content of the final study report of non-interventional post-authorisation safety studies (PASS). [https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guidance-format-content-final-study-report-non-interventional-post-authorisation-safety-studies\\_en.pdf](https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guidance-format-content-final-study-report-non-interventional-post-authorisation-safety-studies_en.pdf)

ENCePP Checklist for Study Protocols. [https://www.encepp.eu/standards\\_and\\_guidances/checkListProtocols.shtml](https://www.encepp.eu/standards_and_guidances/checkListProtocols.shtml)

ENCePP Code of Conduct. ENCePP. [https://www.encepp.eu/code\\_of\\_conduct/index.shtml](https://www.encepp.eu/code_of_conduct/index.shtml)

EU PAS Register. ENCePP. [https://www.encepp.eu/encepp\\_studies/indexRegister.shtml](https://www.encepp.eu/encepp_studies/indexRegister.shtml)

Good pharmacovigilance practices. European Medicines Agency. <https://www.ema.europa.eu/en/human-regulatory/post-authorisation/pharmacovigilance/good-pharmacovigilance-practices>

GRACE Principles—Good ReseArch for Comparative Effectiveness. <https://www.graceprinciples.org/>

Guidance for the format and content of the protocol of non-interventional post-authorisation safety studies. European Medicines Agency. [https://www.ema.europa.eu/en/documents/other/guidance-format-content-protocol-non-interventional-post-authorisation-safety-studies\\_en.pdf](https://www.ema.europa.eu/en/documents/other/guidance-format-content-protocol-non-interventional-post-authorisation-safety-studies_en.pdf)

Guidelines for Good Pharmacoepidemiology Practices (GPP)—International Society for Pharmacoepidemiology. (2015). ISPE. <https://www.pharmacoepi.org/resources/policies/guidelines-08027/>

ICJME Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly work in Medical Journals. International Committee of Medical Journal Editors (ICJME). <https://www.icmje.org/>

International Epidemiological Association (IEA). <http://www.ieaweb.org/>



Kelly, W. N., Arellano, F. M., Barnes, J., Bergman, U., Edwards, I. R., Fernandez, A. M., Freedman, S. B., Goldsmith, D. I., Huang, K., Jones, J. K., McLeay, R., Moore, N., Stather, R. H., Trenque, T., Troutman, W. G., van Puijenbroek, E., Williams, F., & Wise, R. P. (2007). Guidelines for submitting adverse event reports for publication. *Pharmacoepidemiology and Drug Safety*, 16(5), 581–587. <https://doi.org/10.1002/pds.1399>

Langan, S. M., Schmidt, S. A., Wing, K., Ehrenstein, V., Nicholls, S. G., Filion, K. B., Klungel, O., Petersen, I., Sorensen, H. T., Dixon, W. G., Guttman, A., Harron, K., Hemkens, L. G., Moher, D., Schneeweiss, S., Smeeth, L., Sturkenboom, M., Elm, E. von, Wang, S. V., & Benchimol, E. I. (2018). The reporting of studies conducted using observational routinely collected health data statement for pharmacoepidemiology (RECORD-PE). *BMJ*, 363, k3532. <https://doi.org/10.1136/bmj.k3532>

Moher, D., Liberati, A., Tetzlaff, J., & Altman, D. G. (2009). Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. *BMJ*, 339, b2535. <https://doi.org/10.1136/bmj.b2535>

Nicholls, S. G., Quach, P., Elm, E. von, Guttman, A., Moher, D., Petersen, I., Sørensen, H. T., Smeeth, L., Langan, S. M., & Benchimol, E. I. (2015). The REporting of Studies Conducted Using Observational Routinely-Collected Health Data (RECORD) Statement: Methods for Arriving at Consensus and Developing Reporting Guidelines. *PLOS ONE*, 10(5), e0125620. <https://doi.org/10.1371/journal.pone.0125620>

Open Science Forum. Open Science Forum. <https://osf.io/>

Preprints & Conference Proceedings | Nature Portfolio. <https://www.nature.com/nature-portfolio/editorial-policies/preprints-and-conference-proceedings>

Preprints with The Lancet. The Lancet. <https://www.thelancet.com/preprints>

PROSPERO - International prospective register of systematic reviews. <https://www.crd.york.ac.uk/PROSPERO/>

Publications of STROBE Statement. <https://www.strobe-statement.org/strobe-publications/>

Schneeweiss, S., Rassen, J. A., Brown, J. S., Rothman, K. J., Happe, L., Arlett, P., Dal Pan, G., Goettsch, W., Murk, W., & Wang, S. V. (2019). Graphical Depiction of Longitudinal Study Designs in Health Care Databases. *Annals of Internal Medicine*, 170(6), 398–406. <https://doi.org/10.7326/M18-3079>

Schulz, K. F., Altman, D. G., & Moher, D. (2010). CONSORT 2010 Statement: Updated guidelines for reporting parallel group randomised trials. *BMJ*, 340, c332. <https://doi.org/10.1136/bmj.c332>

Simera, I., Moher, D., Hoey, J., Schulz, K. F., & Altman, D. G. (2010). A catalogue of reporting guidelines for health research. *European Journal of Clinical Investigation*, 40(1), 35–53. <https://doi.org/10.1111/j.1365-2362.2009.02234.x>

STROBE statement. STROBE. <https://www.strobe-statement.org/>

Stroup, D. F., Berlin, J. A., Morton, S. C., Olkin, I., Williamson, G. D., Rennie, D., Moher, D., Becker, B. J., Sipe, T. A., Thacker, S. B., & for the Meta-analysis Of Observational Studies in Epidemiology (MOOSE) Group. (2000). Meta-analysis of Observational Studies in Epidemiology A Proposal for Reporting. *JAMA*, 283(15), 2008–2012. <https://doi.org/10.1001/jama.283.15.2008>

The EQUATOR Network | Enhancing the QUALity and Transparency Of Health Research. <https://www.equator-network.org/>

Wang, S. V., Schneeweiss, S., Berger, M. L., Brown, J., de Vries, F., Douglas, I., Gagne, J. J., Gini, R., Klungel, O., Mullins, C. D., Nguyen, M. D., Rassen, J. A., Smeeth, L., Sturkenboom, M., & Making, on behalf of the joint I.-I. S. T. F. on R. W. E. in H. C. D. (2017a). Reporting to Improve Reproducibility and Facilitate Validity Assessment for Healthcare Database Studies V1.0. *Pharmacoepidemiology and Drug Safety*, 26(9), 1018–1032. <https://doi.org/10.1002/pds.4295>

Wang, S. V., Schneeweiss, S., Berger, M. L., Brown, J., de Vries, F., Douglas, I., Gagne, J. J., Gini, R., Klungel, O., Mullins, C. D., Nguyen, M. D., Rassen, J. A., Smeeth, L., Sturkenboom, M., & Making, on behalf of the joint I.-I. S. T. F. on R. W. E. in H. C. D. (2017b). Reporting to Improve Reproducibility and Facilitate Validity Assessment for Healthcare Database Studies V1.0. *Pharmacoepidemiology and Drug Safety*, 26(9), 1018–1032. <https://doi.org/10.1002/pds.4295>

WMA - The World Medical Association-WMA Declaration of Helsinki – Ethical Principles for Medical Research Involving Human Subjects. <https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/>

Zwarenstein, M., Treweek, S., Gagnier, J. J., Altman, D. G., Tunis, S., Haynes, B., Oxman, A. D., & Moher, D. (2008). Improving the reporting of pragmatic trials: An extension of the CONSORT statement. *BMJ*, 337, a2390. <https://doi.org/10.1136/bmj.a2390>

## **14. Data protection and ethical aspects**

### **14.1. Personal data protection in the European Union**

Article 29 Working Party | European Data Protection Board. European Data Protection Board. [https://edpb.europa.eu/about-edpb/more-about-edpb/article-29-working-party\\_en](https://edpb.europa.eu/about-edpb/more-about-edpb/article-29-working-party_en)

Commission Directive 2005/28/EC. (2005). European Commission. <http://data.europa.eu/eli/dir/2005/28/oj/eng>

Commission Implementing Regulation (EU) No 520/2012—EC. [https://eur-lex.europa.eu/eli/reg\\_impl/2012/520/oj](https://eur-lex.europa.eu/eli/reg_impl/2012/520/oj)

Data Privacy, Medical Record Confidentiality, and Research in the Interest of Public Health—International Society for Pharmacoepidemiology. ISPE. <https://www.pharmacoepi.org/resources/policies/privacy/>

Directive 2001/20/EC. [https://ec.europa.eu/health/system/files/2016-11/dir\\_2001\\_20\\_en\\_0.pdf](https://ec.europa.eu/health/system/files/2016-11/dir_2001_20_en_0.pdf)

EudraLex—EC. European Commission. [https://ec.europa.eu/health/medicinal-products/eudralex\\_en](https://ec.europa.eu/health/medicinal-products/eudralex_en)

EDPB | European Data Protection Board. European Data Protection Board. [https://edpb.europa.eu/edpb\\_en](https://edpb.europa.eu/edpb_en)

EDPB Guidelines 3/2018 on the territorial scope of the GDPR. [https://edpb.europa.eu/sites/default/files/files/file1/edpb\\_guidelines\\_3\\_2018\\_territorial\\_scope\\_after\\_public\\_consultation\\_en\\_1.pdf](https://edpb.europa.eu/sites/default/files/files/file1/edpb_guidelines_3_2018_territorial_scope_after_public_consultation_en_1.pdf)

ENCePP Home Page. <https://www.encepp.eu/structure/index.shtml>

European Data Protection Authorities. European Data Protection Board. [https://edpb.europa.eu/about-edpb/about-edpb/members\\_en](https://edpb.europa.eu/about-edpb/about-edpb/members_en)

General Data Protection Regulation (EU) 2016/679 (GDPR). <https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:32016R0679>

Good pharmacovigilance practices. European Medicines Agency.

<https://www.ema.europa.eu/en/human-regulatory/post-authorisation/pharmacovigilance/good-pharmacovigilance-practices>

Guidelines for Good Pharmacoepidemiology Practices (GPP)—International Society for Pharmacoepidemiology. ISPE. <https://www.pharmacoepi.org/resources/policies/guidelines-08027/>

Human medicines: Regulatory information. European Medicines Agency. <https://www.ema.europa.eu/en/human-medicines-regulatory-information>

Questions and Answers on the interplay between the Clinical Trials Regulation and the General Data Protection Regulation—EC. [https://ec.europa.eu/health/system/files/2019-04/ga\\_clinicaltrials\\_gdpr\\_en\\_0.pdf](https://ec.europa.eu/health/system/files/2019-04/ga_clinicaltrials_gdpr_en_0.pdf)

Regulation (EU) 2018/1725 (EUDPR). [https://edps.europa.eu/sites/default/files/publication/regulation\\_eu\\_2018\\_1725\\_en.pdf](https://edps.europa.eu/sites/default/files/publication/regulation_eu_2018_1725_en.pdf)

Regulation (EU) No 536/2014. <https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:32014R0536&rid=1>

#### **14.2. Scientific integrity and ethical conduct**

Agency for Healthcare Research and Quality (AHRQ). <https://www.ahrq.gov/>

CIOMS International Ethical Guidelines for Health-related Research Involving Humans. <https://cioms.ch/wp-content/uploads/2017/01/WEB-CIOMS-EthicalGuidelines.pdf>

ENCePP Code of Conduct. ENCePP. [https://www.encepp.eu/code\\_of\\_conduct/](https://www.encepp.eu/code_of_conduct/)

EU PAS Register. ENCePP. [https://www.encepp.eu/encepp\\_studies/indexRegister.shtml](https://www.encepp.eu/encepp_studies/indexRegister.shtml)

Guidelines for Good Pharmacoepidemiology Practices (GPP)—International Society for Pharmacoepidemiology. (2015). ISPE. <https://www.pharmacoepi.org/resources/policies/guidelines-08027/>

HMA-EMA Joint Big Data Taskforce Phase II report: Evolving Data-Driven Regulation. (2019). European Medicines Agency. [https://www.ema.europa.eu/en/documents/other/hma-ema-joint-big-data-taskforce-phase-ii-report-evolving-data-driven-regulation\\_en.pdf](https://www.ema.europa.eu/en/documents/other/hma-ema-joint-big-data-taskforce-phase-ii-report-evolving-data-driven-regulation_en.pdf)

IAE Good Epidemiology Practice (GEP)). (2007). International Epidemiological Association. [https://ieaweb.org/IEAWeb/Content/IEA\\_Publications.aspx](https://ieaweb.org/IEAWeb/Content/IEA_Publications.aspx)

ICMJE. <https://www.icmje.org/>

Kurz, X., Bauchau, V., Mahy, P., Glismann, S., van der Aa, L. M., & Simondon, F. (2017). The ADVANCE Code of Conduct for collaborative vaccine studies. *Vaccine*, 35(15), 1844–1855. <https://doi.org/10.1016/j.vaccine.2017.02.039>

Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly work in Medical Journals. (2021). International Committee of Medical Journal Editors (ICJME). <https://www.icmje.org/recommendations/>

Registries for Evaluating Patient Outcomes: A User’s Guide: 4th Edition | Effective Health Care (EHC) Program. (2020). AHRQ. <https://effectivehealthcare.ahrq.gov/products/registries-guide-4th-edition/users-guide>

WMA - The World Medical Association-WMA Declaration of Helsinki – Ethical Principles for Medical Research Involving Human Subjects. World Medical Association. <https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/>

## 15. Specific topics

### 15.1. Comparative effectiveness research

Avorn, J. (2007). In Defense of Pharmacoepidemiology—Embracing the Yin and Yang of Drug Research. *New England Journal of Medicine*, 357(22), 2219–2221. <https://doi.org/10.1056/NEJMp0706892>

Azzolina, D., Berchialla, P., Gregori, D., & Baldi, I. (2021). Prior Elicitation for Use in Clinical Trial Design and Analysis: A Literature Review. *International Journal of Environmental Research and Public Health*, 18(4), 1833. <https://doi.org/10.3390/ijerph18041833>

Cochrane Handbook for Systematic Reviews of Interventions. <https://training.cochrane.org/handbook>  
COMET Initiative. <https://www.comet-initiative.org/>

Concato, J., Shah, N., & Horwitz, R. I. (2000). Randomized, Controlled Trials, Observational Studies, and the Hierarchy of Research Designs. *New England Journal of Medicine*, 342(25), 1887–1892. <https://doi.org/10.1056/NEJM200006223422507>

Crystal, S., Gaboda, D., Lucas, J., Gerhard, T., & Chakravarty, S. (2010). Assessing medication exposures and outcomes in the frail elderly: Assessing research challenges in nursing home pharmacotherapy. *Medical Care*, 48(6 Suppl), S23–31. <https://doi.org/10.1097/MLR.0b013e3181de9d10>

D’Andrea, E., Vinals, L., Patorno, E., Franklin, J. M., Bennett, D., Largent, J. A., Moga, D. C., Yuan, H., Wen, X., Zullo, A. R., Debray, T. P. A., & Sarri, G. (2021). How well can we assess the validity of non-randomised studies of medications? A systematic review of assessment tools. *BMJ Open*, 11(3), e043961. <https://doi.org/10.1136/bmjopen-2020-043961>

Developing a Protocol for Observational Comparative Effectiveness Research: A User’s Guide | Effective Health Care (EHC) Program. <https://effectivehealthcare.ahrq.gov/products/observational-cer-protocol/research>

Dickerman, B. A., Gerlovin, H., Madenci, A. L., Kurgansky, K. E., Ferolito, B. R., Figueroa Muñiz, M. J., Gagnon, D. R., Gaziano, J. M., Cho, K., Casas, J. P., & Hernán, M. A. (2022). Comparative Effectiveness of BNT162b2 and mRNA-1273 Vaccines in U.S. Veterans. *The New England Journal of Medicine*, 386(2), 105–115. <https://doi.org/10.1056/NEJMoa2115463>

Franklin, J. M., Glynn, R. J., Suissa, S., & Schneeweiss, S. (2020). Emulation Differences vs. Biases When Calibrating Real-World Evidence Findings Against Randomized Controlled Trials. *Clinical Pharmacology and Therapeutics*, 107(4), 735–737. <https://doi.org/10.1002/cpt.1793>

Franklin, J. M., Patorno, E., Desai, R. J., Glynn, R. J., Martin, D., Quinto, K., Pawar, A., Bessette, L. G., Lee, H., Garry, E. M., Gautam, N., & Schneeweiss, S. (2021). Emulating Randomized Clinical Trials With Nonrandomized Real-World Evidence Studies: First Results From the RCT DUPLICATE Initiative. *Circulation*, 143(10), 1002–1013. <https://doi.org/10.1161/CIRCULATIONAHA.120.051718>

Franklin, J. M., & Schneeweiss, S. (2017). When and How Can Real World Data Analyses Substitute for Randomized Controlled Trials? *Clinical Pharmacology and Therapeutics*, 102(6), 924–933. <https://doi.org/10.1002/cpt.857>

- Ghadessi, M., Tang, R., Zhou, J., Liu, R., Wang, C., Toyozumi, K., Mei, C., Zhang, L., Deng, C. Q., & Beckman, R. A. (2020). A roadmap to using historical controls in clinical trials – by Drug Information Association Adaptive Design Scientific Working Group (DIA-ADSWG). *Orphanet Journal of Rare Diseases*, 15, 69. <https://doi.org/10.1186/s13023-020-1332-x>
- Gorst, S. L., Gargon, E., Clarke, M., Blazeby, J. M., Altman, D. G., & Williamson, P. R. (2016). Choosing Important Health Outcomes for Comparative Effectiveness Research: An Updated Review and User Survey. *PLOS ONE*, 11(1), e0146444. <https://doi.org/10.1371/journal.pone.0146444>
- GRACE Principles—Good ReseArch for Comparative Effectiveness. <https://www.graceprinciples.org/>
- GRADE working group. GRADE. <https://www.gradeworkinggroup.org/>
- Harker, J., & Kleijnen, J. (2012). What is a rapid review? A methodological exploration of rapid reviews in Health Technology Assessments. *JBI Evidence Implementation*, 10(4), 397–410. <https://doi.org/10.1111/j.1744-1609.2012.00290.x>
- Huang, B., Qiu, T., Chen, C., Neace, A., Zhang, Y., Yue, X., Zahner, J., Adams, M., Seid, M., Lovell, D., Morgan, E., & Brunner, H. (2020). Comparative Effectiveness Research Using Electronic Health Records Data: Ensure Data Quality. SAGE Publications Ltd. <https://doi.org/10.4135/9781529726480>
- ICH E9 (R1) addendum. [https://database.ich.org/sites/default/files/E9-R1\\_Step4\\_Guideline\\_2019\\_1203.pdf](https://database.ich.org/sites/default/files/E9-R1_Step4_Guideline_2019_1203.pdf)
- Johnson, E. S., Bartman, B. A., Briesacher, B. A., Fleming, N. S., Gerhard, T., Kornegay, C. J., Nourjah, P., Sauer, B., Schumock, G. T., Sedrakyan, A., Stürmer, T., West, S. L., & Schneeweiss, S. (2013). The incident user design in comparative effectiveness research. *Pharmacoepidemiology and Drug Safety*, 22(1), 1–6. <https://doi.org/10.1002/pds.3334>
- Lessons Learned from Trial Replication Analyses: Findings from the DUPLICATE Demonstration Project. (n.d.). Margolis Center for Health Policy. <https://healthpolicy.duke.edu/events/findings-duplicate-demonstration-project>
- Lumley, T. (2002). Network meta-analysis for indirect treatment comparisons. *Statistics in Medicine*, 21(16), 2313–2324. <https://doi.org/10.1002/sim.1201>
- Methods Guide for Effectiveness and Comparative Effectiveness Reviews. (2008). Agency for Healthcare Research and Quality (US). <https://effectivehealthcare.ahrq.gov/products/collections/cer-methods-guide>
- Overview of evidence synthesis and network meta-analysis – RWE Navigator. RWE Navigator. <https://rwe-navigator.eu/use-real-world-evidence/summarise-and-synthesise-rwe/overview-of-evidence-synthesis-and-nma/>
- Ray, W. A. (2003). Evaluating Medication Effects Outside of Clinical Trials: New-User Designs. *American Journal of Epidemiology*, 158(9), 915–920. <https://doi.org/10.1093/aje/kwg231>
- RWE Navigator. <https://rwe-navigator.eu/>
- Sarri, G., Patorno, E., Yuan, H., Guo, J. J., Bennett, D., Wen, X., Zullo, A. R., Largent, J., Panaccio, M., Gokhale, M., Moga, D. C., Ali, M. S., & Debray, T. P. A. (2022). Framework for the synthesis of non-randomised studies and randomised controlled trials: A guidance on conducting a systematic review and meta-analysis for healthcare decision making. *BMJ Evidence-Based Medicine*, 27(2), 109–119. <https://doi.org/10.1136/bmjebm-2020-111493>
- Seeger, J. D., Davis, K. J., Iannacone, M. R., Zhou, W., Dreyer, N., Winterstein, A. G., Santanello, N., Gertz, B., & Berlin, J. A. (2020). Methods for external control groups for single arm trials or long-term

uncontrolled extensions to randomized clinical trials. *Pharmacoepidemiology and Drug Safety*, 29(11), 1382–1392. <https://doi.org/10.1002/pds.5141>

Simon, G. E., Platt, R., Watanabe, J. H., Bindman, A. B., John London, A., Horberg, M., Hernandez, A., & Califf, R. M. (2022). When Can We Rely on Real-World Evidence to Evaluate New Medical Treatments? *Clinical Pharmacology and Therapeutics*, 111(1), 30–34. <https://doi.org/10.1002/cpt.2253>

Sox, H. C., & Goodman, S. N. (2012). The methods of comparative effectiveness research. *Annual Review of Public Health*, 33, 425–445. <https://doi.org/10.1146/annurev-publhealth-031811-124610>

The final version of HTA Core Model® and the Methodological Guidelines for Rapid REA of Pharmaceuticals is now available—EUnetHTA. (2013, March 8). EUnetHTA. <https://www.eunetha.eu/the-final-version-of-hta-core-model-and-the-methodological-guidelines-for-rapid-rea-of-pharmaceuticals-is-now-available/>

Valuck, R. J., Anderson, H. O., Libby, A. M., Brandt, E., Bryan, C., Allen, R. R., Staton, E. W., West, D. R., & Pace, W. D. (2012). Enhancing electronic health record measurement of depression severity and suicide ideation: A Distributed Ambulatory Research in Therapeutics Network (DARTNet) study. *Journal of the American Board of Family Medicine: JABFM*, 25(5), 582–593. <https://doi.org/10.3122/jabfm.2012.05.110053>

## **15.2. Vaccine safety and effectiveness**

ACCESS template protocol for safety of COVID-19 vaccines. EU PAS Register. <https://www.encepp.eu/encepp/viewResource.htm?id=39362>

ADVANCE Report on appraisal of vaccine safety methods. [https://vac4eu.org/wp-content/uploads/2019/03/ADVANCE\\_D4-2\\_appraisal-safety-methods\\_final\\_PU.pdf](https://vac4eu.org/wp-content/uploads/2019/03/ADVANCE_D4-2_appraisal-safety-methods_final_PU.pdf)

Ainslie, K. E. C., Shi, M., Haber, M., & Orenstein, W. A. (2019). A Dynamic Model for Evaluation of the Bias of Influenza Vaccine Effectiveness Estimates From Observational Studies. *American Journal of Epidemiology*, 188(2), 451–460. <https://doi.org/10.1093/aje/kwy240>

Andrews, N. (2012). Epidemiological designs for vaccine safety assessment: Methods and pitfalls. *Biologicals: Journal of the International Association of Biological Standardization*, 40(5), 389–392. <https://doi.org/10.1016/j.biologicals.2011.08.010>

Andrews, N., Kent, A., Amin-Chowdhury, Z., Sheppard, C., Fry, N., Ramsay, M., & Ladhani, S. N. (2019). Effectiveness of the seven-valent and thirteen-valent pneumococcal conjugate vaccines in England: The indirect cohort design, 2006–2018. *Vaccine*, 37(32), 4491–4498. <https://doi.org/10.1016/j.vaccine.2019.06.071>

Andrews, N., Stowe, J., Thomas, S. L., Walker, J. L., & Miller, E. (2019). The risk of non-specific hospitalised infections following MMR vaccination given with and without inactivated vaccines in the second year of life. Comparative self-controlled case-series study in England. *Vaccine*, 37(36), 5211–5217. <https://doi.org/10.1016/j.vaccine.2019.07.059>

Andrews, N., Waight, P. A., Borrow, R., Ladhani, S., George, R. C., Slack, M. P. E., & Miller, E. (2011). Using the indirect cohort design to estimate the effectiveness of the seven valent pneumococcal conjugate vaccine in England and Wales. *PloS One*, 6(12), e28435. <https://doi.org/10.1371/journal.pone.0028435>

Background Rates of Adverse Events of Special Interest for COVID-19 Vaccine Safety Monitoring. (2021). US Food and Drug Administration. <https://bestinitiative.org/wp-content/uploads/2021/02/C19-Vaccine-Safety-AESI-Background-Rate-Protocol-FINAL-2020.pdf>

Background rates of Adverse Events of Special Interest for monitoring COVID-19 vaccines (2.0). <https://doi.org/10.5281/ZENODO.5255870>

Baker, M. A., Baer, B., Kulldorff, M., Zichittella, L., Reindel, R., DeLuccia, S., Lipowicz, H., Freitas, K., Jin, R., & Yih, W. K. (2019). Kawasaki disease and 13-valent pneumococcal conjugate vaccination among young children: A self-controlled risk interval and cohort study with null results. *PLoS Medicine*, 16(7), e1002844. <https://doi.org/10.1371/journal.pmed.1002844>

Baker, M. A., Lieu, T. A., Li, L., Hua, W., Qiang, Y., Kawai, A. T., Fireman, B. H., Martin, D. B., & Nguyen, M. D. (2015). A vaccine study design selection framework for the postlicensure rapid immunization safety monitoring program. *American Journal of Epidemiology*, 181(8), 608–618. <https://doi.org/10.1093/aje/kwu322>

Bardenheier, B. H., Gravenstein, S., Blackman, C., Gutman, R., Sarkar, I. N., Feifer, R. A., White, E. M., McConeghy, K., Nanda, A., & Mor, V. (2021). Adverse events following mRNA SARS-CoV-2 vaccination among U.S. nursing home residents. *Vaccine*, 39(29), 3844–3851. <https://doi.org/10.1016/j.vaccine.2021.05.088>

Baum, U., Sundman, J., Jääskeläinen, S., Nohynek, H., Puumalainen, T., & Jokinen, J. (2017). Establishing and maintaining the National Vaccination Register in Finland. *Euro Surveillance: Bulletin European Sur Les Maladies Transmissibles = European Communicable Disease Bulletin*, 22(17), 30520. <https://doi.org/10.2807/1560-7917.ES.2017.22.17.30520>

Beck, C. R., McKenzie, B. C., Hashim, A. B., Harris, R. C., University of Nottingham Influenza and the ImmunoCompromised (UNIIC) Study Group, & Nguyen-Van-Tam, J. S. (2012). Influenza vaccination for immunocompromised patients: Systematic review and meta-analysis by etiology. *The Journal of Infectious Diseases*, 206(8), 1250–1259. <https://doi.org/10.1093/infdis/jis487>

Biggart, R., Finn, A., & Marlow, R. (2018). Lack of impact of rotavirus vaccination on childhood seizure hospitalizations in England – An interrupted time series analysis. *Vaccine*, 36(31), 4589–4592. <https://doi.org/10.1016/j.vaccine.2018.06.029>

Björk, J., Bonander, C., Moghaddassi, M., Rasmussen, M., Malmqvist, U., Kahn, F., & Inghammar, M. (2022). Surveillance of COVID-19 vaccine effectiveness: A real-time case-control study in southern Sweden. *Epidemiology and Infection*, 150, e59. <https://doi.org/10.1017/S0950268822000425>

Black, S. B., Law, B., Chen, R. T., Dekker, C. L., Sturkenboom, M., Huang, W.-T., Gurwith, M., & Poland, G. (2021). The critical role of background rates of possible adverse events in the assessment of COVID-19 vaccine safety. *Vaccine*, 39(19), 2712–2718. <https://doi.org/10.1016/j.vaccine.2021.03.016>

Bollaerts, K., Verstraeten, T., & Cohet, C. (2019). Observational studies of non-specific effects of Diphtheria-Tetanus-Pertussis vaccines in low-income countries: Assessing the potential impact of study characteristics, bias and confounding through meta-regression. *Vaccine*, 37(1), 34–40. <https://doi.org/10.1016/j.vaccine.2018.11.049>

Brighton Collaboration – Home Page—Brighton Collaboration. <https://brightoncollaboration.us/>

Broome, C. V., Facklam, R. R., & Fraser, D. W. (1980). Pneumococcal disease after pneumococcal vaccination: An alternative method to estimate the efficacy of pneumococcal vaccine. *The New England Journal of Medicine*, 303(10), 549–552. <https://doi.org/10.1056/NEJM198009043031003>

Brown, J. S., Kulldorff, M., Chan, K. A., Davis, R. L., Graham, D., Pettus, P. T., Andrade, S. E., Raebel, M. A., Herrinton, L., Roblin, D., Boudreau, D., Smith, D., Gurwitz, J. H., Gunter, M. J., & Platt, R. (2007). Early detection of adverse drug events within population-based health networks: Application of sequential testing methods. *Pharmacoepidemiology and Drug Safety*, 16(12), 1275–1284.  
<https://doi.org/10.1002/pds.1509>

Burn, E., Li, X., Kostka, K., Stewart, H. M., Reich, C., Seager, S., Duarte-Salles, T., Fernandez-Bertolin, S., Aragón, M., Reyes, C., Martinez-Hernandez, E., Marti, E., Delmestri, A., Verhamme, K., Rijnbeek, P., Horban, S., Morales, D. R., & Prieto-Alhambra, D. (2022). Background rates of five thrombosis with thrombocytopenia syndromes of special interest for COVID-19 vaccine safety surveillance: Incidence between 2017 and 2019 and patient profiles from 38.6 million people in six European countries. *Pharmacoepidemiology and Drug Safety*, 31(5), 495–510.  
<https://doi.org/10.1002/pds.5419>

Carvajal, A., Ortega, P. G., Sáinz, M., Velasco, V., Salado, I., Arias, L. H. M., Eiros, J. M., Rubio, A. P., & Castrodeza, J. (2011). Adverse events associated with pandemic influenza vaccines: Comparison of the results of a follow-up study with those coming from spontaneous reporting. *Vaccine*, 29(3), 519–522. <https://doi.org/10.1016/j.vaccine.2010.10.067>

Castilla, J., Beristain, X., Martínez-Artola, V., Navascués, A., García Cenoz, M., Alvarez, N., Polo, I., Mazón, A., Gil-Setas, A., & Barricarte, A. (2012). Effectiveness of rotavirus vaccines in preventing cases and hospitalizations due to rotavirus gastroenteritis in Navarre, Spain. *Vaccine*, 30(3), 539–543.  
<https://doi.org/10.1016/j.vaccine.2011.11.071>

Chodick, G., Tene, L., Patalon, T., Gazit, S., Ben Tov, A., Cohen, D., & Muhsen, K. (2021). Assessment of Effectiveness of 1 Dose of BNT162b2 Vaccine for SARS-CoV-2 Infection 13 to 24 Days After Immunization. *JAMA Network Open*, 4(6), e2115985.  
<https://doi.org/10.1001/jamanetworkopen.2021.15985>

Chrapkowska, C., Galanis, I., Kark, M., Lepp, T., Lindstrand, A., Roth, A., & Nilsson, A. (2020). Validation of the new Swedish vaccination register—Accuracy and completeness of register data. *Vaccine*, 38(25), 4104–4110. <https://doi.org/10.1016/j.vaccine.2020.04.020>

Chua, H., Feng, S., Lewnard, J. A., Sullivan, S. G., Blyth, C. C., Lipsitch, M., & Cowling, B. J. (2020). The use of test-negative controls to monitor vaccine effectiveness: A systematic review of methodology. *Epidemiology (Cambridge, Mass.)*, 31(1), 43–64.  
<https://doi.org/10.1097/EDE.0000000000001116>

CIOMS Guide to Vaccine Safety Communication • COUNCIL FOR INTERNATIONAL ORGANIZATIONS OF MEDICAL SCIENCES. COUNCIL FOR INTERNATIONAL ORGANIZATIONS OF MEDICAL SCIENCES.  
<https://cioms.ch/publications/product/cioms-guide-vaccine-safety-communication/>

Cohort Event Monitoring of safety of COVID-19 vaccines (Early-) Covid-Vaccine-Monitor (1.0).  
<https://doi.org/10.5281/ZENODO.6629550>

Core protocol for ECDC studies of COVID-19 vaccine effectiveness against hospitalisation with Severe Acute Respiratory Infection laboratory-confirmed with SARS-CoV-2, version 1.0. (2021, October 8). European Centre for Disease Prevention and Control. <https://www.ecdc.europa.eu/en/publications-data/core-protocol-ecdc-studies-covid-19-vaccine-effectiveness-against-hospitalisation>

Core protocol for population-based database cohort-studies. DRIVE, 46. [DRIVE D7.2 Core-protocol-for-population-based-database-cohort-studies V1.1.pdf \(drive-eu.org\)](https://drive.eu.org/D7.2_Core-protocol-for-population-based-database-cohort-studies_V1.1.pdf)

COVID-19 Vaccine Safety Active Monitoring Protocol. US Food and Drug Administration.  
<https://bestinitiative.org/wp-content/uploads/2021/02/C19-Vaccine-Safety-Protocol-2021.pdf>



COVID-19 Vaccines: Safety surveillance manual. Module on safety surveillance of COVID-19 vaccines in pregnant and breastfeeding women. <https://www.who.int/publications-detail-redirect/WHO-MHP-RPQ-PVG-2021.1>

COVIDRIVE TND-VE Master Protocol. [https://covidrive.eu/wp-content/uploads/2021/09/COVIDRIVE\\_TND-VE\\_MasterProtocol\\_v3.1.pdf](https://covidrive.eu/wp-content/uploads/2021/09/COVIDRIVE_TND-VE_MasterProtocol_v3.1.pdf)

Crowcroft, N. S., & Klein, N. P. (2018). A framework for research on vaccine effectiveness. *Vaccine*, 36(48), 7286–7293. <https://doi.org/10.1016/j.vaccine.2018.04.016>

Dagan, N., Barda, N., Kepten, E., Miron, O., Perchik, S., Katz, M. A., Hernán, M. A., Lipsitch, M., Reis, B., & Balicer, R. D. (2021). BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting. *The New England Journal of Medicine*, 384(15), 1412–1423. <https://doi.org/10.1056/NEJMoa2101765>

de Bie, S., Verhamme, K. M. C., Straus, S. M. J. M., Stricker, B. H. C., & Sturkenboom, M. C. J. M. (2012). Vaccine-based subgroup analysis in VigiBase: Effect on sensitivity in paediatric signal detection. *Drug Safety*, 35(4), 335–346. <https://doi.org/10.2165/11598120-000000000-00000>

de Lusignan, S., Dos Santos, G., Correa, A., Haguinet, F., Yonova, I., Lair, F., Byford, R., Ferreira, F., Stuttard, K., & Chan, T. (2017). Post-authorisation passive enhanced safety surveillance of seasonal influenza vaccines: Protocol of a pilot study in England. *BMJ Open*, 7(5), e015469. <https://doi.org/10.1136/bmjopen-2016-015469>

De Serres, G., Pilishvili, T., Link-Gelles, R., Reingold, A., Gershman, K., Petit, S., Farley, M. M., Harrison, L. H., Lynfield, R., Bennett, N. M., Baumbach, J., Thomas, A., Schaffner, W., Beall, B., Whitney, C., & Moore, M. (2012). Use of surveillance data to estimate the effectiveness of the 7-valent conjugate pneumococcal vaccine in children less than 5 years of age over a 9 year period. *Vaccine*, 30(27), 4067–4072. <https://doi.org/10.1016/j.vaccine.2012.04.017>

De Smedt, T., Merrall, E., Macina, D., Perez-Vilar, S., Andrews, N., & Bollaerts, K. (2018). Bias due to differential and non-differential disease- and exposure misclassification in studies of vaccine effectiveness. *PLoS One*, 13(6), e0199180. <https://doi.org/10.1371/journal.pone.0199180>

De Vito, C., Manzoli, L., Marzuillo, C., Anastasi, D., Boccia, A., & Villari, P. (2007). A systematic review evaluating the potential for bias and the methodological quality of meta-analyses in vaccinology. *Vaccine*, 25(52), 8794–8806. <https://doi.org/10.1016/j.vaccine.2007.10.034>

Dean, N. E., Hogan, J. W., & Schnitzer, M. E. (2021). Covid-19 Vaccine Effectiveness and the Test-Negative Design. *New England Journal of Medicine*, 385(15), 1431–1433. <https://doi.org/10.1056/NEJMe2113151>

Definition and Application of Terms for Vaccine Pharmacovigilance. <https://www.who.int/publications/m/item/9789290360834>

Dhanda, S., Osborne, V., Lynn, E., & Shakir, S. (2022). Postmarketing studies: Can they provide a safety net for COVID-19 vaccines in the UK? *BMJ Evidence-Based Medicine*, 27(1), 1–6. <https://doi.org/10.1136/bmjebm-2020-111507>

Dickerman, B. A., Gerlovin, H., Madenci, A. L., Kurgansky, K. E., Ferolito, B. R., Figueroa Muñiz, M. J., Gagnon, D. R., Gaziano, J. M., Cho, K., Casas, J. P., & Hernán, M. A. (2022). Comparative Effectiveness of BNT162b2 and mRNA-1273 Vaccines in U.S. Veterans. *The New England Journal of Medicine*, 386(2), 105–115. <https://doi.org/10.1056/NEJMoa2115463>

Dieleman, J., Romio, S., Johansen, K., Weibel, D., Bonhoeffer, J., & Sturkenboom, M. (2011). Guillain-Barré syndrome and adjuvanted pandemic influenza A (H1N1) 2009 vaccine: Multinational case-control study in Europe. *BMJ*, 343, d3908. <https://doi.org/10.1136/bmj.d3908>

DRIVE. <https://www.drive-eu.org/>

DRIVE Core protocol for test-negative design studies. [https://www.drive-eu.org/wp-content/uploads/2020/09/DRIVE\\_D7.1.2\\_Core-protocol-for-test-negative-design-studies.pdf](https://www.drive-eu.org/wp-content/uploads/2020/09/DRIVE_D7.1.2_Core-protocol-for-test-negative-design-studies.pdf)

Drolet, M., Bénard, É., Pérez, N., Brisson, M., & HPV Vaccination Impact Study Group. (2019). Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: Updated systematic review and meta-analysis. *Lancet (London, England)*, 394(10197), 497–509. [https://doi.org/10.1016/S0140-6736\(19\)30298-3](https://doi.org/10.1016/S0140-6736(19)30298-3)

Ebola ça Suffit Ring Vaccination Trial Consortium. (2015). The ring vaccination trial: A novel cluster randomised controlled trial design to evaluate vaccine efficacy and effectiveness during outbreaks, with special reference to Ebola. *BMJ (Clinical Research Ed.)*, 351, h3740. <https://doi.org/10.1136/bmj.h3740>

Escolano, S., Farrington, C. P., Hill, C., & Tubert-Bitter, P. (2011). Intussusception after Rotavirus Vaccination—Spontaneous Reports. *New England Journal of Medicine*, 365(22), 2139–2139. <https://doi.org/10.1056/NEJMc1107771>

Escolano, S., Hill, C., & Tubert-Bitter, P. (2013). A new self-controlled case series method for analyzing spontaneous reports of adverse events after vaccination. *American Journal of Epidemiology*, 178(9), 1496–1504. <https://doi.org/10.1093/aje/kwt128>

European Centre for Disease Prevention and Control. <https://www.ecdc.europa.eu/en>

European Centre for Disease Prevention and Control. (2013a). Effectiveness of rotavirus vaccination: Generic study protocol for retrospective case control studies based on computerised databases : technical document. Publications Office. <https://data.europa.eu/doi/10.2900/64929>

European Centre for Disease Prevention and Control. (2013b). Effectiveness of rotavirus vaccination: Generic study protocol for retrospective cohort studies based on computerised databases. Publications Office. <https://data.europa.eu/doi/10.2900/74897>

European Centre for Disease Prevention and Control. (2013c). Impact of rotavirus vaccination: Generic study protocol. Publications Office. <https://data.europa.eu/doi/10.2900/7583>

European Centre for Disease Prevention and Control. - 2013—Effectiveness of rotavirus vaccination generic st.pdf. <https://www.ecdc.europa.eu/sites/default/files/media/en/publications/Publications/rotavirus-vaccination-case-control-april2013.pdf>

European Centre for Disease Prevention and Control. - 2013—Impact of rotavirus vaccination generic study pro.pdf. <https://www.ecdc.europa.eu/sites/default/files/media/en/publications/Publications/Rotavirus-impact-vaccination-April-2013.pdf>

Evaluation of COVID-19 vaccine effectiveness. [https://www.who.int/publications-detail-redirect/WHO-2019-nCoV-vaccine\\_effectiveness-measurement-2021.1](https://www.who.int/publications-detail-redirect/WHO-2019-nCoV-vaccine_effectiveness-measurement-2021.1)

Evans, S. J. W. (2008). Stratification for Spontaneous Report Databases. *Drug Safety*, 31(11), 1049–1052. <https://doi.org/10.2165/00002018-200831110-00009>

EXPLORING THE FEASIBILITY OF CONDUCTING VACCINE. (n.d.). US Food and Drug Administration. [https://www.sentinelinitiative.org/sites/default/files/Methods/Sentinel\\_PRISM\\_Vaccine\\_Effectiveness\\_White\\_Paper.pdf](https://www.sentinelinitiative.org/sites/default/files/Methods/Sentinel_PRISM_Vaccine_Effectiveness_White_Paper.pdf)

Farrington, C. P. (2004). Control without separate controls: Evaluation of vaccine safety using case-only methods. *Vaccine*, 22(15–16), 2064–2070. <https://doi.org/10.1016/j.vaccine.2004.01.017>

Farrington, C. P., Firth, M. J., Moulton, L. H., Ravn, H., Andersen, P. K., Evans, S., & Working Group on Non-specific Effects of Vaccines. (2009). Epidemiological studies of the non-specific effects of vaccines: II--methodological issues in the design and analysis of cohort studies. *Tropical Medicine & International Health: TM & IH*, 14(9), 977–985. <https://doi.org/10.1111/j.1365-3156.2009.02302.x>

Feikin, D. R., Higdon, M. M., Abu-Raddad, L. J., Andrews, N., Araos, R., Goldberg, Y., Groome, M. J., Huppert, A., O'Brien, K. L., Smith, P. G., Wilder-Smith, A., Zeger, S., Deloria Knoll, M., & Patel, M. K. (2022). Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: Results of a systematic review and meta-regression. *Lancet (London, England)*, 399(10328), 924–944. [https://doi.org/10.1016/S0140-6736\(22\)00152-0](https://doi.org/10.1016/S0140-6736(22)00152-0)

Fell, D. B., Dimitris, M. C., Hutcheon, J. A., Ortiz, J. R., Platt, R. W., Regan, A. K., & Savitz, D. A. (2021). Guidance for design and analysis of observational studies of fetal and newborn outcomes following COVID-19 vaccination during pregnancy. *Vaccine*, 39(14), 1882–1886. <https://doi.org/10.1016/j.vaccine.2021.02.070>

Fine, P. E. M., Williams, T. N., Aaby, P., Källander, K., Moulton, L. H., Flanagan, K. L., Smith, P. G., Benn, C. S., & Working Group on Non-specific Effects of Vaccines. (2009). Epidemiological studies of the 'non-specific effects' of vaccines: I--data collection in observational studies. *Tropical Medicine & International Health: TM & IH*, 14(9), 969–976. <https://doi.org/10.1111/j.1365-3156.2009.02301.x>

Ghebremichael-Weldeselassie, Y., Jabagi, M. J., Botton, J., Bertrand, M., Baricault, B., Drouin, J., Weill, A., Zureik, M., Dray-Spira, R., & Farrington, P. (2022). A modified self-controlled case series method for event-dependent exposures and high event-related mortality, with application to COVID-19 vaccine safety. *Statistics in Medicine*, 41(10), 1735–1750. <https://doi.org/10.1002/sim.9325>

Glanz, J. M., McClure, D. L., Xu, S., Hambidge, S. J., Lee, M., Kolczak, M. S., Kleinman, K., Mullooly, J. P., & France, E. K. (2006). Four different study designs to evaluate vaccine safety were equally validated with contrasting limitations. *Journal of Clinical Epidemiology*, 59(8), 808–818. <https://doi.org/10.1016/j.jclinepi.2005.11.012>

Good pharmacovigilance practices. European Medicines Agency. <https://www.ema.europa.eu/en/human-regulatory/post-authorisation/pharmacovigilance/good-pharmacovigilance-practices>

Gram, M. A., Nielsen, J., Schelde, A. B., Nielsen, K. F., Moustsen-Helms, I. R., Sørensen, A. K. B., Valentiner-Branth, P., & Emborg, H.-D. (2021). Vaccine effectiveness against SARS-CoV-2 infection, hospitalization, and death when combining a first dose ChAdOx1 vaccine with a subsequent mRNA vaccine in Denmark: A nationwide population-based cohort study. *PLoS Medicine*, 18(12), e1003874. <https://doi.org/10.1371/journal.pmed.1003874>

Greene, S. K., Kulldorff, M., Lewis, E. M., Li, R., Yin, R., Weintraub, E. S., Fireman, B. H., Lieu, T. A., Nordin, J. D., Glanz, J. M., Baxter, R., Jacobsen, S. J., Broder, K. R., & Lee, G. M. (2010). Near real-time surveillance for influenza vaccine safety: Proof-of-concept in the Vaccine Safety Datalink Project. *American Journal of Epidemiology*, 171(2), 177–188. <https://doi.org/10.1093/aje/kwp345>

Guidance for the format and content of the protocol of non-interventional post-authorisation safety studies. (n.d.). European Medicines Agency.

[https://www.ema.europa.eu/en/documents/other/guidance-format-content-protocol-non-interventional-post-authorisation-safety-studies\\_en.pdf](https://www.ema.europa.eu/en/documents/other/guidance-format-content-protocol-non-interventional-post-authorisation-safety-studies_en.pdf)

Haas, E. J., Angulo, F. J., McLaughlin, J. M., Anis, E., Singer, S. R., Khan, F., Brooks, N., Smaja, M., Mircus, G., Pan, K., Southern, J., Swerdlow, D. L., Jodar, L., Levy, Y., & Alroy-Preis, S. (2021). Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: An observational study using national surveillance data. *Lancet (London, England)*, 397(10287), 1819–1829.

[https://doi.org/10.1016/S0140-6736\(21\)00947-8](https://doi.org/10.1016/S0140-6736(21)00947-8)

Halloran, M. E., Haber, M., Longini, I. M., Jr, & Struchiner, C. J. (1991). Direct and Indirect Effects in Vaccine Efficacy and Effectiveness. *American Journal of Epidemiology*, 133(4), 323–331.

<https://doi.org/10.1093/oxfordjournals.aje.a115884>

Halloran, M. E., Longini, I., & Struchiner, C. (2010). *Design and Analysis of Vaccine Studies*. Springer. <https://link.springer.com/book/10.1007/978-0-387-68636-3>

Hanquet, G., Valenciano, M., Simondon, F., & Moren, A. (2013a). Vaccine effects and impact of vaccination programmes in post-licensure studies. *Vaccine*, 31(48), 5634–5642.

<https://doi.org/10.1016/j.vaccine.2013.07.006>

Harmonising Immunisation Safety Assessment in Pregnancy Part I. (2016). *Vaccine*, 34(49), IFC.

[https://doi.org/10.1016/S0264-410X\(16\)31046-5](https://doi.org/10.1016/S0264-410X(16)31046-5)

Harmonising Immunisation Safety Assessment in Pregnancy Part II. (2017). *Vaccine*, 35(48, Part A), IFC. [https://doi.org/10.1016/S0264-410X\(17\)31553-0](https://doi.org/10.1016/S0264-410X(17)31553-0)

Harpaz, R., DuMouchel, W., Van Manen, R., Nip, A., Bright, S., Szarfman, A., Tonning, J., & Lerch, M. (2022). Signaling COVID-19 Vaccine Adverse Events. *Drug Safety*. <https://doi.org/10.1007/s40264-022-01186-z>

Harris, R. J., Hall, J. A., Zaidi, A., Andrews, N. J., Dunbar, J. K., & Dabrera, G. (2021). Effect of Vaccination on Household Transmission of SARS-CoV-2 in England. *The New England Journal of Medicine*, 385(8), 759–760. <https://doi.org/10.1056/NEJMc2107717>

Heffernan, J. M., & Keeling, M. J. (2009). Implications of vaccination and waning immunity. *Proceedings of the Royal Society B: Biological Sciences*, 276(1664), 2071–2080.

<https://doi.org/10.1098/rspb.2009.0057>

Heininger, U., Holm, K., Caplanusi, I., Bailey, S. R., & CIOMS Working Group on Vaccine Safety. (2017). Guide to active vaccine safety surveillance: Report of CIOMS working group on vaccine safety - executive summary. *Vaccine*, 35(32), 3917–3921. <https://doi.org/10.1016/j.vaccine.2017.06.033>

Hennessy, S., Liu, Z., Tsai, T. F., Strom, B. L., Wan, C. M., Liu, H. L., Wu, T. X., Yu, H. J., Liu, Q. M., Karabatsos, N., Bilker, W. B., & Halstead, S. B. (1996). Effectiveness of live-attenuated Japanese encephalitis vaccine (SA14-14-2): A case-control study. *Lancet (London, England)*, 347(9015), 1583–1586. [https://doi.org/10.1016/s0140-6736\(96\)91075-2](https://doi.org/10.1016/s0140-6736(96)91075-2)

Hocine, M. N., Farrington, C. P., Touzé, E., Whitaker, H. J., Fourrier, A., Moreau, T., & Tubert-Bitter, P. (2007). Hepatitis B vaccination and first central nervous system demyelinating events: Reanalysis of a case-control study using the self-controlled case series method. *Vaccine*, 25(31), 5938–5943.

<https://doi.org/10.1016/j.vaccine.2007.05.032>

Hviid, A., Svanström, H., Scheller, N. M., Grönlund, O., Pasternak, B., & Arnheim-Dahlström, L. (2018). Human papillomavirus vaccination of adult women and risk of autoimmune and neurological diseases. *Journal of Internal Medicine*, 283(2), 154–165. <https://doi.org/10.1111/joim.12694>

- Jackson, M. L., & Nelson, J. C. (2013). The test-negative design for estimating influenza vaccine effectiveness. *Vaccine*, 31(17), 2165–2168. <https://doi.org/10.1016/j.vaccine.2013.02.053>
- Jefferson, T., Rivetti, D., Rivetti, A., Rudin, M., Di Pietrantonj, C., & Demicheli, V. (2005). Efficacy and effectiveness of influenza vaccines in elderly people: A systematic review. *Lancet (London, England)*, 366(9492), 1165–1174. [https://doi.org/10.1016/S0140-6736\(05\)67339-4](https://doi.org/10.1016/S0140-6736(05)67339-4)
- Kahn, R., Schrag, S. J., Verani, J. R., & Lipsitch, M. (2022). Identifying and Alleviating Bias Due to Differential Depletion of Susceptible People in Postmarketing Evaluations of COVID-19 Vaccines. *American Journal of Epidemiology*, 191(5), 800–811. <https://doi.org/10.1093/aje/kwac015>
- Karlstad, Ø., Hovi, P., Husby, A., Härkänen, T., Selmer, R. M., Pihlström, N., Hansen, J. V., Nohynek, H., Gunnes, N., Sundström, A., Wohlfahrt, J., Nieminen, T. A., Grünewald, M., Gulseth, H. L., Hviid, A., & Ljung, R. (2022). SARS-CoV-2 Vaccination and Myocarditis in a Nordic Cohort Study of 23 Million Residents. *JAMA Cardiology*, 7(6), 600–612. <https://doi.org/10.1001/jamacardio.2022.0583>
- Katsoularis, I., Fonseca-Rodríguez, O., Farrington, P., Lindmark, K., & Fors Connolly, A.-M. (2021). Risk of acute myocardial infarction and ischaemic stroke following COVID-19 in Sweden: A self-controlled case series and matched cohort study. *Lancet (London, England)*, 398(10300), 599–607. [https://doi.org/10.1016/S0140-6736\(21\)00896-5](https://doi.org/10.1016/S0140-6736(21)00896-5)
- Kerr, S., Joy, M., Torabi, F., Bedston, S., Akbari, A., Agrawal, U., Beggs, J., Bradley, D., Chuter, A., Docherty, A. B., Ford, D., Hobbs, R., Katikireddi, S. V., Lowthian, E., de Lusignan, S., Lyons, R., Marple, J., McCowan, C., McGagh, D., ... Sheikh, A. (2022). First dose ChAdOx1 and BNT162b2 COVID-19 vaccinations and cerebral venous sinus thrombosis: A pooled self-controlled case series study of 11.6 million individuals in England, Scotland, and Wales. *PLoS Medicine*, 19(2), e1003927. <https://doi.org/10.1371/journal.pmed.1003927>
- Kharbanda, E. O., Haapala, J., DeSilva, M., Vazquez-Benitez, G., Vesco, K. K., Naleway, A. L., & Lipkind, H. S. (2021). Spontaneous Abortion Following COVID-19 Vaccination During Pregnancy. *JAMA*, 326(16), 1629–1631. <https://doi.org/10.1001/jama.2021.15494>
- Klein, N. P. (2011). Vaccine safety in special populations. *Human Vaccines*, 7(2), 269–271. <https://doi.org/10.4161/hv.7.2.13860>
- Kulldorff, M., Dashevsky, I., Avery, T. R., Chan, A. K., Davis, R. L., Graham, D., Platt, R., Andrade, S. E., Boudreau, D., Gunter, M. J., Herrinton, L. J., Pawloski, P. A., Raebel, M. A., Roblin, D., & Brown, J. S. (2013). Drug safety data mining with a tree-based scan statistic. *Pharmacoepidemiology and Drug Safety*, 22(5), 517–523. <https://doi.org/10.1002/pds.3423>
- Lai, L. Y., Arshad, F., Areia, C., Alshammari, T. M., Alghoul, H., Casajust, P., Li, X., Dawoud, D., Nyberg, F., Pratt, N., Hripcsak, G., Suchard, M. A., Prieto-Alhambra, D., Ryan, P., & Schuemie, M. J. (2022). Current Approaches to Vaccine Safety Using Observational Data: A Rationale for the EUMAEUS (Evaluating Use of Methods for Adverse Events Under Surveillance-for Vaccines) Study Design. *Frontiers in Pharmacology*, 13, 837632. <https://doi.org/10.3389/fphar.2022.837632>
- Lasky, T., McMahon, A. W., Hua, W., & Forshee, R. (2021). Methodologic approaches in studies using real-world data (RWD) to measure pediatric safety and effectiveness of vaccines administered to pregnant women: A scoping review. *Vaccine*, 39(29), 3814–3824. <https://doi.org/10.1016/j.vaccine.2021.05.071>
- Layton, D., & Shakir, S. A. W. (2015). Specialist Cohort Event Monitoring studies: A new study method for risk management in pharmacovigilance. *Drug Safety*, 38(2), 153–163. <https://doi.org/10.1007/s40264-014-0260-x>

- Leino, T., Ollgren, J., Salo, H., Tiihonen, P., & Kilpi, T. (2012). First year experience of rotavirus immunisation programme in Finland. *Vaccine*, 31(1), 176–182. <https://doi.org/10.1016/j.vaccine.2012.10.068>
- Leite, A., Andrews, N. J., & Thomas, S. L. (2016). Near real-time vaccine safety surveillance using electronic health records—A systematic review of the application of statistical methods. *Pharmacoepidemiology and Drug Safety*, 25(3), 225–237. <https://doi.org/10.1002/pds.3966>
- Levi et al. - Ritva Syrjänen (6 – THL) ritva.syrjanen@thl.fi Ulr.pdf. [https://www.drive-eu.org/wp-content/uploads/2018/12/DRIVE\\_D7.2\\_Core-protocol-for-population-based-database-cohort-studies\\_V1.1.pdf](https://www.drive-eu.org/wp-content/uploads/2018/12/DRIVE_D7.2_Core-protocol-for-population-based-database-cohort-studies_V1.1.pdf)
- Li, X., Lai, L. Y., Ostropolets, A., Arshad, F., Tan, E. H., Casajust, P., Alshammari, T. M., Duarte-Salles, T., Minty, E. P., Areia, C., Pratt, N., Ryan, P. B., Hripcsak, G., Suchard, M. A., Schuemie, M. J., & Prieto-Alhambra, D. (2021). Bias, Precision and Timeliness of Historical (Background) Rate Comparison Methods for Vaccine Safety Monitoring: An Empirical Multi-Database Analysis. *Frontiers in Pharmacology*, 12, 773875. <https://doi.org/10.3389/fphar.2021.773875>
- Li, X., Ostropolets, A., Makadia, R., Shoaibi, A., Rao, G., Sena, A. G., Martinez-Hernandez, E., Delmestri, A., Verhamme, K., Rijnbeek, P. R., Duarte-Salles, T., Suchard, M. A., Ryan, P. B., Hripcsak, G., & Prieto-Alhambra, D. (2021). Characterising the background incidence rates of adverse events of special interest for covid-19 vaccines in eight countries: Multinational network cohort study. *BMJ*, 373, n1435. <https://doi.org/10.1136/bmj.n1435>
- Lipsitch, M., Goldstein, E., Ray, G. T., & Fireman, B. (2019). Depletion-of-susceptibles bias in influenza vaccine waning studies: How to ensure robust results. *Epidemiology and Infection*, 147, e306. <https://doi.org/10.1017/S0950268819001961>
- Lopez Bernal, J., Andrews, N., Gower, C., Robertson, C., Stowe, J., Tessier, E., Simmons, R., Cottrell, S., Roberts, R., O’Doherty, M., Brown, K., Cameron, C., Stockton, D., McMenamin, J., & Ramsay, M. (2021). Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: Test negative case-control study. *BMJ (Clinical Research Ed.)*, 373, n1088. <https://doi.org/10.1136/bmj.n1088>
- Madewell, Z. J., Dean, N. E., Berlin, J. A., Coplan, P. M., Davis, K. J., Struchiner, C. J., & Halloran, M. E. (2021). Challenges of evaluating and modelling vaccination in emerging infectious diseases. *Epidemics*, 37, 100506. <https://doi.org/10.1016/j.epidem.2021.100506>
- Magnus, M. C., Örtqvist, A. K., Dahlqvist, E., Ljung, R., Skår, F., Oakley, L., Macsali, F., Pasternak, B., Gjessing, H. K., Håberg, S. E., & Stephansson, O. (2022). Association of SARS-CoV-2 Vaccination During Pregnancy With Pregnancy Outcomes. *JAMA*, 327(15), 1469–1477. <https://doi.org/10.1001/jama.2022.3271>
- Mahaux, O., Bauchau, V., & Van Holle, L. (2016a). Pharmacoepidemiological considerations in observed-to-expected analyses for vaccines. *Pharmacoepidemiology and Drug Safety*, 25(2), 215–222. <https://doi.org/10.1002/pds.3918>
- Marin, M., Marti, M., Kambhampati, A., Jeram, S. M., & Seward, J. F. (2016). Global Varicella Vaccine Effectiveness: A Meta-analysis. *Pediatrics*, 137(3), e20153741. <https://doi.org/10.1542/peds.2015-3741>
- Marshall, H. S., McMillan, M., Koehler, A. P., Lawrence, A., Sullivan, T. R., MacLennan, J. M., Maiden, M. C. J., Ladhani, S. N., Ramsay, M. E., Trotter, C., Borrow, R., Finn, A., Kahler, C. M., Whelan, J., Vadivelu, K., & Richmond, P. (2020). Meningococcal B Vaccine and Meningococcal Carriage in

Adolescents in Australia. *The New England Journal of Medicine*, 382(4), 318–327.

<https://doi.org/10.1056/NEJMoa1900236>

Martín Arias, L. H., Sanz, R., Sáinz, M., Treceño, C., & Carvajal, A. (2015). Guillain-Barré syndrome and influenza vaccines: A meta-analysis. *Vaccine*, 33(31), 3773–3778.

<https://doi.org/10.1016/j.vaccine.2015.05.013>

Master Protocol: Assessment of Risk of Safety Outcomes Following COVID-19 Vaccination. (2021). US Food and Drug Administration. <https://bestinitiative.org/wp-content/uploads/2021/04/COVID-19-Vaccine-Safety-Inferential-Draft-Master-Protocol.pdf>

McClure, D. L., Glanz, J. M., Xu, S., Hambidge, S. J., Mullooly, J. P., & Baggs, J. (2008). Comparison of epidemiologic methods for active surveillance of vaccine safety. *Vaccine*, 26(26), 3341–3345.

<https://doi.org/10.1016/j.vaccine.2008.03.074>

Menni, C., Klaser, K., May, A., Polidori, L., Capdevila, J., Louca, P., Sudre, C. H., Nguyen, L. H., Drew, D. A., Merino, J., Hu, C., Selvachandran, S., Antonelli, M., Murray, B., Canas, L. S., Molteni, E., Graham, M. S., Modat, M., Joshi, A. D., ... Spector, T. D. (2021). Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: A prospective observational study. *The Lancet. Infectious Diseases*, 21(7), 939–949. [https://doi.org/10.1016/S1473-3099\(21\)00224-3](https://doi.org/10.1016/S1473-3099(21)00224-3)

Menni, C., May, A., Polidori, L., Louca, P., Wolf, J., Capdevila, J., Hu, C., Ourselin, S., Steves, C. J., Valdes, A. M., & Spector, T. D. (2022). COVID-19 vaccine waning and effectiveness and side-effects of boosters: A prospective community study from the ZOE COVID Study. *The Lancet. Infectious Diseases*, 22(7), 1002–1010. [https://doi.org/10.1016/S1473-3099\(22\)00146-3](https://doi.org/10.1016/S1473-3099(22)00146-3)

Miller, E., Andrews, N., Stellitano, L., Stowe, J., Winstone, A. M., Shneerson, J., & Verity, C. (2013). Risk of narcolepsy in children and young people receiving AS03 adjuvanted pandemic A/H1N1 2009 influenza vaccine: Retrospective analysis. *BMJ (Clinical Research Ed.)*, 346, f794.

<https://doi.org/10.1136/bmj.f794>

Milman, O., Yelin, I., Aharony, N., Katz, R., Herzog, E., Ben-Tov, A., Kuint, J., Gazit, S., Chodick, G., Patalon, T., & Kishony, R. (2021). Community-level evidence for SARS-CoV-2 vaccine protection of unvaccinated individuals. *Nature Medicine*, 27(8), 1367–1369. <https://doi.org/10.1038/s41591-021-01407-5>

Murray, J., & Cohen, A. L. (2017). Infectious Disease Surveillance. *International Encyclopedia of Public Health*, 222–229. <https://doi.org/10.1016/B978-0-12-803678-5.00517-8>

Nelson, J. C., Cook, A. J., Yu, O., Dominguez, C., Zhao, S., Greene, S. K., Fireman, B. H., Jacobsen, S. J., Weintraub, E. S., & Jackson, L. A. (2012). Challenges in the design and analysis of sequentially monitored postmarket safety surveillance evaluations using electronic observational health care data. *Pharmacoepidemiology and Drug Safety*, 21 Suppl 1, 62–71. <https://doi.org/10.1002/pds.2324>

Omersel, J., & Karas Kuželički, N. (2020). Vaccinomics and Adversomics in the Era of Precision Medicine: A Review Based on HBV, MMR, HPV, and COVID-19 Vaccines. *Journal of Clinical Medicine*, 9(11), E3561. <https://doi.org/10.3390/jcm9113561>

Ortiz, J. R., & Neuzil, K. M. (2022). The value of vaccine programme impact monitoring during the COVID-19 pandemic. *Lancet (London, England)*, 399(10320), 119–121.

[https://doi.org/10.1016/S0140-6736\(21\)02322-9](https://doi.org/10.1016/S0140-6736(21)02322-9)

Ostropolets, A., Li, X., Makadia, R., Rao, G., Rijnbeek, P. R., Duarte-Salles, T., Sena, A. G., Shaoibi, A., Suchard, M. A., Ryan, P. B., Prieto-Alhambra, D., & Hripcsak, G. (2022). Factors Influencing

Background Incidence Rate Calculation: Systematic Empirical Evaluation Across an International Network of Observational Databases. *Frontiers in Pharmacology*, 13, 814198.  
<https://doi.org/10.3389/fphar.2022.814198>

Panozzo et al. - EXPLORING THE FEASIBILITY OF CONDUCTING VACCINE.pdf.  
[https://www.sentinelinitiative.org/sites/default/files/Methods/Sentinel\\_PRISM\\_Vaccine\\_Effectiveness\\_White\\_Paper.pdf](https://www.sentinelinitiative.org/sites/default/files/Methods/Sentinel_PRISM_Vaccine_Effectiveness_White_Paper.pdf)

Patel, M. M., Jackson, M. L., & Ferdinands, J. (2020). Postlicensure Evaluation of COVID-19 Vaccines. *JAMA*, 324(19), 1939–1940. <https://doi.org/10.1001/jama.2020.19328>

Pebody, R. (2012). Vaccine registers—Experiences from Europe and elsewhere. *Euro Surveillance: Bulletin European Sur Les Maladies Transmissibles = European Communicable Disease Bulletin*, 17(17), 20159. <https://doi.org/10.2807/ese.17.17.20159-en>

Pottegård, A., Lund, L. C., Karlstad, Ø., Dahl, J., Andersen, M., Hallas, J., Lidegaard, Ø., Tapia, G., Gulseth, H. L., Ruiz, P. L.-D., Wattle, S. V., Mikkelsen, A. P., Pedersen, L., Sørensen, H. T., Thomsen, R. W., & Hviid, A. (2021). Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: Population based cohort study. *BMJ (Clinical Research Ed.)*, 373, n1114. <https://doi.org/10.1136/bmj.n1114>

Praet, N., Asante, K. P., Bozonnat, M.-C., Akité, E. J., Ansah, P. O., Baril, L., Boahen, O., Mendoza, Y. G., Haine, V., Kariuki, S., Lamy, M., Maleta, K., Mungwira, R., Ndeketa, L., Oduro, A., Ogutu, B., Olewe, F., Onoko, M., Orsini, M., ... Pirçon, J.-Y. (2022). Assessing the safety, impact and effectiveness of RTS,S/AS01E malaria vaccine following its introduction in three sub-Saharan African countries: Methodological approaches and study set-up. *Malaria Journal*, 21(1), 132.  
<https://doi.org/10.1186/s12936-022-04144-3>

Prasad, S., Kalafat, E., Blakeway, H., Townsend, R., O'Brien, P., Morris, E., Draycott, T., Thangaratinam, S., Le Doare, K., Ladhani, S., von Dadelszen, P., Magee, L. A., Heath, P., & Khalil, A. (2022). Systematic review and meta-analysis of the effectiveness and perinatal outcomes of COVID-19 vaccination in pregnancy. *Nature Communications*, 13(1), 2414. <https://doi.org/10.1038/s41467-022-30052-w>

Protocol for Cluster Investigations to Measure Influenza Vaccine Effectiveness. ECDC.  
[https://www.ecdc.europa.eu/sites/default/files/media/en/publications/Publications/0912\\_TED\\_Protocol\\_for\\_Cluster\\_Investigations\\_to\\_Measure\\_Influenza\\_Vaccine\\_Effectiveness.pdf](https://www.ecdc.europa.eu/sites/default/files/media/en/publications/Publications/0912_TED_Protocol_for_Cluster_Investigations_to_Measure_Influenza_Vaccine_Effectiveness.pdf)

Protocol template to be used as template for observational study protocols for sentinel surveillance of adverse events of special interest (AESIs) after vaccination with COVID-19 vaccines.  
<https://www.who.int/publications-detail-redirect/9789240029507>

Prunas, O., Warren, J. L., Crawford, F. W., Gazit, S., Patalon, T., Weinberger, D. M., & Pitzer, V. E. (2022). Vaccination with BNT162b2 reduces transmission of SARS-CoV-2 to household contacts in Israel. *Science (New York, N.Y.)*, 375(6585), 1151–1154. <https://doi.org/10.1126/science.aba4292>

Public health surveillance for COVID-19: Interim guidance. World Health Organization.  
<https://www.who.int/publications-detail-redirect/WHO-2019-nCoV-SurveillanceGuidance-2022.1>

Rapid assessment of COVID-19 vaccines safety concerns through electronic health records- a protocol template from the ACCESS project. <https://vac4eu.org/wp-content/uploads/2021/02/3b.Rapid-assessment-of-COVID-19-vaccines-safety-concerns-through-electronic-health-records-a-protocol-template-from-the-ACCESS-project-.pdf>



Rasmussen, T. A., Jørgensen, M. R. S., Bjerrum, S., Jensen-Fangel, S., Støvring, H., Østergaard, L., & Søgaard, O. S. (2012). Use of population based background rates of disease to assess vaccine safety in childhood and mass immunisation in Denmark: Nationwide population based cohort study. *The BMJ*, 345, e5823. <https://doi.org/10.1136/bmj.e5823>

Remschmidt, C., Rieck, T., Bödeker, B., & Wichmann, O. (n.d.). Application of the screening method to monitor influenza vaccine effectiveness among the elderly in Germany | *BMC Infectious Diseases* <https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-015-0882-3>

Renoud, L., Khouri, C., Revol, B., Lepelley, M., Perez, J., Roustit, M., & Cracowski, J.-L. (2021). Association of Facial Paralysis With mRNA COVID-19 Vaccines: A Disproportionality Analysis Using the World Health Organization Pharmacovigilance Database. *JAMA Internal Medicine*, 181(9), 1243–1245. <https://doi.org/10.1001/jamainternmed.2021.2219>

Rodriguez-Nava, G., Egoryan, G., Trelles-Garcia, D. P., Yanez-Bello, M. A., & Murguia-Fuentes, R. (2021). Disproportionality analysis of anaphylactic reactions after vaccination with messenger RNA coronavirus disease 2019 vaccines in the United States. *Annals of Allergy, Asthma & Immunology: Official Publication of the American College of Allergy, Asthma, & Immunology*, 127(1), 139–140. <https://doi.org/10.1016/j.anai.2021.04.004>

Rondy, M., Issifou, D., Ibrahim, A. S., Maman, Z., Kadade, G., Omou, H., Fati, S., Kissling, E., Meyer, S., & Ronveaux, O. (2016). Vaccine Effectiveness of Polysaccharide Vaccines Against Clinical Meningitis—Niamey, Niger, June 2015. *PLoS Currents*, 8, ecurrents.outbreaks.5d6e9c1d071a2088109c242771b68886. <https://doi.org/10.1371/currents.outbreaks.5d6e9c1d071a2088109c242771b68886>

Rondy, M., Launay, O., Puig-Barberà, J., Gefenaite, G., Castilla, J., de Gaetano Donati, K., Galtier, F., Hak, E., Guevara, M., Costanzo, S., European hospital IVE network, & Moren, A. (2015). 2012/13 influenza vaccine effectiveness against hospitalised influenza A(H1N1)pdm09, A(H3N2) and B: Estimates from a European network of hospitals. *Euro Surveillace: Bulletin European Sur Les Maladies Transmissibles = European Communicable Disease Bulletin*, 20(2), 21011. <https://doi.org/10.2807/1560-7917.es2015.20.2.21011>

Rosillon, D., Willame, C., Tavares Da Silva, F., Guignard, A., Caterina, S., Welby, S., & Struyf, F. (2020). Meta-analysis of the risk of autoimmune thyroiditis, Guillain-Barré syndrome, and inflammatory bowel disease following vaccination with AS04-adjuvanted human papillomavirus 16/18 vaccine. *Pharmacoepidemiology and Drug Safety*, 29(9), 1159–1167. <https://doi.org/10.1002/pds.5063>

Schnitzer, M. E. (2022). Estimands and Estimation of COVID-19 Vaccine Effectiveness Under the Test-Negative Design: Connections to Causal Inference. *Epidemiology (Cambridge, Mass.)*, 33(3), 325–333. <https://doi.org/10.1097/EDE.0000000000001470>

Seabroke, S., Candore, G., Juhlin, K., Quarcoo, N., Wisniewski, A., Arani, R., Painter, J., Tregunno, P., Norén, G. N., & Slattery, J. (2016). Performance of Stratified and Subgrouped Disproportionality Analyses in Spontaneous Databases. *Drug Safety*, 39(4), 355–364. <https://doi.org/10.1007/s40264-015-0388-3>

Simpson, C. R., Lone, N. I., Kavanagh, K., Ritchie, L. D., Robertson, C., Sheikh, A., & McMenamin, J. (2015). Trivalent inactivated seasonal influenza vaccine effectiveness for the prevention of laboratory-confirmed influenza in a Scottish population 2000 to 2009. *Euro Surveillace: Bulletin European Sur Les Maladies Transmissibles = European Communicable Disease Bulletin*, 20(8), 21043. <https://doi.org/10.2807/1560-7917.es2015.20.8.21043>

Simpson, C. R., Shi, T., Vasileiou, E., Katikireddi, S. V., Kerr, S., Moore, E., McCowan, C., Agrawal, U., Shah, S. A., Ritchie, L. D., Murray, J., Pan, J., Bradley, D. T., Stock, S. J., Wood, R., Chuter, A., Beggs, J., Stagg, H. R., Joy, M., ... Sheikh, A. (2021). First-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland. *Nature Medicine*, 27(7), 1290–1297. <https://doi.org/10.1038/s41591-021-01408-4>

Singanayagam, A., Hakki, S., Dunning, J., Madon, K. J., Crone, M. A., Koycheva, A., Derqui-Fernandez, N., Barnett, J. L., Whitfield, M. G., Varro, R., Charlett, A., Kundu, R., Fenn, J., Cutajar, J., Quinn, V., Conibear, E., Barclay, W., Freemont, P. S., Taylor, G. P., ... ATACCC Study Investigators. (2022). Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: A prospective, longitudinal, cohort study. *The Lancet. Infectious Diseases*, 22(2), 183–195. [https://doi.org/10.1016/S1473-3099\(21\)00648-4](https://doi.org/10.1016/S1473-3099(21)00648-4)

Sullivan, S. G., Tchetgen Tchetgen, E. J., & Cowling, B. J. (2016). Theoretical Basis of the Test-Negative Study Design for Assessment of Influenza Vaccine Effectiveness. *American Journal of Epidemiology*, 184(5), 345–353. <https://doi.org/10.1093/aje/kww064>

Systematic overview of data sources for drug safet.pdf.

[https://www.encepp.eu/structure/documents/Data\\_sources\\_for\\_medicines\\_in\\_pregnancy\\_research.pdf](https://www.encepp.eu/structure/documents/Data_sources_for_medicines_in_pregnancy_research.pdf)

Tavares-Da-Silva, F., Co, M. M., Dessart, C., Hervé, C., López-Fauqued, M., Mahaux, O., Van Holle, L., & Stegmann, J.-U. (2020). Review of the initial post-marketing safety surveillance for the recombinant zoster vaccine. *Vaccine*, 38(18), 3489–3500. <https://doi.org/10.1016/j.vaccine.2019.11.058>

Théophile, H., Moore, N., Robinson, P., Bégau, B., & Pariente, A. (2016). Vaccine Case-Population: A New Method for Vaccine Safety Surveillance. *Drug Safety*, 39(12), 1197–1209. <https://doi.org/10.1007/s40264-016-0449-2>

Tokars, J. I., Lewis, P., DeStefano, F., Wise, M., Viray, M., Morgan, O., Gargiullo, P., & Vellozzi, C. (2012). The risk of Guillain-Barré syndrome associated with influenza A (H1N1) 2009 monovalent vaccine and 2009–2010 seasonal influenza vaccines: Results from self-controlled analyses. *Pharmacoepidemiology and Drug Safety*, 21(5), 546–552. <https://doi.org/10.1002/pds.3220>

VAC4EU platform. <https://vac4eu.org/covid-19-tool/>

Vaccination Programmes: Epidemiology, Monitoring, Evaluation. (2021a). Routledge. <https://doi.org/10.4324/9781315166414>

Vaccine Effectiveness Simulation. <https://apps.p-95.com/VEMisclassification/>

Vaccine Safety Basics. WHO. <https://openwho.org/courses/vaccine-safety-basics>

Vaccine Safety Datalink (VSD) | VSD | Monitoring | Ensuring Safety | Vaccine Safety | CDC. (2022, May 11). <https://www.cdc.gov/vaccinesafety/ensuringsafety/monitoring/vsd/index.html>

Van Holle, L., & Bauchau, V. (2013). Optimization of a quantitative signal detection algorithm for spontaneous reports of adverse events post immunization. *Pharmacoepidemiology and Drug Safety*, 22(5), 477–487. <https://doi.org/10.1002/pds.3392>

Vandenbroucke, J. P., & Pearce, N. (2019). Test-Negative Designs: Differences and Commonalities with Other Case-Control Studies with 'Other Patient' Controls. *Epidemiology (Cambridge, Mass.)*, 30(6), 838–844. <https://doi.org/10.1097/EDE.0000000000001088>

Verani, J. R., Baqui, A. H., Broome, C. V., Cherian, T., Cohen, C., Farrar, J. L., Feikin, D. R., Groome, M. J., Hajjeh, R. A., Johnson, H. L., Madhi, S. A., Mulholland, K., O'Brien, K. L., Parashar, U. D., Patel, M. M., Rodrigues, L. C., Santosham, M., Scott, J. A., Smith, P. G., ... Zell, E. R. (2017a). Case-control

- vaccine effectiveness studies: Data collection, analysis and reporting results. *Vaccine*, 35(25), 3303–3308. <https://doi.org/10.1016/j.vaccine.2017.04.035>
- Verani, J. R., Baqui, A. H., Broome, C. V., Cherian, T., Cohen, C., Farrar, J. L., Feikin, D. R., Groome, M. J., Hajjeh, R. A., Johnson, H. L., Madhi, S. A., Mulholland, K., O'Brien, K. L., Parashar, U. D., Patel, M. M., Rodrigues, L. C., Santosham, M., Scott, J. A., Smith, P. G., ... Zell, E. R. (2017b). Case-control vaccine effectiveness studies: Preparation, design, and enrollment of cases and controls. *Vaccine*, 35(25), 3295–3302. <https://doi.org/10.1016/j.vaccine.2017.04.037>
- Wacholder, S., Chen, B. E., Wilcox, A., Macones, G., Gonzalez, P., Befano, B., Hildesheim, A., Rodríguez, A. C., Solomon, D., Herrero, R., Schiffman, M., & CVT group. (2010). Risk of miscarriage with bivalent vaccine against human papillomavirus (HPV) types 16 and 18: Pooled analysis of two randomised controlled trials. *BMJ (Clinical Research Ed.)*, 340, c712. <https://doi.org/10.1136/bmj.c712>
- Watt, A. E., Sherry, N. L., Andersson, P., Lane, C. R., Johnson, S., Wilmot, M., Horan, K., Sait, M., Ballard, S. A., Crachi, C., Beck, D. J., Marshall, C., Kainer, M. A., Stuart, R., McGrath, C., Kwong, J. C., Bass, P., Kelley, P. G., Crowe, A., ... Howden, B. P. (2022). State-wide genomic epidemiology investigations of COVID-19 in healthcare workers in 2020 Victoria, Australia: Qualitative thematic analysis to provide insights for future pandemic preparedness. *The Lancet Regional Health. Western Pacific*, 25, 100487. <https://doi.org/10.1016/j.lanwpc.2022.100487>
- Whitaker, J. A., Ovsyannikova, I. G., & Poland, G. A. (2015). Adversomics: A new paradigm for vaccine safety and design. *Expert Review of Vaccines*, 14(7), 935–947. <https://doi.org/10.1586/14760584.2015.1038249>
- WHO Coronavirus (COVID-19) Dashboard. <https://covid19.who.int>
- WHO Covid-19 vaccines: Safety surveillance manual. [https://www.who.int/docs/default-source/covid-19-vaccines-safety-surveillance-manual/covid19vaccines\\_manual\\_surveillance\\_systems.pdf](https://www.who.int/docs/default-source/covid-19-vaccines-safety-surveillance-manual/covid19vaccines_manual_surveillance_systems.pdf)
- Wijnans, L., Dodd, C. N., Weibel, D., & Sturkenboom, M. (2017). Bell's palsy and influenza(H1N1)pdm09 containing vaccines: A self-controlled case series. *PLoS One*, 12(5), e0175539. <https://doi.org/10.1371/journal.pone.0175539>
- Willame, C., Dodd, C., van der Aa, L., Picelli, G., Emborg, H.-D., Kahlert, J., Gini, R., Huerta, C., Martín-Merino, E., McGee, C., de Lusignan, S., Roberto, G., Villa, M., Weibel, D., Titievsky, L., & Sturkenboom, M. C. J. M. (2021). Incidence Rates of Autoimmune Diseases in European Healthcare Databases: A Contribution of the ADVANCE Project. *Drug Safety*, 44(3), 383–395. <https://doi.org/10.1007/s40264-020-01031-1>
- Wiyeh, A. B., Abdullahi, L. H., Wonkam, A., Wiysonge, C. S., & Kaba, M. (2018). Effects of vaccines in patients with sickle cell disease: A systematic review protocol. *BMJ Open*, 8(3), e021140. <https://doi.org/10.1136/bmjopen-2017-021140>
- Woo, E. J., Ball, R., Burwen, D. R., & Braun, M. M. (2008). Effects of stratification on data mining in the US Vaccine Adverse Event Reporting System (VAERS). *Drug Safety*, 31(8), 667–674. <https://doi.org/10.2165/00002018-200831080-00003>
- World Health Organization. (2017). Evaluation of influenza vaccine effectiveness: A guide to the design and interpretation of observational studies. World Health Organization. <https://apps.who.int/iris/handle/10665/255203>
- World Health Organization. Quality Assurance and Safety of Medicines Team. (2006). The safety of medicines in public health programmes: Pharmacovigilance, an essential tool. World Health Organization. <https://apps.who.int/iris/handle/10665/43384>

Xie, J., Feng, S., Li, X., Gea-Mallorquí, E., Prats-Uribe, A., & Prieto-Alhambra, D. (2022). Comparative effectiveness of the BNT162b2 and ChAdOx1 vaccines against Covid-19 in people over 50. *Nature Communications*, 13(1), 1519. <https://doi.org/10.1038/s41467-022-29159-x>

Xie, J., Prats-Uribe, A., Gordillo Maranon, M., Y. Strauss, V., Gill, D., & Prieto-Alhambra, D. (n.d.). Genetic risk and incident venous thromboembolism in middle-aged and older adults following Covid-19 vaccination. *MedRxiv*. <https://doi.org/10.1101/2022.04.14.22273865>

Xu, R., Luo, Y., & Chambers, C. (2012). Assessing the effect of vaccine on spontaneous abortion using time-dependent covariates Cox models. *Pharmacoepidemiology and Drug Safety*, 21(8), 844–850. <https://doi.org/10.1002/pds.3301>

Yanni, E. A., Ferreira, G., Guennec, M., El Hahi, Y., El Ghachi, A., Haguinet, F., Espie, E., & Bianco, V. (2018). Burden of herpes zoster in 16 selected immunocompromised populations in England: A cohort study in the Clinical Practice Research Datalink 2000–2012. *BMJ Open*, 8(6), e020528. <https://doi.org/10.1136/bmjopen-2017-020528>

Yih, W. K., Kulldorff, M., Dashevsky, I., & Maro, J. C. (2021). A Broad Safety Assessment of the 9-Valent Human Papillomavirus Vaccine. *American Journal of Epidemiology*, 190(7), 1253–1259. <https://doi.org/10.1093/aje/kwab022>

Yih, W. K., Kulldorff, M., Fireman, B. H., Shui, I. M., Lewis, E. M., Klein, N. P., Baggs, J., Weintraub, E. S., Belongia, E. A., Naleway, A., Gee, J., Platt, R., & Lieu, T. A. (2011). Active surveillance for adverse events: The experience of the Vaccine Safety Datalink project. *Pediatrics*, 127 Suppl 1, S54-64. <https://doi.org/10.1542/peds.2010-1722I>

Young-Xu, Y., Snider, J. T., van Aalst, R., Mahmud, S. M., Thommes, E. W., Lee, J. K. H., Greenberg, D. P., & Chit, A. (2019). Analysis of relative effectiveness of high-dose versus standard-dose influenza vaccines using an instrumental variable method. *Vaccine*, 37(11), 1484–1490. <https://doi.org/10.1016/j.vaccine.2019.01.063>

### **15.3. Design, implementation and analysis of pharmacogenetic studies**

Alshabeeb, M. A., Deneer, V. H. M., Khan, A., & Asselbergs, F. W. (2019). Use of Pharmacogenetic Drugs by the Dutch Population. *Frontiers in Genetics*, 0. <https://doi.org/10.3389/fgene.2019.00567>

Andrews, N., Stowe, J., Kirsebom, F., Toffa, S., Rickeard, T., Gallagher, E., Gower, C., Kall, M., Groves, N., O'Connell, A.-M., Simons, D., Blomquist, P. B., Zaidi, A., Nash, S., Iwani Binti Abdul Aziz, N., Thelwall, S., Dabrera, G., Myers, R., Amirthalingam, G., ... Lopez Bernal, J. (2022). Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant. *New England Journal of Medicine*, 386(16), 1532–1546. <https://doi.org/10.1056/NEJMoa2119451>

Avram, M. J., Stika, C. S., Rasmussen-Torvik, L. J., Ciolino, J. D., Pinheiro, E., George, A. L., & Wisner, K. L. (2016). Rationale and design for an investigation to optimize selective serotonin reuptake inhibitor treatment for pregnant women with depression. *Clinical Pharmacology and Therapeutics*, 100(1), 31–33. <https://doi.org/10.1002/cpt.375>

Betcher, H. K., & George, A. L. (2020). Pharmacogenomics in Pregnancy. *Seminars in Perinatology*, 44(3), 151222. <https://doi.org/10.1016/j.semperi.2020.151222>

Bozkurt, Ö., Verschuren, W. M. M., van Wieren-de Wijer, B. M. A., Knol, M. J., de Boer, A., Grobbee, D. E., Geerlings, M. I., Heerdink, E. R., & Klungel, O. H. (2008). Genetic variation in the renin-angiotensin system modifies the beneficial effects of ACE inhibitors on the risk of diabetes mellitus among

hypertensives. *Journal of Human Hypertension*, 22(11), 774–780.

<https://doi.org/10.1038/jhh.2008.62>

Carleton, B., Poole, R., Smith, M., Leeder, J., Ghannadan, R., Ross, C., Phillips, M., & Hayden, M. (2009). Adverse drug reaction active surveillance: Developing a national network in Canada's children's hospitals. *Pharmacoepidemiology and Drug Safety*, 18(8), 713–721.

<https://doi.org/10.1002/pds.1772>

Carr, D. F., O'Meara, H., Jorgensen, A. L., Campbell, J., Hobbs, M., McCann, G., van Staa, T., & Pirmohamed, M. (2013). SLCO1B1 Genetic Variant Associated With Statin-Induced Myopathy: A Proof-of-Concept Study Using the Clinical Practice Research Datalink. *Clinical Pharmacology & Therapeutics*, 94(6), 695–701. <https://doi.org/10.1038/clpt.2013.161>

Cavallari, L., Beitelshes, A., Blake, K., Dressler, L., Duarte, J., Elsey, A., Eichmeyer, J., Empey, P., Franciosi, J., Hicks, J., Holmes, A., Jeng, L., Lee, C., Lima, J., Limdi, N., Modlin, J., Obeng, A., Petry, N., Pratt, Vm., ... Johnson, J. (2017). The IGNITE Pharmacogenetics Working Group: An Opportunity for Building Evidence with Pharmacogenetic Implementation in a Real-World Setting. *Clinical and Translational Science*, 10(3), 143–146. <https://doi.org/10.1111/cts.12456>

Chambliss, A. B., & Chan, D. W. (2016). Precision medicine: From pharmacogenomics to pharmacoproteomics. *Clinical Proteomics*, 13(1), 25. <https://doi.org/10.1186/s12014-016-9127-8>

Chan, H. T., Chin, Y. M., & Low, S.-K. (2019). The Roles of Common Variation and Somatic Mutation in Cancer Pharmacogenomics. *Oncology and Therapy*, 7(1), 1–32. <https://doi.org/10.1007/s40487-018-0090-6>

Chaplin, M., Kirkham, J. J., Dwan, K., Sloan, D. J., Davies, G., & Jorgensen, A. L. (2020). STrengthening the Reporting Of Pharmacogenetic Studies: Development of the STROPS guideline. *PLOS Medicine*, 17(9), e1003344. <https://doi.org/10.1371/journal.pmed.1003344>

Chen, P., Lin, J.-J., Lu, C.-S., Ong, C.-T., Hsieh, P. F., Yang, C.-C., Tai, C.-T., Wu, S.-L., Lu, C.-H., Hsu, Y.-C., Yu, H.-Y., Ro, L.-S., Lu, C.-T., Chu, C.-C., Tsai, J.-J., Su, Y.-H., Lan, S.-H., Sung, S.-F., Lin, S.-Y., ... Shen, C.-Y. (2011). Carbamazepine-Induced Toxic Effects and HLA-B\*1502 Screening in Taiwan. *New England Journal of Medicine*, 364(12), 1126–1133.

<https://doi.org/10.1056/NEJMoa1009717>

Clinical Pharmacogenetics Implementation Consortium. <https://cpicpgx.org/>

COVID-19 Host Genetics Initiative. <https://www.covid19hg.org/>

CPNDS | The Canadian Pharmacogenomics Network for Drug Safety. <https://cpnds.ubc.ca/>

Dennis, J., Hawken, S., Krewski, D., Birkett, N., Gheorghe, M., Frei, J., McKeown-Eyssen, G., & Little, J. (2011). Bias in the case-only design applied to studies of gene–environment and gene–gene interaction: A systematic review and meta-analysis. *International Journal of Epidemiology*, 40(5), 1329–1341. <https://doi.org/10.1093/ije/dyr088>

DPWG: Dutch Pharmacogenetics Working Group. PharmGKB. <https://www.pharmgkb.org/page/dpwg>

Drews, J. (2000). Drug Discovery: A Historical Perspective. *Science*, 287(5460), 1960–1964. <https://doi.org/10.1126/science.287.5460.1960>

Duconge, J., & Ruaño, G. (2018). Preventing the exacerbation of health disparities by iatrogenic pharmacogenomic applications: Lessons from warfarin. *Pharmacogenomics*, 19(11), 875–881. <https://doi.org/10.2217/pgs-2018-0055>

Dunnenberger, H. M., Biszewski, M., Bell, G. C., Sereika, A., May, H., Johnson, S. G., Hulick, P. J., & Khandekar, J. (2016). Implementation of a multidisciplinary pharmacogenomics clinic in a community health system. *American Journal of Health-System Pharmacy*, 73(23), 1956–1966.

<https://doi.org/10.2146/ajhp160072>

Ehmann, F., Caneva, L., Prasad, K., Paulmichl, M., Maliepaard, M., Llerena, A., Ingelman-Sundberg, M., & Papaluca-Amati, M. (2015). Pharmacogenomic information in drug labels: European Medicines Agency perspective. *The Pharmacogenomics Journal*, 15(3), 201–210.

<https://doi.org/10.1038/tpj.2014.86>

EMA. (2018, September 17). Pharmacogenomics Working Party. European Medicines Agency.

<https://www.ema.europa.eu/en/committees/working-parties-other-groups/chmp/pharmacogenomics-working-party>

EMA recommendations on DPD testing prior to treatment with fluorouracil, capecitabine, tegafur and flucytosine. (2020). European Medicines Agency. <https://www.ema.europa.eu/en/news/ema-recommendations-dpd-testing-prior-treatment-fluorouracil-capecitabine-tegafur-flucytosine>

Evans, D. M., & Davey Smith, G. (2015). Mendelian Randomization: New Applications in the Coming Age of Hypothesis-Free Causality. *Annual Review of Genomics and Human Genetics*, 16, 327–350.

<https://doi.org/10.1146/annurev-genom-090314-050016>

Evans, W. E., & Relling, M. V. (1999). Pharmacogenomics: Translating Functional Genomics into Rational Therapeutics. *Science*, 286(5439), 487–491. <https://doi.org/10.1126/science.286.5439.487>

Evans, W. E., & Relling, M. V. (2004). Moving towards individualized medicine with pharmacogenomics. *Nature*, 429(6990), 464–468. <https://doi.org/10.1038/nature02626>

Gatto, N. M., Campbell, U. B., Rundle, A. G., & Ahsan, H. (2004). Further development of the case-only design for assessing gene–environment interaction: Evaluation of and adjustment for bias. *International Journal of Epidemiology*, 33(5), 1014–1024. <https://doi.org/10.1093/ije/dyh306>

Grady, B. J., & Ritchie, M. D. (2011). Statistical Optimization of Pharmacogenomics Association Studies: Key Considerations from Study Design to Analysis. *Current Pharmacogenomics and Personalized Medicine*, 9(1), 41–66. <https://doi.org/10.2174/187569211794728805>

Hayney, M. S. (2002). Pharmacogenomics and infectious diseases: Impact on drug response and applications to disease management. *American Journal of Health-System Pharmacy*, 59(17), 1626–1631. <https://doi.org/10.1093/ajhp/59.17.1626>

Hellwege, J. N., Keaton, J. M., Giri, A., Gao, X., Velez Edwards, D. R., & Edwards, T. L. (2017). Population Stratification in Genetic Association Studies. *Current Protocols in Human Genetics*, 95(1), 1.22.1-1.22.23. <https://doi.org/10.1002/cphg.48>

Hingorani, A. D., Windt, D. A. van der, Riley, R. D., Abrams, K., Moons, K. G. M., Steyerberg, E. W., Schroter, S., Sauerbrei, W., Altman, D. G., & Hemingway, H. (2013). Prognosis research strategy (PROGRESS) 4: Stratified medicine research. *BMJ*, 346, e5793. <https://doi.org/10.1136/bmj.e5793>

Jorgensen, A. L., & Williamson, P. R. (2008). Methodological quality of pharmacogenetic studies: Issues of concern. *Statistics in Medicine*, 27(30), 6547–6569. <https://doi.org/10.1002/sim.3420>

Karlsen, T. H. (2022). Understanding COVID-19 through genome-wide association studies. *Nature Genetics*, 54(4), 368–369. <https://doi.org/10.1038/s41588-021-00985-x>

- Khoury, M. J., & Flanders, W. D. (1996). Nontraditional Epidemiologic Approaches in the Analysis of Gene Environment Interaction: Case-Control Studies with No Controls! *American Journal of Epidemiology*, 144(3), 207–213. <https://doi.org/10.1093/oxfordjournals.aje.a008915>
- Leitsalu, L., Haller, T., Esko, T., Tammesoo, M.-L., Alavere, H., Snieder, H., Perola, M., Ng, P. C., Mägi, R., Milani, L., Fischer, K., & Metspalu, A. (2015). Cohort Profile: Estonian Biobank of the Estonian Genome Center, University of Tartu. *International Journal of Epidemiology*, 44(4), 1137–1147. <https://doi.org/10.1093/ije/dyt268>
- Liu, Y., Nyunoya, T., Leng, S., Belinsky, S. A., Tesfaigzi, Y., & Bruse, S. (2013). Softwares and methods for estimating genetic ancestry in human populations. *Human Genomics*, 7(1), 1. <https://doi.org/10.1186/1479-7364-7-1>
- Mallal, S., Phillips, E., Carosi, G., Molina, J.-M., Workman, C., Tomažič, J., Jägel-Guedes, E., Rugina, S., Kozyrev, O., Cid, J. F., Hay, P., Nolan, D., Hughes, S., Hughes, A., Ryan, S., Fitch, N., Thorborn, D., & Benbow, A. (2008). HLA-B\*5701 Screening for Hypersensitivity to Abacavir. *New England Journal of Medicine*, 358(6), 568–579. <https://doi.org/10.1056/NEJMoa0706135>
- McInnes, G., & Altman, R. B. (2020). Drug Response Pharmacogenetics for 200,000 UK Biobank Participants. In *Biocomputing 2021* (pp. 184–195). WORLD SCIENTIFIC. [https://doi.org/10.1142/9789811232701\\_0018](https://doi.org/10.1142/9789811232701_0018)
- McInnes, G., Lavertu, A., Sangkuhl, K., Klein, T. E., Whirl-Carrillo, M., & Altman, R. B. (2021). Pharmacogenetics at Scale: An Analysis of the UK Biobank. *Clinical Pharmacology & Therapeutics*, 109(6), 1528–1537. <https://doi.org/10.1002/cpt.2122>
- Molokhia, M., & McKeigue, P. (2006). EUDRAGENE: European collaboration to establish a case-control DNA collection for studying the genetic basis of adverse drug reactions. *Pharmacogenomics*, 7(4), 633–638. <https://doi.org/10.2217/14622416.7.4.633>
- Niemi, M. E. K., Karjalainen, J., Liao, R. G., Neale, B. M., Daly, M., Ganna, A., Pathak, G. A., Andrews, S. J., Kanai, M., Veerapen, K., Fernandez-Cadenas, I., Schulte, E. C., Striano, P., Marttila, M., Minica, C., Marouli, E., Karim, M. A., Wendt, F. R., Savage, J., ... Admin team leader. (2021). Mapping the human genetic architecture of COVID-19. *Nature*, 600(7889), 472–477. <https://doi.org/10.1038/s41586-021-03767-x>
- Pereira, N. L., Farkouh, M. E., So, D., Lennon, R., Geller, N., Mathew, V., Bell, M., Bae, J.-H., Jeong, M. H., Chavez, I., Gordon, P., Abbott, J. D., Cagin, C., Baudhuin, L., Fu, Y.-P., Goodman, S. G., Hasan, A., Iturriaga, E., Lerman, A., ... Rihal, C. (2020). Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy on Ischemic Outcomes After Percutaneous Coronary Intervention: The TAILOR-PCI Randomized Clinical Trial. *JAMA*, 324(8), 761–771. <https://doi.org/10.1001/jama.2020.12443>
- Peters, B. J. M., Rodin, A. S., De Boer, A., & Maitland-van der Zee, A.-H. (2010). Methodological and statistical issues in pharmacogenomics. *Journal of Pharmacy and Pharmacology*, 62(2), 161–166. <https://doi.org/10.1211/jpp.62.02.0002>
- Peterson, J. F., Field, J. R., Shi, Y., Schildcrout, J. S., Denny, J. C., McGregor, T. L., Van Driest, S. L., Pulley, J. M., Lubin, I. M., Laposata, M., Roden, D. M., & Clayton, E. W. (2016). Attitudes of clinicians following large-scale pharmacogenomics implementation. *The Pharmacogenomics Journal*, 16(4), 393–398. <https://doi.org/10.1038/tpj.2015.57>
- PharmGKB. <https://www.pharmgkb.org/>

Pritchard, J. K., Stephens, M., Rosenberg, N. A., & Donnelly, P. (2000). Association Mapping in Structured Populations. *The American Journal of Human Genetics*, 67(1), 170–181. <https://doi.org/10.1086/302959>

Psaty, B. M., & Sitlani, C. (2013). The Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium as a Model of Collaborative Science. *Epidemiology*, 24(3), 346–348. <https://doi.org/10.1097/EDE.0b013e31828b2cbb>

Psaty, B. M., Smith, N. L., Heckbert, S. R., Vos, H. L., Lemaitre, R. N., Reiner, A. P., Siscovick, D. S., Bis, J., Lumley, T., Longstreth, J., W. T., & Rosendaal, F. R. (2002). Diuretic Therapy, the  $\alpha$ -Adducin Gene Variant, and the Risk of Myocardial Infarction or Stroke in Persons With Treated Hypertension. *JAMA*, 287(13), 1680–1689. <https://doi.org/10.1001/jama.287.13.1680>

Rafi, I., Crinson, I., Dawes, M., Rafi, D., Pirmohamed, M., & Walter, F. M. (2020). The implementation of pharmacogenomics into UK general practice: A qualitative study exploring barriers, challenges and opportunities. *Journal of Community Genetics*, 11(3), 269–277. <https://doi.org/10.1007/s12687-020-00468-2>

Reisberg, S., Krebs, K., Lepamets, M., Kals, M., Mägi, R., Metsalu, K., Lauschke, V. M., Vilo, J., & Milani, L. (2019). Translating genotype data of 44,000 biobank participants into clinical pharmacogenetic recommendations: Challenges and solutions. *Genetics in Medicine*, 21(6), 1345–1354. <https://doi.org/10.1038/s41436-018-0337-5>

Robarge, J. D., Li, L., Desta, Z., Nguyen, A., & Flockhart, D. A. (2007). The Star-Allele Nomenclature: Retooling for Translational Genomics. *Clinical Pharmacology & Therapeutics*, 82(3), 244–248. <https://doi.org/10.1038/sj.clpt.6100284>

Ross, S., Anand, S. S., Joseph, P., & Paré, G. (2012). Promises and challenges of pharmacogenetics: An overview of study design, methodological and statistical issues. *JRSM Cardiovascular Disease*, 1(1), 1–13. <https://doi.org/10.1258/cvd.2012.012001>

Sissung, T. M., McKeeby, J. W., Patel, J., Lertora, J. J., Kumar, P., Flegel, W. A., Adams, S. D., Eckes, E. J., Mickey, F., Plona, T. M., Mellott, S. D., Baugher, R. N., Wu, X., Soppet, D. R., Barcus, M. E., Datta, V., Pike, K. M., DiPatrizio, G., Figg, W. D., & Goldspiel, B. R. (2017). Pharmacogenomics Implementation at the National Institutes of Health Clinical Center. *The Journal of Clinical Pharmacology*, 57(S10), S67–S77. <https://doi.org/10.1002/jcph.993>

Smit, R. a. j., Noordam, R., le Cessie, S., Trompet, S., & Jukema, J. w. (2018). A critical appraisal of pharmacogenetic inference. *Clinical Genetics*, 93(3), 498–507. <https://doi.org/10.1111/cge.13178>

Storey, J. D., & Tibshirani, R. (2003). Statistical significance for genomewide studies. *Proceedings of the National Academy of Sciences*, 100(16), 9440–9445. <https://doi.org/10.1073/pnas.1530509100>

Sudlow, C., Gallacher, J., Allen, N., Beral, V., Burton, P., Danesh, J., Downey, P., Elliott, P., Green, J., Landray, M., Liu, B., Matthews, P., Ong, G., Pell, J., Silman, A., Young, A., Sprosen, T., Peakman, T., & Collins, R. (2015). UK Biobank: An Open Access Resource for Identifying the Causes of a Wide Range of Complex Diseases of Middle and Old Age. *PLOS Medicine*, 12(3), e1001779. <https://doi.org/10.1371/journal.pmed.1001779>

Swen, J., Nijenhuis, M., de Boer, A., Grandia, L., Maitland-van der Zee, A., Mulder, H., Rongen, G., van Schaik, R., Schalekamp, T., Touw, D., van der Weide, J., Wilffert, B., Deneer, V., & Guchelaar, H.-J. (2011). Pharmacogenetics: From Bench to Byte— An Update of Guidelines. *Clinical Pharmacology & Therapeutics*, 89(5), 662–673. <https://doi.org/10.1038/clpt.2011.34>



Taylor, C., Crosby, I., Yip, V., Maguire, P., Pirmohamed, M., & Turner, R. M. (2020). A Review of the Important Role of CYP2D6 in Pharmacogenomics. *Genes*, 11(11), 1295.

<https://doi.org/10.3390/genes11111295>

The COVID-19 Host Genetics Initiative. (2020). The COVID-19 Host Genetics Initiative, a global initiative to elucidate the role of host genetic factors in susceptibility and severity of the SARS-CoV-2 virus pandemic. *European Journal of Human Genetics*, 28(6), 715–718.

<https://doi.org/10.1038/s41431-020-0636-6>

Thorn, C. F., Whirl-Carrillo, M., Hachad, H., Johnson, J. A., McDonagh, E. M., Ratain, M. J., Relling, M. V., Scott, S. A., Altman, R. B., & Klein, T. E. (2019). Essential Characteristics of Pharmacogenomics Study Publications. *Clinical Pharmacology & Therapeutics*, 105(1), 86–91.

<https://doi.org/10.1002/cpt.1279>

van der Baan, F. H., Klungel, O. H., Egberts, A. C., Leufkens, H. G., Grobbee, D. E., Roes, K. C., & Knol, M. J. (2011). Pharmacogenetics in randomized controlled trials: Considerations for trial design. *Pharmacogenomics*, 12(10), 1485–1492. <https://doi.org/10.2217/pgs.11.95>

van der Baan, F. H., Knol, M. J., Klungel, O. H., Egberts, A. C., Grobbee, D. E., & Roes, K. C. (2012). Potential of adaptive clinical trial designs in pharmacogenetic research. *Pharmacogenomics*, 13(5), 571–578. <https://doi.org/10.2217/pgs.12.10>

van der Wouden, C., Cambon-Thomsen, A., Cecchin, E., Cheung, K., Dávila-Fajardo, C., Deneer, V., Dolžan, V., Ingelman-Sundberg, M., Jönsson, S., Karlsson, M., Kriek, M., Mitropoulou, C., Patrinos, G., Pirmohamed, M., Samwald, M., Schaeffeler, E., Schwab, M., Steinberger, D., Stingl, J., ... Consortium, on behalf of the U. P. (2017). Implementing Pharmacogenomics in Europe: Design and Implementation Strategy of the Ubiquitous Pharmacogenomics Consortium. *Clinical Pharmacology & Therapeutics*, 101(3), 341–358. <https://doi.org/10.1002/cpt.602>

van Wieren-de Wijer, D. B., Maitland-van der Zee, A.-H., de Boer, A., Kroon, A. A., de Leeuw, P. W., Schiffers, P., Janssen, R. G., Psaty, B. M., van Duijn, C. M., Ch. Stricker, B. H., & Klungel, O. H. (2009). Interaction between the Gly460Trp  $\alpha$ -adducin gene variant and diuretics on the risk of myocardial infarction. *Journal of Hypertension*, 27(1), 61–68.

<https://doi.org/10.1097/HJH.0b013e328317a74d>

Wang, R., Chen, J., Gao, K., & Wei, G.-W. (2021). Vaccine-escape and fast-growing mutations in the United Kingdom, the United States, Singapore, Spain, India, and other COVID-19-devastated countries. *Genomics*, 113(4), 2158–2170. <https://doi.org/10.1016/j.ygeno.2021.05.006>

Zhang, H., Liu, L., Wang, X., & Gruen, J. R. (2007). Guideline for data analysis of genomewide association studies. *Cancer Genomics & Proteomics*, 4(1), 27–34.

<https://cgp.iiarjournals.org/content/4/1/27.long>

#### **15.4. Methods for pharmacovigilance impact research**

Banerjee, A. K., Zomerdijk, I. M., Wooder, S., Ingate, S., & Mayall, S. J. (2014a). Post-Approval Evaluation of Effectiveness of Risk Minimisation: Methods, Challenges and Interpretation. *Drug Safety*, 37(1), 33–42. <https://doi.org/10.1007/s40264-013-0126-7>

Bernal, J. L., Cummins, S., & Gasparrini, A. (2017). Interrupted time series regression for the evaluation of public health interventions: A tutorial. *International Journal of Epidemiology*, 46(1), 348–355. <https://doi.org/10.1093/ije/dyw098>

Bradley, C. J., Penberthy, L., Devers, K. J., & Holden, D. J. (2010). Health Services Research and Data Linkages: Issues, Methods, and Directions for the Future. *Health Services Research*, 45(5p2), 1468–1488. <https://doi.org/10.1111/j.1475-6773.2010.01142.x>

Charlton, R. A., Bettoli, V., Bos, H. J., Engeland, A., Garne, E., Gini, R., Hansen, A. V., de Jong-van den berg, L. T. W., Jordan, S., Klungsoyr, K., Neville, A. J., Pierini, A., Puccini, A., Sinclair, M., Thayer, D., & Dolk, H. (2018). The limitations of some European healthcare databases for monitoring the effectiveness of pregnancy prevention programmes as risk minimisation measures. *European Journal of Clinical Pharmacology*, 74(4), 513–520. <https://doi.org/10.1007/s00228-017-2398-9>

Cohen, A., Rabbani, A., Shah, N., & Alexander, G. C. (2010). Changes in Glitazone Use Among Office-Based Physicians in the U.S., 2003–2009. *Diabetes Care*, 33(4), 823–825. <https://doi.org/10.2337/dc09-1834>

Crijns, H. J. M. J., van Rein, N., Gispens-de Wied, C. C., Straus, S. M., & de Jong-van den Berg, L. T. W. (2012). Prescriptive contraceptive use among isotretinoin users in the Netherlands in comparison with non-users: A drug utilisation study. *Pharmacoepidemiology and Drug Safety*, 21(10), 1060–1066. <https://doi.org/10.1002/pds.3200>

Crijns, I., Mantel-Teeuwisse, A., Bloemberg, R., Pinas, E., Straus, S., & de Jong-van den Berg, L. (2013). Healthcare professional surveys to investigate the implementation of the isotretinoin Pregnancy Prevention Programme: A descriptive study. *Expert Opinion on Drug Safety*, 12(1), 29–38. <https://doi.org/10.1517/14740338.2013.745850>

Durbin, J., & Watson, G. S. (1950). Testing for serial correlation in least squares regression. I. *Biometrika*, 37(3–4), 409–428.

Durbin, J., & Watson, G. S. (1951). Testing for serial correlation in least squares regression. II. *Biometrika*, 38(1–2), 159–178.

Eccles, M., Grimshaw, J., Campbell, M., & Ramsay, C. (2003). Research designs for studies evaluating the effectiveness of change and improvement strategies. *BMJ Quality & Safety*, 12(1), 47–52. <https://doi.org/10.1136/qhc.12.1.47>

Eworuke, E., Lee, J.-Y., Soule, L., Popat, V., & Moeny, D. G. (2017). The impact of the boxed warning on the duration of use for depot medroxyprogesterone acetate. *Pharmacoepidemiology and Drug Safety*, 26(7), 827–836. <https://doi.org/10.1002/pds.4227>

Feldstein, A. C., Smith, D. H., Perrin, N., Yang, X., Rix, M., Raebel, M. A., Magid, D. J., Simon, S. R., & Soumerai, S. B. (2006). Improved Therapeutic Monitoring With Several Interventions: A Randomized Trial. *Archives of Internal Medicine*, 166(17), 1848–1854. <https://doi.org/10.1001/archinte.166.17.1848>

Goedecke, T., Morales, D. R., Pacurariu, A., & Kurz, X. (2018). Measuring the impact of medicines regulatory interventions – Systematic review and methodological considerations. *British Journal of Clinical Pharmacology*, 84(3), 419–433. <https://doi.org/10.1111/bcp.13469>

Good pharmacovigilance practices. European Medicines Agency. <https://www.ema.europa.eu/en/human-regulatory/post-authorisation/pharmacovigilance/good-pharmacovigilance-practices>

Haneuse, S., & Daniels, M. (2016). A General Framework for Considering Selection Bias in EHR-Based Studies: What Data are Observed and Why? *EGEMs (Generating Evidence & Methods to Improve Patient Outcomes)*, 4(1), 16. <https://doi.org/10.13063/2327-9214.1203>

Hawton, K., Bergen, H., Simkin, S., Dodd, S., Pocock, P., Bernal, W., Gunnell, D., & Kapur, N. (2013). Long term effect of reduced pack sizes of paracetamol on poisoning deaths and liver transplant activity in England and Wales: Interrupted time series analyses. *BMJ*, 346, f403.

<https://doi.org/10.1136/bmj.f403>

Hedenmalm, K., Kurz, X., & Morales, D. (2019). Effect of withdrawal of fusafungine from the market on prescribing of antibiotics and other alternative treatments in Germany: A pharmacovigilance impact study. *European Journal of Clinical Pharmacology*, 75(7), 979–984. <https://doi.org/10.1007/s00228-019-02650-z>

Heller, R. F., Buchan, I., Edwards, R., Lyratzopoulos, G., McElduff, P., & Leger, S. S. (2003). Communicating risks at the population level: Application of population impact numbers. *BMJ*, 327(7424), 1162–1165. <https://doi.org/10.1136/bmj.327.7424.1162>

Horton, D. B., Gerhard, T., Davidow, A., & Strom, B. L. (2017). Impact of the black triangle label on prescribing of new drugs in the United Kingdom: Lessons for the United States at a time of deregulation. *Pharmacoepidemiology and Drug Safety*, 26(11), 1307–1313.

<https://doi.org/10.1002/pds.4304>

Jordan, S., Gabe-Walters, M. E., Watkins, A., Humphreys, I., Newson, L., Snelgrove, S., & Dennis, M. S. (2015). Nurse-Led Medicines' Monitoring for Patients with Dementia in Care Homes: A Pragmatic Cohort Stepped Wedge Cluster Randomised Trial. *PLOS ONE*, 10(10), e0140203.

<https://doi.org/10.1371/journal.pone.0140203>

Jordan, S., Morris, J. K., Davies, G. I., Tucker, D., Thayer, D. S., Luteijn, J. M., Morgan, M., Garne, E., Hansen, A. V., Klungsøyr, K., Engeland, A., Boyle, B., & Dolk, H. (2016). Selective Serotonin Reuptake Inhibitor (SSRI) Antidepressants in Pregnancy and Congenital Anomalies: Analysis of Linked Databases in Wales, Norway and Funen, Denmark. *PLOS ONE*, 11(12), e0165122.

<https://doi.org/10.1371/journal.pone.0165122>

Juhaeri, J., Juhaeri, J., Mt-Isa, S., Chan, E., Genov, G., Genov, G., & Hirsch, I. IMI Work Package 5: Benefit –Risk Integration and Visual Representation. PROTECT.

<https://protectbenefitrisk.eu/documents/JuhaerietalBenefitRiskWave1CasestudyreportRimonabantOct2011.pdf>

Kendrick, T., Stuart, B., Newell, C., Geraghty, A. W. A., & Moore, M. (2015). Changes in rates of recorded depression in English primary care 2003–2013: Time trend analyses of effects of the economic recession, and the GP contract quality outcomes framework (QOF). *Journal of Affective Disorders*, 180, 68–78. <https://doi.org/10.1016/j.jad.2015.03.040>

Kim, H.-J., Fay, M. P., Feuer, E. J., & Midthune, D. N. (2000). Permutation tests for joinpoint regression with applications to cancer rates. *Statistics in Medicine*, 19(3), 335–351.

[https://doi.org/10.1002/\(SICI\)1097-0258\(20000215\)19:3<335::AID-SIM336>3.0.CO;2-Z](https://doi.org/10.1002/(SICI)1097-0258(20000215)19:3<335::AID-SIM336>3.0.CO;2-Z)

Lopez Bernal, J., Cummins, S., & Gasparrini, A. (2018). The use of controls in interrupted time series studies of public health interventions. *International Journal of Epidemiology*, 47(6), 2082–2093.

<https://doi.org/10.1093/ije/dyy135>

Madison, T., Donner, B., Mutter, R., Mingrino, R., & Alvaro, G. (2019). Effectiveness of Risk Minimization Measures to Prevent Pregnancy Exposure to Mycophenolate-Containing Medicines in Europe. *Pharmaceutical Medicine*, 33(5), 395–406. <https://doi.org/10.1007/s40290-019-00304-0>

Marston, L., Nazareth, I., Petersen, I., Walters, K., & Osborn, D. P. J. (2014). Prescribing of antipsychotics in UK primary care: A cohort study. *BMJ Open*, 4(12), e006135.

<https://doi.org/10.1136/bmjopen-2014-006135>

Martin, R. M., Wheeler, B. W., Metcalfe, C., & Gunnell, D. (2010). What was the immediate impact on population health of the recent fall in hormone replacement therapy prescribing in England? Ecological study. *Journal of Public Health*, 32(4), 555–564. <https://doi.org/10.1093/pubmed/fdq021>

Mohammad, I., Korkis, B., & Garwood, C. L. (2017). Incorporating Comprehensive Management of Direct Oral Anticoagulants into Anticoagulation Clinics. *Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy*, 37(10), 1284–1297. <https://doi.org/10.1002/phar.1991>

Morales, D. R., Morant, S. V., MacDonald, T. M., Mackenzie, I. S., Doney, A. S. F., Mitchell, L., Bennie, M., Robertson, C., Hallas, J., Pottegard, A., Ernst, M. T., Wei, L., Nicholson, L., Morris, C., Herings, R. M. C., Overbeek, J. A., Smits, E., & Flynn, R. W. V. (2020). Impact of EMA regulatory label changes on systemic diclofenac initiation, discontinuation, and switching to other pain medicines in Scotland, England, Denmark, and The Netherlands. *Pharmacoepidemiology and Drug Safety*, 29(3), 296–305. <https://doi.org/10.1002/pds.4955>

Morrato, E. H., Nicol, G. E., Maahs, D., Druss, B. G., Hartung, D. M., Valuck, R. J., Campagna, E., & Newcomer, J. W. (2010). Metabolic Screening in Children Receiving Antipsychotic Drug Treatment. *Archives of Pediatrics & Adolescent Medicine*, 164(4), 344–351. <https://doi.org/10.1001/archpediatrics.2010.48>

Nkeng, L., Cloutier, A.-M., Craig, C., Leloirier, J., & Moride, Y. (2012). Impact of Regulatory Guidances and Drug Regulation on Risk Minimization Interventions in Drug Safety. *Drug Safety*, 35(7), 535–546. <https://doi.org/10.2165/11599720-000000000-00000>

Nyeland, M. E., Laursen, M. V., & Callréus, T. (2017). Evaluating the effectiveness of risk minimisation measures: The application of a conceptual framework to Danish real-world dabigatran data. *Pharmacoepidemiology and Drug Safety*, 26(6), 607–614. <https://doi.org/10.1002/pds.4203>

Practical Approaches to Risk Minimisation for Medicinal Products: Report of CIOMS Working Group IX • COUNCIL FOR INTERNATIONAL ORGANIZATIONS OF MEDICAL SCIENCES. (2014). CIOMS. <https://cioms.ch/publications/product/practical-approaches-to-risk-minimisation-for-medicinal-products-report-of-cioms-working-group-ix/>

Rubino, A., & Artime, E. (2017). A descriptive review of additional risk minimisation measures applied to EU centrally authorised medicines 2006-2015. *Expert Opinion on Drug Safety*, 16(8), 877–884. <https://doi.org/10.1080/14740338.2017.1335303>

Shi, L., Zhao, Y., Szymanski, K., Yau, L., & Fonseca, V. (2011). Impact of thiazolidinedione safety warnings on medication use patterns and glycemic control among veterans with diabetes mellitus. *Journal of Diabetes and Its Complications*, 25(3), 143–150. <https://doi.org/10.1016/j.jdiacomp.2010.06.003>

Singh, R. R., & Nayak, R. (2016). Impact of FDA Black Box Warning on Psychotropic Drug Use in Noninstitutionalized Elderly Patients Diagnosed With Dementia: A Retrospective Study. *Journal of Pharmacy Practice*, 29(5), 495–502. <https://doi.org/10.1177/0897190015579451>

Sobel, R. E., Blackwell, W., Fram, D. M., & Bate, A. (2019). A Novel Approach to Visualize Risk Minimization Effectiveness: Peeping at the 2012 UK Proton Pump Inhibitor Label Change Using a Rapid Cycle Analysis Tool. *Drug Safety*, 42(11), 1365–1376. <https://doi.org/10.1007/s40264-019-00853-y>

Sultana, J., Fontana, A., Giorgianni, F., Pasqua, A., Cricelli, C., Spina, E., Gambassi, G., Ivanovic, J., Ferrajolo, C., Molokhia, M., Ballard, C., Sharp, S., Sturkenboom, M., & Trifirò, G. (2016). The Effect of Safety Warnings on Antipsychotic Drug Prescribing in Elderly Persons with Dementia in the United Kingdom and Italy: A Population-Based Study. *CNS Drugs*, 30(11), 1097–1109. <https://doi.org/10.1007/s40263-016-0366-z>

Sultana, J., Fontana, A., Giorgianni, F., Tillati, S., Cricelli, C., Pasqua, A., Patorno, E., Ballard, C., Sturkenboom, M., & Trifirò, G. (2019). Measuring the Effectiveness of Safety Warnings on the Risk of Stroke in Older Antipsychotic Users: A Nationwide Cohort Study in Two Large Electronic Medical Records Databases in the United Kingdom and Italy. *Drug Safety*, 42(12), 1471–1485.  
<https://doi.org/10.1007/s40264-019-00860-z>

THE INTERNATIONAL MARCÉ SOCIETY FOR PERINATAL MENTAL HEALTH BIENNIAL SCIENTIFIC CONFERENCE. (2015). *Archives of Women's Mental Health*, 18(2), 269–408.  
<https://doi.org/10.1007/s00737-014-0488-6>

Thompson, C. A., Kurian, A. W., & Luft, H. S. (2015). Linking Electronic Health Records to Better Understand Breast Cancer Patient Pathways Within and Between Two Health Systems. *EGEMs (Generating Evidence & Methods to Improve Patient Outcomes)*, 3(1), 5.  
<https://doi.org/10.13063/2327-9214.1127>

Torun, P., Heller, R. F., & Verma, A. (2009). Potential population impact of changes in heroin treatment and smoking prevalence rates: Using Population Impact Measures. *European Journal of Public Health*, 19(1), 28–31. <https://doi.org/10.1093/eurpub/ckn103>

Valuck, R. J., Libby, A. M., Orton, H. D., Morrato, E. H., Allen, R., & Baldessarini, R. J. (2007). Spillover Effects on Treatment of Adult Depression in Primary Care After FDA Advisory on Risk of Pediatric Suicidality With SSRIs. *American Journal of Psychiatry*, 164(8), 1198–1205.  
<https://doi.org/10.1176/appi.ajp.2007.07010007>

Van Ganse, E., Belhassen, M., Ginoux, M., Chrétien, E., Cornu, C., Ecoffey, C., & Aubrun, F. (2018). Use of analgesics in France, following dextropropoxyphene withdrawal. *BMC Health Services Research*, 18(1), 231. <https://doi.org/10.1186/s12913-018-3058-1>

van Hunsel, F., Gardarsdottir, H., de Boer, A., & Kant, A. (2019). Measuring the impact of pharmacovigilance activities, challenging but important. *British Journal of Clinical Pharmacology*, 85(10), 2235–2237. <https://doi.org/10.1111/bcp.14042>

Verma, A., Torun, P., Harris, E., Edwards, R., Gemmell, I., Harrison, R. A., Buchan, I. E., Davies, L., Patterson, L., & Heller, R. F. (2012). Population Impact Analysis: A framework for assessing the population impact of a risk or intervention. *Journal of Public Health*, 34(1), 83–89.  
<https://doi.org/10.1093/pubmed/fdr026>

Weatherburn, C. J., Guthrie, B., Dreischulte, T., & Morales, D. R. (2020). Impact of medicines regulatory risk communications in the UK on prescribing and clinical outcomes: Systematic review, time series analysis and meta-analysis. *British Journal of Clinical Pharmacology*, 86(4), 698–710.  
<https://doi.org/10.1111/bcp.14104>

Zhou, H., Taber, C., Arcona, S., & Li, Y. (2016). Difference-in-Differences Method in Comparative Effectiveness Research: Utility with Unbalanced Groups. *Applied Health Economics and Health Policy*, 14, 419–429. <https://doi.org/10.1007/s40258-016-0249-y>

Zipitis, C. S., Mughal, Z. M., & Clayton, P. E. (2016). Assessing the population impact of low rates of vitamin D supplementation on type 1 diabetes using a new statistical method. *JRSM Open*, 7(11), 2054270416653522. <https://doi.org/10.1177/2054270416653522>

Zomerdijk, I. M., Ruiter, R., Houweling, L. M. A., Herings, R. M. C., Sturkenboom, M. C. J. M., Straus, S. M. J. M., & Stricker, B. H. (2014). Isotretinoin exposure during pregnancy: A population-based study in The Netherlands. *BMJ Open*, 4(11), e005602. <https://doi.org/10.1136/bmjopen-2014-005602>

## 15.5. Artificial intelligence in pharmacoepidemiology (New chapter)

- Bayer, S., Clark, C., Dang, O., Aberdeen, J., Brajovic, S., Swank, K., Hirschman, L., & Ball, R. (2021). ADE Eval: An Evaluation of Text Processing Systems for Adverse Event Extraction from Drug Labels for Pharmacovigilance. *Drug Safety*, 44(1), 83–94. <https://doi.org/10.1007/s40264-020-00996-3>
- Cannas, M., & Arpino, B. (2019). A comparison of machine learning algorithms and covariate balance measures for propensity score matching and weighting. *Biometrical Journal*, 61(4), 1049–1072. <https://doi.org/10.1002/bimj.201800132>
- Chapman, A. B., Peterson, K. S., Alba, P. R., DuVall, S. L., & Patterson, O. V. (2019). Detecting Adverse Drug Events with Rapidly Trained Classification Models. *Drug Safety*, 42(1), 147–156. <https://doi.org/10.1007/s40264-018-0763-y>
- Correia Pinheiro, L., Durand, J., & Dogné, J. (2020). An Application of Machine Learning in Pharmacovigilance: Estimating Likely Patient Genotype From Phenotypical Manifestations of Fluoropyrimidine Toxicity. *Clinical Pharmacology and Therapeutics*, 107(4), 944–947. <https://doi.org/10.1002/cpt.1789>
- Gates, A., Johnson, C., & Hartling, L. (2018). Technology-assisted title and abstract screening for systematic reviews: A retrospective evaluation of the Abstrackr machine learning tool. *Systematic Reviews*, 7(1), 45. <https://doi.org/10.1186/s13643-018-0707-8>
- Härkänen, M., Paananen, J., Murrells, T., Rafferty, A. M., & Franklin, B. D. (2019). Identifying risks areas related to medication administrations—Text mining analysis using free-text descriptions of incident reports. *BMC Health Services Research*, 19(1), 791. <https://doi.org/10.1186/s12913-019-4597-9>
- Nath, N., Lee, S.-H., & Lee, I. (2022). NEAR: Named entity and attribute recognition of clinical concepts. *Journal of Biomedical Informatics*, 130, 104092. <https://doi.org/10.1016/j.jbi.2022.104092>
- Pfaff, E. R., Girvin, A. T., Bennett, T. D., Bhatia, A., Brooks, I. M., Deer, R. R., Dekermanjian, J. P., Jolley, S. E., Kahn, M. G., Kostka, K., McMurry, J. A., Moffitt, R., Walden, A., Chute, C. G., Haendel, M. A., Bramante, C., Dorr, D., Morris, M., Parker, A. M., ... Niehaus, E. (2022). Identifying who has long COVID in the USA: A machine learning approach using N3C data. *The Lancet Digital Health*, 0(0). [https://doi.org/10.1016/S2589-7500\(22\)00048-6](https://doi.org/10.1016/S2589-7500(22)00048-6)
- Reps, J. M., Garibaldi, J. M., Aickelin, U., Gibson, J. E., & Hubbard, R. B. (2015). A supervised adverse drug reaction signalling framework imitating Bradford Hill’s causality considerations. *Journal of Biomedical Informatics*, 56, 356–368. <https://doi.org/10.1016/j.jbi.2015.06.011>
- Savova, G. K., Masanz, J. J., Ogren, P. V., Zheng, J., Sohn, S., Kipper-Schuler, K. C., & Chute, C. G. (2010). Mayo clinical Text Analysis and Knowledge Extraction System (cTAKES): Architecture, component evaluation and applications. *Journal of the American Medical Informatics Association*, 17(5), 507–513. <https://doi.org/10.1136/jamia.2009.001560>
- Seinen, T. M., Fridgeirsson, E. A., Ioannou, S., Jeannetot, D., John, L. H., Kors, J. A., Markus, A. F., Pera, V., Rekkas, A., Williams, R. D., Yang, C., van Mulligen, E. M., & Rijnbeek, P. R. (2022). Use of unstructured text in prognostic clinical prediction models: A systematic review. *Journal of the American Medical Informatics Association*, 29(7), 1292–1302. <https://doi.org/10.1093/jamia/ocac058>
- Swerdel, J. N., Hripcsak, G., & Ryan, P. B. (2019). PheValuator: Development and evaluation of a phenotype algorithm evaluator. *Journal of Biomedical Informatics*, 97, 103258. <https://doi.org/10.1016/j.jbi.2019.103258>

Tian, Y., Schuemie, M. J., & Suchard, M. A. (2018). Evaluating large-scale propensity score performance through real-world and synthetic data experiments. *International Journal of Epidemiology*, 47(6), 2005–2014. <https://doi.org/10.1093/ije/dyy120>

Tiftikci, M., Özgür, A., He, Y., & Hur, J. (2019). Machine learning-based identification and rule-based normalization of adverse drug reactions in drug labels. *BMC Bioinformatics*, 20(21), 707. <https://doi.org/10.1186/s12859-019-3195-5>

Uzuner, Ö., South, B. R., Shen, S., & DuVall, S. L. (2011). 2010 i2b2/VA challenge on concepts, assertions, and relations in clinical text. *Journal of the American Medical Informatics Association*, 18(5), 552–556. <https://doi.org/10.1136/amiajnl-2011-000203>

Wang, G., Jung, K., Winnenburger, R., & Shah, N. H. (2015). A method for systematic discovery of adverse drug events from clinical notes. *Journal of the American Medical Informatics Association*, 22(6), 1196–1204. <https://doi.org/10.1093/jamia/ocv102>

Wynants, L., Calster, B. V., Collins, G. S., Riley, R. D., Heinze, G., Schuit, E., Bonten, M. M. J., Dahly, D. L., Damen, J. A., Debray, T. P. A., Jong, V. M. T. de, Vos, M. D., Dhiman, P., Haller, M. C., Harhay, M. O., Henckaerts, L., Heus, P., Kammer, M., Kreuzberger, N., ... Smeden, M. van. (2020). Prediction models for diagnosis and prognosis of covid-19: Systematic review and critical appraisal. *BMJ*, 369, m1328. <https://doi.org/10.1136/bmj.m1328>

Yang, C., Kors, J. A., Ioannou, S., John, L. H., Markus, A. F., Rekkas, A., de Ridder, M. A. J., Seinen, T. M., Williams, R. D., & Rijnbeek, P. R. (2022). Trends in the conduct and reporting of clinical prediction model development and validation: A systematic review. *Journal of the American Medical Informatics Association*, 29(5), 983–989. <https://doi.org/10.1093/jamia/ocac002>

Yang, X., Bian, J., Gong, Y., Hogan, W. R., & Wu, Y. (2019). MADEx: A System for Detecting Medications, Adverse Drug Events, and Their Relations from Clinical Notes. *Drug Safety*, 42(1), 123–133. <https://doi.org/10.1007/s40264-018-0761-0>

Yang, Z., Dehmer, M., Yli-Harja, O., & Emmert-Streib, F. (2020). Combining deep learning with token selection for patient phenotyping from electronic health records. *Scientific Reports*, 10(1), 1432. <https://doi.org/10.1038/s41598-020-58178-1>

### **15.6. Real-world evidence and pharmacoepidemiology (New chapter)**

Canada, H. (2020, March 4). Elements of real world data/evidence quality throughout the prescription drug product life cycle [Guidance]. <https://www.canada.ca/en/services/health/publications/drugs-health-products/real-world-data-evidence-drug-lifecycle-report.html>

Cave, A., Kurz, X., & Arlett, P. (2019). Real-World Data for Regulatory Decision Making: Challenges and Possible Solutions for Europe. *Clinical Pharmacology & Therapeutics*, 106(1), 36–39. <https://doi.org/10.1002/cpt.1426>

Commissioner, O. of the. Real-World Evidence. US Food and Drug Administration (FDA). <https://www.fda.gov/science-research/science-and-research-special-topics/real-world-evidence>

Concato, J., & Corrigan-Curay, J. (2022). Real-World Evidence—Where Are We Now? *New England Journal of Medicine*, 386(18), 1680–1682. <https://doi.org/10.1056/NEJMp2200089>

Concato, J., Stein, P., Dal Pan, G. J., Ball, R., & Corrigan-Curay, J. (2020). Randomized, observational, interventional, and real-world—What’s in a name? *Pharmacoepidemiology and Drug Safety*, 29(11), 1514–1517. <https://doi.org/10.1002/pds.5123>

DARWIN EU®: Multi-stakeholder information webinar (2022).

[https://www.ema.europa.eu/en/documents/presentation/presentation-darwin-eu-multi-stakeholder-information-webinar\\_en.pdf](https://www.ema.europa.eu/en/documents/presentation/presentation-darwin-eu-multi-stakeholder-information-webinar_en.pdf)

Eichler, H., Pignatti, F., Schwarzer-Daum, B., Hidalgo-Simon, A., Eichler, I., Arlett, P., Humphreys, A., Vamvakas, S., Brun, N., & Rasi, G. (2021). Randomized Controlled Trials Versus Real World Evidence: Neither Magic Nor Myth. *Clinical Pharmacology and Therapeutics*, 109(5), 1212–1218.

<https://doi.org/10.1002/cpt.2083>

Eskola, S. M., Leufkens, H. G. M., Bate, A., De Bruin, M. L., & Gardarsdottir, H. (2022). Use of Real-World Data and Evidence in Drug Development of Medicinal Products Centrally Authorized in Europe in 2018–2019. *Clinical Pharmacology & Therapeutics*, 111(1), 310–320. <https://doi.org/10.1002/cpt.2462>

Flynn, R., Plueschke, K., Quinten, C., Strassmann, V., Duijnhoven, R. G., Gordillo-Marañón, M., Rueckbeil, M., Cohet, C., & Kurz, X. (2022). Marketing Authorization Applications Made to the European Medicines Agency in 2018–2019: What was the Contribution of Real-World Evidence? *Clinical Pharmacology & Therapeutics*, 111(1), 90–97. <https://doi.org/10.1002/cpt.2461>

Franklin, J. M., Liaw, K.-L., Iyasu, S., Critchlow, C. W., & Dreyer, N. A. (2021). Real-world evidence to support regulatory decision making: New or expanded medical product indications.

*Pharmacoepidemiology and Drug Safety*, 30(6), 685–693. <https://doi.org/10.1002/pds.5222>

Franklin, J. M., Patorno, E., Desai, R. J., Glynn, R. J., Martin, D., Quinto, K., Pawar, A., Bessette, L. G., Lee, H., Garry, E. M., Gautam, N., & Schneeweiss, S. (2021). Emulating Randomized Clinical Trials With Nonrandomized Real-World Evidence Studies. *Circulation*, 143(10), 1002–1013.

<https://doi.org/10.1161/CIRCULATIONAHA.120.051718>

Franklin, J. M., & Schneeweiss, S. (2017). When and How Can Real World Data Analyses Substitute for Randomized Controlled Trials? *Clinical Pharmacology & Therapeutics*, 102(6), 924–933.

<https://doi.org/10.1002/cpt.857>

Guidance for Industry – Considerations for the Use of Real-World Data and Real-World Evidence to Support Regulatory Decision-Making for Drug and Biological Products. US Food and Drug Administration (FDA). <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/considerations-use-real-world-data-and-real-world-evidence-support-regulatory-decision-making-drug>

Guideline on registry-based studies. European Medicines Agency.

[https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-registry-based-studies\\_en-0.pdf](https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-registry-based-studies_en-0.pdf)

MHRA guidance on the use of real-world data in clinical studies to support regulatory decisions.

<https://www.gov.uk/government/publications/mhra-guidance-on-the-use-of-real-world-data-in-clinical-studies-to-support-regulatory-decisions/mhra-guidance-on-the-use-of-real-world-data-in-clinical-studies-to-support-regulatory-decisions>

MHRA guideline on randomised controlled trials using real-world data to support regulatory decisions.

(GOV.UK. <https://www.gov.uk/government/publications/mhra-guidance-on-the-use-of-real-world-data-in-clinical-studies-to-support-regulatory-decisions/mhra-guideline-on-randomised-controlled-trials-using-real-world-data-to-support-regulatory-decisions>

Purpura, C. A., Garry, E. M., Honig, N., Case, A., & Rassen, J. A. (2022). The Role of Real-World Evidence in FDA-Approved New Drug and Biologics License Applications. *Clinical Pharmacology & Therapeutics*, 111(1), 135–144. <https://doi.org/10.1002/cpt.2474>



Real-World Data: Assessing Electronic Health Records and Medical Claims Data To Support Regulatory Decision-Making for Drug and Biological Products – US Food and Drug Administration (FDA).

<https://www.fda.gov/media/152503/download>

Simon, G. E., Platt, R., Watanabe, J. H., Bindman, A. B., John London, A., Horberg, M., Hernandez, A., & Califf, R. M. (2021). When Can We Rely on Real-World Evidence to Evaluate New Medical Treatments? *Clinical Pharmacology and Therapeutics*, 10.1002/cpt.2253.

<https://doi.org/10.1002/cpt.2253>

Wang, S. V., & Schneeweiss, S. (2022). Assessing and Interpreting Real-World Evidence Studies: Introductory Points for New Reviewers. *Clinical Pharmacology & Therapeutics*, 111(1), 145–149.

<https://doi.org/10.1002/cpt.2398>

Wang, S. V., Schneeweiss, S., Berger, M. L., Brown, J., de Vries, F., Douglas, I., Gagne, J. J., Gini, R., Klungel, O., Mullins, C. D., Nguyen, M. D., Rassen, J. A., Smeeth, L., Sturkenboom, M., & Making, on behalf of the joint I.-I. S. T. F. on R. W. E. in H. C. D. (2017). Reporting to Improve Reproducibility and Facilitate Validity Assessment for Healthcare Database Studies V1.0. *Pharmacoepidemiology and Drug Safety*, 26(9), 1018–1032. <https://doi.org/10.1002/pds.4295>